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Abstract 
 
CMV infections post hematopoietic stem cell transplantation (HSCT) can be effectively 
controlled through the adoptive transfer of donor derived CMV-specific T cells (CMV-
T). Current strategies involve a second leukapheresis collection from the original donor 
to manufacture CMV-T, which is undesirable in the related donor setting and often not 
possible in unrelated donor transplants. To overcome these limitations I have 
investigated using a small aliquot of the original granulocyte-colony stimulating factor 
(G-CSF) mobilised HSCT graft to manufacture CMV-T. I have explored the T cell 
response to CMVpp65 peptide stimulation in G-CSF mobilised PBMC and 
subsequently examined the identification and isolation of CMV-T based on the 
activation markers CD154 and CD25. CD25+ enriched CMV-T from G-CSF mobilised 
PBMC were shown to contain a higher proportion of FoxP3 expressing cells than non-
mobilised PBMC and also showed superior suppression of T cell proliferation. The 
successful expansion of CMV-T enriched through CD154 created a product which 
contained CD4+ and CD8+ cells, demonstrated a high specificity for CMV, secreted 
cytotoxic effector molecules and lysed CMVpp65 peptide loaded PHA blasts. These 
data provided the first published evidence that CMV-T can be effectively manufactured 
from G-CSF mobilised PBMC and that they share the same characteristics as CMV-T 
isolated in an identical manner from conventional non-mobilised PBMC. This provides 
a novel strategy for adoptive immunotherapy that abrogates the need for successive 
donation. The final part of the thesis explored the clinical scale-up of CD154 based 
enrichment of CMV-T from a G-CSF mobilised donor to assess the feasibility of 
manufacturing a viable therapeutic cell therapy. This has involved developing a GMP 
compliant, clinical scale system for the isolation of functional CD154+ CMV-T and has 
demonstrated the feasibility of translating this process into routine clinical practice, for 
the prophylactic and pre-emptive treatment of CMV reactivation following allogeneic 
HSCT. 
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Chapter 1  
 
General Introduction 
 
1.1 Haematopoiesis and the Components of the Immune System 
 
Haematopoiesis, derived from the Ancient Greek, hemat (“blood”) and poieo (“to 
make”), is the formation of blood cellular components. Haematopoiesis starts from a 
common haematopoietic stem cell (HSC) that resides in the medulla of the bone marrow 
and is able to differentiate into specialised lineages of blood cells. This ability to give 
rise to all different types of blood cells means HSCs are often referred to as pluripotent. 
Approximately 10
11
 – 1012 new blood cells are produced daily, and HSCs have the 
capacity for self-renewal so as they proliferate, the overall cellularity of the bone 
marrow remains in a normal steady state. The maturation of HSCs down erythroid, 
myeloid and lymphoid lineages occurs under the influence of haematopoietic growth 
factors that regulate proliferation and differentiation together with the 
microenvironment of the bone marrow, provided by a stromal matrix on which HSCs 
grow and divide.  
 
The immune system has evolved into many distinct and complex defence mechanisms 
against infection by foreign organisms, such as bacterial and viral pathogens. The 
immune system comprises of two distinct layers, innate immunity and adaptive 
immunity. The innate immune system is not specific to a single pathogen but recognizes 
common features of pathogens through receptors such as the family of Toll-like 
receptors (TLR) which can trigger macrophage activation and subsequent phagocytosis. 
Innate immunity does not lead to immunological memory and some pathogens are able 
to overcome this first line of defence. Natural killer (NK) cells are an important cellular 
component of the immune system, providing rapid response to virally infected cells and 
are critical to the innate immune response. NK cells kill virus-infected cells by targeting 
the presence of antibody or changes in receptors on the surface infected cells. However 
in recent reports, activation of NK cells has been shown to induce memory cell-like 
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functions, capable of cytokine secretion upon reactivation (Sun et al, 2009; Cooper et 
al, 2009), thereby suggestive of a role in the adaptive immune response.  
 
The adaptive immune response is defined by specificity and memory to immune 
responses, such as antibody production in defence against bacteria. The key effector 
cells of the adaptive immune system are lymphocytes, both T and B cells which derive 
from the common lymphoid progenitor and originate in the bone marrow where B cells 
mature, whereas the precursor T cells migrate to the thymus to undergo maturation. The 
process of T cell development and maturation occurs in the thymus, where T cell 
receptor (TCR) genes are randomly rearranged in every T cell to generate a highly 
diverse repertoire of T cells. TCRs consist of two transmembrane glycoprotein chains, α 
and β. Each chain consists of a constant region and a highly polymorphic variable 
region which binds to processed antigenic peptide when presented to the TCR in 
association with a major histocompatibility complex (MHC) molecule. The expression 
of co-receptor molecules CD8 and CD4 occurs following TCR gene rearrangement.  
Immature T cells initially express both CD4 and CD8 molecules, but after interaction 
with stromal cells in the thymus they mature into single positive CD4+ T helper cells 
(Th) or CD8+ cytotoxic T cells (CTL) (Zuniga-Pflucker, 2004). T cells undergo clonal 
activation and proliferation when they encounter antigen and migrate from the thymus 
to establish the peripheral T cell pool. Some T cells are capable of recognizing self-
antigen presented by dendritic cells (DCs) within the thymic microenvironment, termed 
self-reactive, and undergo deletion in the thymus, thereby preventing autoimmunity. T 
cells with affinity for self antigens may escape the thymus and are normally inhibited by 
clonal anergy or by T regulatory cells. A small minority of T cells bear TCRs composed 
of γ and δ chains, but unlike conventional αβ T cells are able to recognise antigen 
directly without the requirement for presentation by an MHC molecule and they may 
bind peptides presented by non-classical MHC-like molecules.  
 
B cells mature in the bone marrow where they receive signals from local stromal cells 
that initiate their division and maturation, and enter the bloodstream to migrate to the 
peripheral lymphoid organs. B cells express surface immunoglobulin (sIg) antigen 
receptors and respond to antigens together with T cell help from CD4+ T cells by 
undergoing plasma cell differentiation which is followed by the secretion of antibody, 
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identical to sIg, into the extracellular space. This process is referred to as the humoral 
immune response as opposed to the T cell response which is generally referred to as the 
cell-mediated immune response.  
 
1.2 Antigen Processing and Presentation 
 
T cell activation and the subsequent destruction of foreign pathogens is a process that 
requires the recognition of antigens displayed in the peptide-binding groove of the 
MHC Class I and Class II molecules on the cell surface by specific T cell receptors 
(TCR). MHC molecules acquire peptide antigens for presentation in two distinct 
pathways, endogenous and exogenous, which determines the class of MHC they are 
assigned to. MHC Class I molecules are composed of heavy chains and an invariant 
light chain, known as the ß2-microglobulin, and report on intracellular events such as 
viral or bacterial infection via endogenous processing and the presentation of peptides to 
CD8+ T cells. Peptides (8-10 amino acids) are loaded onto MHC class I molecules in 
the endoplasmic reticulum (ER) from proteins degraded by proteasomes.The peptides 
are transported to the ER by the transporter associated with antigen processing (TAP) 
complex. Peptides are loaded onto MHC class I molecules with the aid of members of 
the peptide-loading complex, proteins such as tapasin, calreticulin and ERp57. Peptide 
loaded MHC class I molecules are subsequently trafficked to the cell surface via the 
Golgi apparatus where they are recognized by specific TCRs on CD8+ T cells.  
 
MHC Class II molecules present peptides that are taken up by the cell exogenously 
from the extracellular environment via the endocytic pathway and present these peptides 
to CD4+ T cells. MHC class II molecules are synthesised in the ER where the α- and ß-
chains associate with the invariant chain (Ii; CD74), a protein that enables correct 
folding, trafficking and protection of the peptide binding groove. MHC class II 
molecules are then transported from the ER where they fuse with lysosomes containing 
peptides. Prior to fusing, proteins are degraded in the lysosomes by acidic proteasomes 
(cathepsins) to peptides 12-25 amino acids in length. Peptide-loaded MHC class II 
molecules are subsequentlytransported to the cell surface, where they engage CD4+ T 
cells.  
 
 Chapter 1 
 
 
25 
 
MHC class II expression is mostly restricted to antigen presenting cells (APCs), which 
include macrophages, B cells and DCs. Immature DCs reside at high density in tissues 
that interface with the external environment, like the skin, lungs and gastrointestinal 
tract, where they encounter antigen. Following antigen take-up by endocytosis, DCs 
traffic to the lymph nodes where they are able to present antigen to T cells. This 
mechanism of presentation of antigen to T cells by DCs is central to the activation of 
naïve T cells and directs the adaptive immune response against invading 
microorganisms. The presentation of antigen to naïve T cells requires both the 
interaction of MHC loaded with peptide on APCs with the specific TCR as well as a 
second signal to initiate activation of the T cell. The most important of these signals, 
often referred to as the co-stimulatory signal, occurs when CD28 on APCs ligates with 
B7.1 (CD80) and B7.2 (CD86) molecules on T cells. The membrane proteins CD4 and 
CD8 also enhance T cell responses by helping to stabilise weak TCR and MHC 
interactions and augmenting T cell signalling. Lack of co-stimulation during antigen 
presentation to T cells can lead to a state of unresponsiveness known as T cell anergy.  
 
In addition to the processing of antigen via the endocytic pathway for loading onto 
MHC class II molecules, DCs have the ability to process these exogenous antigens and 
transfer them to the MHC class I pathway, a mechanism often referred to as cross-
presentation (Ackerman & Cresswell, 2004). The cross presentation of peptides 
processed in this manner is critical for initiating CD8+ T cell responses to viruses that 
do not infect APCs and therefore allows access to the MHC class I presentation 
pathway. Recent studies have indicated that cross-presentation generally results from 
the uptake of proteins by DCs from the extracellular milieu that require further 
processing (Jensen, 2007). One such mechanism involves the transport of proteins, 
rather than peptides, from phagosomes into the cytoplasm where they enter the MHC 
class I pathway as substrates for proteasomes. Although there is still some controversy 
regarding the mechanics of cross-presentation with regard to antigen processing, it is 
evident that there are several overlapping pathways in antigen presentation through 
MHC class I and class II molecules. 
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1.3 The Biology of Haematological Malignancy 
 
Haematological malignancies arise from the transformation of rare progenitors in the 
bone marrow or thymus by way of genetic alteration which leads to clonal expansion of 
abnormal cells. Chronic myeloid leukaemia (CML) was the first human disease in 
which a specific chromosomal abnormality, the Philadelphia (Ph) chromosome, could 
be linked to pathogenic leukemogeneis (Nowell & Hungerford, 1960). Leukaemia can 
be classified into four distinct categories; acute and chronic leukaemia which can be 
further sub-divided into lymphoid or myeloid malignancies.  
 
Acute leukaemias are usually aggressive diseases, categorised by the accumulation of 
early bone marrow hematopoietic progenitors, commonly referred to as blast cells, 
which arise after malignant transformation. In acute lymphoblastic leukaemia (ALL) the 
bulk of the leukaemia cells resemble lymphoid precursors whereas the origin of 
leukaemic transformation in acute myeloid leukaemia (AML) has in the past been the 
subject of some controversy (Russell, 1997). In some AML patients leukemic clones 
have been shown to originate from erythroid, myeloid and megakaryocytic lineages 
confirmed by conventional cytogenetics and fluorescence in-situ hybridisation (FISH) 
(Keinanen et al, 1988). In a minority of cases of acute leukaemia, blast cells show 
characteristics of both myeloid and lymphoid lineages and are termed bi-phenotypic. 
The accumulation of these abnormal blast cells in the bone marrow and the blood can 
lead to anaemia, neutropenia and thrompbocytopenia due to bone marrow failure and 
infiltration of the organs such as the liver, spleen and lymph nodes leading to organ 
failure. The accumulation of blast cells is driven from their failure to progress through 
the expected programme of differentiation and to undergo apoptosis coupled with the 
retention or aquisition of stem cell characteristic of self-renewal. The most common 
molecular mutation associated with AML occurs within the FLT3 ligand. This is highly 
expressed in CD34+ HSC playing an important role in normal haematopoiesis by 
supporting the viability of candidate HSCs (Sitnicka et al, 2003). FLT3 ligand 
mutations lead to constitutive activation that results in cell proliferation (Rocnik et al, 
2006). 
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Chronic leukaemias are distinguished from acute leukaemias by their slow progression 
and paradoxically are almost always more difficult to cure. CML involves myeloid, 
monocytic, erythroid, megakaryocytic, B-lymphoid and occasionally T-lymphoid 
lineages (Fialkow et al, 1977) and was among the first neoplastic diseases in which 
therapy with a biological agent (interferon) was shown to suppress the leukaemic clone 
and prolong survival (Talpaz et al, 1987). Diagnosis of CML is assisted by the presence, 
in the overwhelming majority of patients, of the Philadelphia chromosome (Ph), 
characterised by the t(9; 22)(q34; q11) translocation between chromosomes 9 and 22. 
The Ph translocation creates a hybrid BCR-ABL gene encoding a fusion protein which 
induces tyrosine kinase activity leading to increased cell proliferation. The leukaemia 
stem cell in CML gives rise to increased numbers of myeloid progenitor cells that fill 
the marrow, suppressing haematopoiesis and leading to neutropenia, thrombocytopenia 
and concomitant infections and bleeding.  
 
Malignant lymphomas are a significant classification of haematological malignancy, 
arising by the accumulation of malignant lymphocytes that accumulate in lymph nodes, 
leading to the characteristic clinical feature of lymphadenopathy. The accumulation of 
malignant lymphocytes in the lymph nodes can lead to spill over into the blood, known 
as the ‘leukaemic phase’. Lymphomas can be divided based on the presence of Reed-
Sternberg (RS) cells determined by histology. In lymphomas where RS cells are 
identified, Hodgkin’s disease is diagnosed, whereas the absence or RS cells 
characterises non-Hodgkin’s lymphoma. Non-Hodgkin’s lymphomas are a diverse 
group of diseases that can manifest as highly proliferative and rapidly fatal to indolent 
and well tolerated malignancies.  
 
Over the last 30 years HSCT has become a therapeutic option in the treatment of most 
haematological malignancies and is indeed standard practice in many leukaemias and 
lymphomas. HSCT can take the form of autologous, where the patient’s own HSCs are 
collected during a period of remission, frozen down, and then infused once the patient 
has undergone a course of conditioning. Alternatively HSCT can be allogeneic, where 
either a sibling or unrelated donor undergo HSC donation after which they are infused 
fresh into the patient without the need for cryopreserving. The indications for 
autologous or allogeneic HSCT in haematological malignancy are dependent on the 
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stage of the disease and are based on certain risk factors, such as cytogenetics in the 
case of AML. 
 
1.4 Allogeneic Haematopoietic Stem Cell Transplantation 
 
The treatment of a variety of haematological malignancies through allogeneic 
haematopoietic stem cell transplantation (HSCT) is now regarded as common practice. 
The procedure of allogeneic HSCT requires the elimination of the recipient’s 
haematopoietic and immune system through pre-transplant chemotherapy and/or 
radiotherapy, which provides space for incoming cells to engraft. They also act to kill 
most residual cancer cells and to lymphodeplete the recipient, preventing graft rejection. 
The treatment-related mortality from this myeloblative conditioning has largely 
restricted the use of allogeneic HSCT to healthier younger patients whose tolerance of 
the radiotherapy makes this approach feasible. However in recent years, allogeneic 
HSCT has been extended to older patients through the introduction of reduced intensity 
conditioning (RIC) regimens (Jimenez et al, 2007). RIC regimens avoid much of the 
toxicity associated with myeloblative regimens but require stronger immunosuppression 
to allow engraftment of incoming cells as the conditioning is not sufficient to eradicate 
the endogenous bone marrow cells.  
 
The first allogeneic HSCT were performed in patients with acute leukaemia (Thomas et 
al, 1971) and aplastic anaemia (Pillow et al, 1966) whose life expectancy was deemed 
to be limited without such intervention. Allogeneic HSCT was successfully extended to 
patients with chronic myeloid leukaemia (CML) in the early 1980’s (Goldman et al, 
1986) and was quickly followed with the use of unrelated donor bone marrow for 
allogeneic HSCT (Beatty et al, 1989;McGlave et al, 1990). 
 
With the successful establishment of HSCT for a wide spectrum of haematological 
malignancies has come the quest to resolve the associated allogeneic immune response 
between donor and recipient that is responsible for both the beneficial effects of graft-
versus-leukaemia (GvL) response as well as graft-versus-host disease (GvHD). The 
delicate balancing act associated with the favourable effects of GvL and the morbidity 
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and mortality associated with GvHD is one which transplant physicians and scientists 
have long been attempting to resolve.  
  
1.4.1 Immunological basis for GvHD 
 
The phenomenon of GvHD describes the alloreactivity that results from allogeneic 
HSCT. Allogeneic haematopoietic stem cell grafts contain immunocompetent cells that 
are capable of recognising the host as foreign and attempt to reject the host tissues, most 
commonly the tissues of the skin, gut and liver. GvHD was first documented when 
irradiated mice were infused with allogeneic marrow and although they recovered from 
radiation injury and marrow aplasia they subsequently died with secondary disease 
consisting of diarrhoea, weight loss, skin changes and liver abnormalities (Van Bekkum 
et al, 1967), the hallmarks of GvHD. In 1966, Billingham formulated the necessary 
requirements for the development of GvHD. First, the graft must contain 
immunocompetent cells; second, the recipient must not have the capacity to mount an 
immune response to eradicate the transplanted cells; and third, the recipient must 
express tissue antigens i.e. HLA or minor histocompatibility antigens (mHags) that are 
not present in the donor (Billingham, 1966).  
 
GvHD that occurs earlier than 100 days post HSCT is commonly referred to as acute 
GvHD and can develop within days following HSCT, whereas chronic GvHD is defined 
as GvHD occurring more than 100 days following HSCT. The development of acute 
GvHD has been proposed to involve a three-step process where donor immune cells are 
responsible for the initiation and subsequent injury to host tissues after complex 
interactions with cytokines. The three-step model first described by Ferrara (Ferrara et 
al, 1996) is initiated by the recipient’s conditioning regimen (irradiation and/or 
chemotherapy) which leads to damage and activation of host tissues, inducing the 
secretion of inflammatory cytokines. These pro-inflammatory cytokines cause the 
increased expression of MHC antigens and co-stimulatory/adhesion molecules on 
APCs, thereby enhancing the recognition of host tissue by donor T cells after HSCT. 
Following this first phase, donor T cell activation occurs and is characterised by their 
proliferation and secretion of IL-2 and IFN-γ. This phase in the 
immunopathophysiology of GvHD, is initiated by donor T cells encountering activated 
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host APCs bearing recipient allogeneic antigens (alloantigens) which drives their 
proliferation and differentiation, leading to cytokine dysregulation. The final step 
incorporates the resulting damage and necrosis of healthy recipient tissues in the form 
of GvHD. It has recently become evident that GvHD is a result of naïve donor T cell 
responses and that central and effector memory T cells do not appear to induce GvHD 
but may however mediate GvL responses (Zheng et al, 2008). 
 
In allogeneic HSCT, where donor and recipient are mismatched at MHC level, GvHD is 
driven predominantly by donor T cells being activated by allogeneic MHC molecules 
present on recipient APCs. In the MHC-matched setting, the alloresponse is driven by 
mHags, most notably HA-1 (den Haan et al, 1998) presented in the context of MHC 
which can induce potent responses in donor T cells, often manifested as GvHD.  
 
Several strategies have been employed by transplant physicians to minimise the 
debilitating effects of GvHD following allogeneic HSCT. Pharmacological agents such 
as corticosteroids, cyclosporine A and methotrexate are commonly used 
prophylactically to suppress donor T cell activation through inhibition of cell signalling 
pathways. T cell depletion of the HSC graft using monoclonal antibodies such as 
Campath 1H, which ligates CD52 on T cells and causes their destruction via the 
complement cascade upon infusion of the graft, is also common practice. This strategy, 
however, also eliminates donor T cells responsible for anti-leukaemia responses and can 
lead to increased rates of patient relapse (Horowitz et al, 1990). Approaches to reduce 
the conditioning induced morbidity through the use of non-myeloblative regimens have 
been successful in AML (Alyea et al, 2006) by reducing the incidence of GvHD, whilst 
relying on the beneficial effects of GvL from the graft to eliminate residual malignant 
cells. Reduced intensity conditioning regimens commonly consist of a combination of 
the purine analog fludarabine with either alkylating agents like busulfan, melphalan or 
cyclophosphamide or in conjunction with low dose total body irradiation (TBI). These 
protocols reduce the inflammation in the host often seen in myeloblative regimens, thus 
preventing step 1 in the 3-step GvHD induction process. 
 
In more recent years, studies to minimise GvHD have also focussed on the removal of 
alloreactive donor T cells from the graft by selective depletion prior to infusion as an 
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alternative strategy, whilst retaining donor T cells that are capable of mounting a GvL 
response. Strategies have focussed on negative selection of donor T cells expressing 
activation markers such as CD25 and CD69 (Koh et al, 1999; Fehse et al, 2000), killing 
activated T cells by photodynamic purging (Chen et al, 2002) or inducing Fas-mediated 
apoptosis (Hartwig et al, 2002). 
 
1.4.2 Immunological basis for GvL 
 
The GvL response is the mechanism by which immunocompetent transplanted cells 
mount a sustained response directed towards malignant cells of the recipient and is vital 
for both long term and disease-free survival. The hypothesis that HSCT was associated 
with an anti-leukaemic effect was first proposed as early as the 1950’s (Barnes et al, 
1956). Evidence that donor cells are capable of exerting a GvL effect was first provided 
by a large retrospective study of more than 2,000 recipients of allogeneic HSCT for the 
treatment of haematological malignancy. Results showed that recipients were at an 
increased risk of relapse if they had received a graft that had been depleted of T cells to 
reduce the risk of GvHD (Horowitz et al, 1990). Direct evidence of the GvL effect 
mediated by donor T cells was first provided by the use of donor lymphocyte infusions 
(DLI) for the treatment of relapse in patients with CML, where subsequent complete 
cytogenetic remissions was demonstrated (Kolb et al, 1990). This was an early example 
of adoptive immunotherapy post-allogeneic HSCT. DLI has subsequently been 
extended to different haematological malignancies, and dose escalation protocols 
established (Mackinnon et al, 1995) but DLI still remains most effective in the 
treatment of CML. The major effector cells of GvL are considered to be donor T cells 
with both CD4+ and CD8+ cytotoxic anti-leukaemia T cell lines or clones reported 
(Faber et al, 1995;Jiang et al, 1991). There is also evidence for the implication of other 
cell subsets in the GvL effect, most notably NK cells (Ruggeri et al, 1999).  
 
Studies have demonstrated a strong association between the presence of GvHD and 
protection from relapse after HSCT through the GvL effect (Horowitz et al, 1990;  
Bacigalupo et al, 1991) . A fundamental question in the field of HSCT is whether the 
mechanism or effectors of GvL are fundamentally different from those of GvHD, or 
whether GvL simply represents a subset of GvH reactions. The elusive goal in HSCT 
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continues to be the ability to induce GvL to cure the patient whilst eliminating GvHD. 
Despite the development of several strategies to separate GvHD and GvL effects, it 
remains unclear whether they indeed can be separated. Most of these approaches have 
attempted to separate GvL and GvHD by either the use of RIC regimens to abrogate the 
release of pro-inflammatory cytokines, usually in conjunction with DLI. Or through 
advances in cellular therapy including increasing specificity of donor cells towards 
tumour associated antigens by gene-therapy. Tumour-associated antigens preferentially 
expressed on malignant cells have been identified as potential targets for incoming 
donor T cells, most commonly in CML (Schmitt et al, 2006), which offer the potential 
for manipulation of DLI for clinical benefit. A relevant example of this approach 
includes the Wilms’ Tumour antigen-1 (WT1) targeted immunotherapy (Xue et al, 
2004). WT-1 is expressed at elevated levels in most leukaemias and can be effectively 
killed by allorestricted CTL.  
 
1.4.3 Stem cell source 
 
There are three main sources of HSCs for clinical transplantation – bone marrow, 
peripheral blood stem cells (PBSC) and umbilical cord blood (UCB). The principle 
source of haematopoietic stem cells in both autologous and allogeneic HSCT continues 
to be PBSCs collected by apheresis after granulocyte colony stimulating factor (G-CSF) 
mobilisation. The original source of HSCs was bone marrow but its use in HSCT has 
declined over the years, as the requirement for anaesthesia and hospitalisation in order 
to obtain a sufficient volume of bone marrow (10-15ml/kg recipient weight) is seen as a 
strong disadvantage of this approach. In 2009, The European Group for Blood and 
Marrow Transplantation (EBMT) survey of over 600 transplant centres reporting a total 
of 31,322 HSCT found that over 70% of allogeneic HSCT were conducted using PBSCs 
(Baldomero et al, 2011). The move away from bone marrow harvests as a source of 
CD34+ stem cells is largely due to the fact that G-CSF mobilisation enables the 
collection of significantly larger numbers of CD34+ cells compared to traditional bone 
marrow harvests, as well as an increase in the numbers of committed myeloid, erythroid 
and megakaryocytic progenitors (Russell et al, 1996). Furthermore a meta-analysis of 
nine randomized trials comparing allogeneic PBSCs with bone marrow transplantation 
concluded that mobilised stem cells are associated with faster engraftment, reduced 
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rates of relapse in haematological malignancy, and improvement in overall and disease-
free survival in patients with late-onset disease. However, the use of mobilised stem 
cells is also associated with more acute GvHD grades 2-4 and a significant risk of 
extensive, chronic GvHD (Stem Cell Trialists' Collaborative Group, 2005), than 
traditional bone marrow grafts; thought to be related to the higher T cell dose 
contaminating the graft. 
 
UCB is also a rich source of HSCs and is associated with a decreased incidence of 
GvHD and reduced histocompatibility requirements due to the naïve immunological 
state of lymphocytes within the UCB graft. This has led to the establishment of a 
number of cord blood banks over the past decade. The first human UCB transplant was 
performed in 1988 in a child with Fanconi anaemia, where the UCB from an HLA-
identical sibling was used (Gluckman et al, 1989). HSCT using UCB has largely been 
restricted to paediatrics and small adults due to the dose limitations of UCB. UCB 
collections contain a significantly reduced total number of CD34+ cells due to the 
collection volume (50-200ml), which when used in adults can have the impact of 
delayed or failed engraftment compared with PBSCs. In more recent years, dual cord 
blood transplants have been performed to maximise CD34+ cell numbers and therefore 
reduce the time to engraftment in the adult setting. To overcome the limitation of UCB 
in terms of progenitor cell numbers, several studies (McNiece et al, 2000) have 
investigated the expansion of CD34+ cells in short term culture from UCB. However, 
these studies have yet to be translated into clinical practice. 
 
1.4.4 Human Leukocyte Antigens  
 
The recognition and destruction of virally infected and tumour cells by T cells is a 
process controlled through the binding of peptide fragments originating from foreign 
antigens to molecules termed the MHC. The MHC is polygenic, containing several 
MHC Class I and MHC Class II genes coding for a diverse range of peptide binding 
specificities; and polymorphic, meaning that there are multiple variants of each gene 
within the population. The genes coding the MHC are located on chromosome 6 in 
humans is an area known as the human leukocyte antigen (HLA) region. The genomic 
region on chromosome 6 contains the class I subregion at one end which contains genes 
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encoding the class I molecules HLA-A, -B, -C, as well as the non-classical molecules 
HLA-E, -F and –G. Class I genes code for a heavy α chain which becomes linked to a 
non-polymorphic light chain, ß2-microglobulin, whose gene is on chromosome 15. The 
class II subregion contains the classical HLA-DR, -DP, and –DQ genes which code for 
both α and ß chains. Classical HLA class I molecules are expressed on the majority of 
tissues and blood cells whereas HLA Class II molecules are constitutively expressed on 
B cells, monocytes and dendritic cells, and can be detected on activated T cells in 
humans. 
 
Following the identification of the HLA system in 1965 (Dausett and Rapaport, 1965), 
it became evident that HLA discrepancy between donor and recipient was responsible 
for graft rejection, increased GvHD and mortality in allogeneic HSCT. A retrospective 
analysis of 948 unrelated donor allogeneic HSCTs found that a single HLA allele or 
antigen mismatch was associated with increased mortality compared to no HLA 
mismatch (Petersdorf et al, 2004). HLA typing of both donor and recipient is a 
prerequisite in the field of transplantation. This was initially carried out using 
serological methods but has now been replaced with more sensitive DNA sequencing 
which can detect single nucleotide differences between two unique HLA alleles of the 
same antigen. Most of the DNA sequencing techniques make use of the polymerase 
chain reaction (PCR) to amplify the specific genes to be analysed, including PCR-SSP 
(PCR-sequencing-specific priming) and PCR-SSOP (PCR-sequencing-specific 
oligonucleotide probing). As one would expect, the outcome after allogeneic HSCT is 
much improved by fully matching HLA alleles of donor and recipient, but the 
associated risks when using an unrelated donor compared with a sibling donor have yet 
to be fully resolved. A retrospective study of 1448 recipients of T-replete HSCT after 
myeloblative conditioning showed that no statistical differences were found between 
fully matched unrelated donors (10/10 alleles) compared with HLA-identical siblings in 
survival, disease-free survival (DFS) and relapse when patients had high-risk disease 
and bone marrow is the graft source. However, significant differences were observed 
when patients had intermediate stage diseases and peripheral blood monocyte cells 
(PBMCs) were the graft source. Recipients of HLA-matched unrelated donors also had 
a higher incidence of both acute and chronic GvHD (Woolfrey et al, 2010). These 
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results clearly highlight the number of factors that need to be considered when selecting 
suitable donors, beyond that of HLA typing. 
 
1.5 Human Cytomegalovirus 
 
Cytomegalovirus (CMV) is a member of the family of herpes viruses and infects 
approximately 60-70% of normal healthy individuals in Western societies and up to 
100% in some parts of Africa and Asia (Bego & St, 2006). In almost all cases, CMV 
infection remains entirely asymptomatic, with the virus persisting in a latent state for 
the life of the host. The occasional viral reactivations that occur are controlled by the 
host immune system.  
 
The virion structure of CMV is an icosahedral nucleocapsid, containing a 230-kbp, 
double-stranded linear DNA genome surrounded by a layer known as the tegument or 
matrix, which, in turn, is enclosed by a lipid bilayer envelope containing viral 
glycoproteins. Most of the tegument proteins are phosphorylated and are highly 
immunogenic, the most abundant of which are pp150 or basic phosphoprotein (UL32) 
and pp65 (UL83). The virus is usually acquired through the transfer of saliva and also 
through intrauterine or perinatal infection. In addition, transmission can also occur 
following solid organ transplantation and through blood transfusion (Roback, 2002). 
Monocytes and endothelial cells have been implicated as sites of CMV latency and viral 
replication, contributing extensively to maintaining life-long infection (Jarvis & Nelson, 
2002;Taylor-Wiedeman et al, 1991). 
 
Whilst CMV seropositive individuals show no morbidity through effective immune 
control of the virus, in individuals who are immunocompromised, such as in bone 
marrow transplant recipients, or following HIV infection, CMV can cause life 
threatening disease. Infectious complications arising from the reactivation of human 
CMV following allogeneic HSCT continues to be a significant cause of morbidity and 
mortality (Chakrabarti et al, 2002; Gooley et al, 2010), with the incidence of 
reactivation being reported to be as high as 70% (Reusser et al, 1991). Untreated, CMV 
can cause a variety of diseases including pneumonitis, retinitis, gastrointestinal disease 
and hepatitis. The biology of CMV infection in immunocompetent individuals is one 
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that is often described as an evolutionary balance between the host cellular immune 
system and the viral mechanisms of persistence and evasion that results in lifelong 
maintenance of infection. Remarkably, unlike any other known persistent human virus, 
the ongoing T cell responses required to control reactivation is so large that CMV-
reactive T cells can be directly enumerated in peripheral blood of seropositive 
individuals in the absence of active disease.  
 
1.5.1 Immune response to CMV 
 
During primary CMV infection, replication is initiated in the mucosal epithelium and 
subsequently disseminates to monocytic cells of myeloid lineage, where it establishes 
latent infection. Replication of human CMV leads to the expression of three classes of 
viral genes known as immediate-early (IE), early (E) and late (L). Each gene plays an 
important role in the coordination of CMV replication. IE genes are independent of any 
viral de novo synthesis and encode mostly regulatory trans—acting factors, a DNA 
sequence that contains a gene. The expression of E genes is dependent on the presence 
of viral IE proteins and provides an essential number of factors including viral DNA 
replication proteins and repair enzymes. L genes contribute to the assembly and 
morphogenesis of the virion and are expressed after the onset of viral DNA replication 
(Ma et al, 2012). The phosphoprotein pp65 is produced early during viral replication, 
and regulation of its expression is controlled by the major IE promoter (MIEP), which is 
thought to be central in the control of the latent state. In healthy individuals, viral 
replication is mediated by both the innate and adaptive immune systems with 
independent roles played by NK cells, B cells and both CD4+ and CD8+ T cells. The 
humoral response to CMV is in the form of neutralising antibodies which are directed 
towards multiple CMV proteins including structural tegument proteins, envelope 
glycoproteins and non-structural proteins. Neutralising antibodies directed towards 
epitopes of the envelope glycoprotein B have been shown to be of particular 
importance. Studies have shown approximately 40% to 70% of the total serum virus-
neutralising antibody activity of individuals with previous infection were directed 
against this single envelope protein (Britt et al, 1990). In murine studies, mice 
immunised against murine CMV glycoprotein B are protected against a lethal challenge 
(Rapp et al, 1992). More recently it has been found that antibodies directed towards 
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glycoprotein H/glycoprotein L complexes display an inhibitory activity on human CMV 
plaque formations and leukocyte transfer of virus from infected cells (Gerna et al, 
2008).  
 
Early studies demonstrated a protective role for NK cells in murine CMV infection, 
where NK cells were activated rapidly and the level of activity correlates with the 
degree of resistance (Bancroft et al, 1981). Although NK cells offer an important first 
line defence against CMV when specific immunity has yet to be fully developed, 
studies involving the CMV response and NK cells have tended to concentrate more on 
the evasion mechanisms that the virus has developed. Such mechanisms includes the 
human CMV UL40 glycoprotein protein that promotes efficient cell surface expression 
of the non-classical MHC class I molecule HLA-E, which binds the NK cell inhibitory 
receptor CD94/NKG2A, protecting the cell harbouring the virus from lysis (Tomasec et 
al, 2000). Furthermore in HSCT patients, NK cells appear to engraft rapidly following 
transplantation, at a time when patients reactivate CMV or become infected, which 
suggests that they are unlikely to play a key role in susceptibility to viral infection. In 
contrast, the absence of reconstitution of CMV-T cell immunity following HSCT is 
strongly associated with reactivation of CMV and subsequent CMV disease (Reusser et 
al, 1991). 
 
1.5.2 T cell immunity to CMV 
 
Studies in both humans and animal models have demonstrated a critical role for both 
CD4+ and CD8+ T cells in the control of CMV replication and the prevention of CMV 
disease. In CMV-infected mice, a major fraction of CD8+ cytotoxic T cells (CTL) 
specific for the IE-1 protein were shown to mediate protection (Koszinowski et al, 
1990). Extensive research in humans has demonstrated that the CTL response to CMV 
is dominated by the structural proteins pp65 (UL83) (Wills et al, 1996; Laughlin-Taylor 
et al, 1994) and IE-1 (UL123) (Davignon et al, 1995). The protective role of CD8+ 
CMV-reactive T cells was first successfully shown after the adoptive transfer of donor 
derived T cell clones, in three bone marrow transplant recipients (Riddell et al, 1992). 
Evaluation of CMV-specific CTL responses demonstrated that CD8+ clones persisted 
for at least a month and none of the three patients developed CMV viraemia providing 
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evidence of protection from CMV disease. The magnitude of lyic activity of 
reconstituted CD8+ CMV-specific immunity detected in all recipients after a third cell 
dose was shown to be equivalent to or greater than that observed in the 
immunocompetent bone marrow donors. The association of CD8+ CTL with protection 
against CMV replication and subsequent disease was elegantly demonstrated by using 
CMVpp65 specific class I HLA-tetramers to show that CD8+ CTL numbers increased 
significantly after episodes of CMV infection following HSCT (Cwynarski et al, 2001). 
Furthermore, in HSCT recipients undergoing a high-level of CMV replication, 
frequencies of CD8+ CMV-specific CTL have been shown to be as much as 20% 
(Gratama et al, 2001; Aubert et al, 2001). HLA tetramers have helped to define a series 
of phenotypic markers of CMV-specific CD8+ T cells, characterising them as a late 
effector, fully differentiated phenotype (CD45RA+, CD27-, CCR7-) (Appay et al, 
2002a).  
 
Although previous work on CMV-specific T cell immunity has focused primarily on the 
two principle dominant proteins, pp65 and IE-1, the true breadth of the total T cell 
response to CMV proteins has been shown using 13,687 overlapping 15mer peptides 
encompassing all 213 known CMV open reading frames (ORFs) in 33 CMV 
seropositive healthy subjects (Sylwester et al, 2005). In this very substantial 
publication, Sylwester and colleagues were able to show that at least 151 CMV ORFs 
are immunogenic for CD4+ and/or CD8+ T cells, with 44 ORFs recognised by CD4+ T 
cells only and 26 recognised by CD8+ T cells only, as summarised in Figure 1.1. Whilst 
the majority of CMV seropositive individuals mount T cell responses to epitopes of 
pp65 and IE-1, it is clear that the anti-CMV response is also directed towards other 
targets, such as pp28, pp71 and IE-2 (Sylwester et al, 2005).  
 
The importance of CD8+ CTL in conferring protection against CMV disease is well 
described; however, the function of proliferating CD4+ T cells in resistance to CMV is 
still somewhat unclear and a role for CD4+ T cells with cytotoxic capabilities is still 
controversial. Identification of a population of CD4+ T cells that can mediate killing of 
virally infected cells has been successfully shown in both mice depleted of CD8+ T 
cells (Stuller & Flano, 2009) and deficient in MHC class I expression (Hou et al, 1993). 
These studies provided evidence of cytokine secreting CD4+ T cells with anti-viral 
 Chapter 1 
 
 
39 
 
properties which were not seen when CD8+ T cells were present. CD4+ T cells have 
been shown to be important for maintaining adequate numbers of CD8+ CMV-specific 
T cells in CMV disorders related to acquired immune deficiency syndrome (AIDS) 
(Komanduri et al, 2001). The importance of CD4+ T cells in maintaining CD8+ 
numbers with respect to CMV is further supported by evidence that CMV-specific 
CD8+ T cells increase in number after infusion of CD4+ CMV-specific T cells in vivo 
(Einsele et al, 2002). The minimum repertoire of CMV-reactive T cells needed for 
containment of CMV remains unresolved. 
 
Although αβ T cells are the principle effector cells in controlling CMV disease, recent 
interest has focussed on the role of γδ T cells, a minor population of circulating T cells 
(<5%) in humans which primarily reside in epithelial tissues, where they function as the 
first line of defence. It has been shown that γδ T cells play an important role in the 
immune response to CMV, demonstrated by the oligoclonal expansion and cytotoxic 
function of CMV-reactive Vδ1 and Vδ3 γδ T cell subsets in the peripheral blood of 
patients receiving renal allografts (Lafarge et al, 2001; Dechanet et al, 1999). More 
recently the protective role of Vδ1 and Vδ3 γδ T cells in CMV-seropositive patients 
with documented CMV reactivation, following allogeneic HSCT has been 
demonstrated. Isolated γδ T cells subsets from these patients showed significant 
expansion and potent antiviral capacity in vivo (Knight et al, 2010) 
 
Figure 1.1 Percent of 213 HCMV ORFs recognised by CD4+ and/or CD8+ T cells 
in 33 CMV seropositive donors. Figure reproduced from (Sylwester et al, 2005). 
Neither CD4+ nor CD8+ 
T cells 
Both CD4+ and CD8+ T 
cells 
CD4+ T cells only 
CD8+ T cells only 
62 ORFs 
(29.1%) 
81 ORFs 
(38.0%) 
44 ORFs 
(20.7%) 
26 ORFs 
(12.2%) 
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1.5.3 CMV and HSCT 
 
CMV infections continue to prove problematic following allogeneic HSCT and disease 
can manifest as pneumonitis, gastrointestinal syndromes, hepatitis, retinitis or bone 
marrow suppression. CMV pneumonitis is one of the major causes of morbidity and 
mortality following transplantation due to the cytopathic effect of CMV replication in 
the lungs. The risk of HSCT- associated CMV disease is defined by the CMV status of 
both donor and recipient. A predictor for a high risk of CMV disease is transplantation 
of a CMV-seronegative donor into CMV-seropositive recipient and vice versa. The 
combination of both donor and recipient seropositivity is associated with a lower risk 
while the combination of donor and recipient seronegativity is associated with no 
intrinsic CMV risk. 
 
With the incidence of CMV disease following HSCT being reported to be as high as 
70% (Reusser et al, 1991), a reduction in disease has been achieved through the 
prophylactic and pre-emptive use of anti-viral drugs including Ganciclovir and 
Foscarnet (Goodrich et al, 1993) coupled with detection and quantification of viral 
DNA by polymerase chain reaction (PCR) based assays (Einsele et al, 1995). Although 
the prophylactic and pre-emptive administration of anti-viral drugs has helped to reduce 
CMV disease in the first 100 days following allogeneic HSCT, they have not been 
effective in improving overall survival in the long term and they are associated with 
delayed immune reconstitution and late onset CMV disease (Boeckh et al, 2003).  
 
The development of a cellular immune response against CMV is the most important 
factor in conferring protection from CMV infection and this has lead to an increasing 
number of studies using adoptive immunotherapy to prevent CMV disease in patients at 
high risk of reactivation. Attempts to restore anti-viral immunity in humans has 
stemmed from initial observations from preclinical murine models that adoptive transfer 
of CD8+ virus-specific T cells protects mice against otherwise lethal viral challenge 
(Reddehase et al, 1985). 
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1.5.4 Adoptive Immunotherapy for CMV 
 
Prior to the transfer of donor T cells with specific anti-viral properties, DLI were used 
post-HSCT on the premise that these cells contained T cells capable of mediating both 
anti-tumour and anti-viral activity. DLI has been used extensively to provide anti-
tumour immunity for relapsed leukaemia patients (Porter et al, 1994; Collins, Jr. et al, 
1997; Kolb et al, 1995) but to a lesser extent for anti-viral immunity. DLI contain high 
numbers of alloreactive T cells and so dosing is limited due to the potential for GvHD. 
This in turn limits the dose of virus-specific T cells received, which prompted the 
investigation of generating a T cell product with the sole role of providing anti-viral 
immunity without the high risk of GvHD. However, the potential for anti-CMV T cells 
to cross-react with allogeneic HLA and thus cause GvHD remains a distinct possibility. 
 
The first proof-of-principle studies involving adoptive transfer of donor-derived CMV-
specific T cells (CMV-T) involved the use of CD8+ T cell clones expanded by repeated 
restimulation in long term culture (Riddell et al, 1992; Walter et al, 1995). Although 
these studies showed CMV-T reconstitution in all cases, they were poorly maintained 
due to the absence of CD4+ T cell help. However, these studies were the first clinical 
evidence for the role of CTLs in controlling CMV infection, and paved the way for 
several strategies in the field of immunotherapy for CMV disease following HSCT. 
Strategies for the manufacture of CMV adoptive immunotherapy can be grouped into 4 
distinct categories: CMV-specific T cell clones, CMV-specific T cell lines, multi-
specific T cell lines and direct selection as outlined in Figure 1.2 (Peggs, 2009). In all 
instances, the manufacture of CMV-T has involved the use of either donor lymphocytes 
collected by steady state apheresis or collection of whole blood via a single blood draw 
as starting material. 
 
1.5.4.1 CMV-specific T cell clones 
 
In the study of Walter et al. (Walter et al, 1995) CD8+ T cell clones were administered 
to 14 patients in high cell numbers, the highest dose being 2 x 10
9
 cloned CMV-T in 
total. Manufacturing such a large number of cloned cells required long culture periods 
of 8 to 12 weeks. Despite the clinical success of this pioneering study, the translation 
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into routine clinical practice was limited by the logistics of such long culture periods. 
Adoptive transfer of CD4+ T cell clones has also been used prophylactically for CMV 
disease after allogeneic HSCT. In the study of Perruccio and colleagues (Perruccio et al, 
2005), 25 patients received donor CMV-specific CD4+ T cell clones at a dose range of 
10
5
 to 10
6
 cells/kg body weight. This resulted in the detection of both CD4+ and CD8+ 
anti-CMV responses after transfer, and control of CMV antigenemia. Just as with the 
CD8+ T cell clones generated by Walter and colleagues, the generation of CD4+ T cell 
clones requires a complex logistics of manufacture that has made their widespread 
clinical application unfeasible. 
 
 
  
 
 
C
h
a
p
ter 1 
4
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 CMV adoptive immunotherapy strategies. Figure reproduced from (Peggs, 2009). 
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1.5.4.2 CMV-specific T cell lines 
 
The adoptive transfer of oligo- or polyclonal T cell lines is an alternative approach to 
the transfer of T cell clones that has followed on from earlier studies involving the 
infusion of gene modified T cell lines specific for Epstein Barr virus (EBV) (Heslop et 
al, 1996). Heslop and colleagues showed that cultured cells were associated with the 
establishment of long-term immunity, as demonstrated by re-challenge up to 18 months 
post infusion, and were also associated with a limited risk of GvHD. CMV-specific T 
cell lines for adoptive transfer have been manufactured in culture to contain CD4+, 
CD8+ and a mixture of both using different strategies. Einsele and colleagues generated 
a predominantly CD4+ CMV-specific T cell line by pulsing PBMCs with CMV lysate, 
followed by repetitive stimulation in a 3 to 4 week culture (Einsele et al, 2002). Eight 
patients were treated following HSCT who lacked CMV-specific T cell proliferation, 
with 5/8 patients achieving viral clearance with associated CMV-specific T cell 
proliferation after transfer of 10
7
 T cells/m
2
. A second strategy for manufacture of 
CMV-specific T cell lines is pulsing monocyte derived dendritic cells (MoDC) with 
CMV lysate or with a single peptide. Pulsing MoDC with CMV lysate has been 
demonstrated to result in a mixed CD4+ and CD8+ T cell line, that when transferred to 
recipients at low doses ( 1 x 10
5
 CD4+ and CD8+ CMV-reactive cells/kg) resulted in 
massive in vivo expansions within days of transfer (Peggs et al, 2003). A total of 16 
patients were treated after the first episode of CMV viraemia, at a median of 36 days 
following transplantation, with eight patients clearing viral DNA without the need for 
antiviral drugs. Three patients developed cutaneous Grade I acute GvHD after adoptive 
cellular therapy but no clinically relevant GvHD was seen. 
 
The use of MoDC has also been investigated for generation of CMV-specific T cell 
lines by pulsing with the HLA-A2 restricted peptide NLVPMVATV (NLV) derived 
from the CMVpp65 protein in a 21 day culture (Micklethwaite et al, 2007). Expanded 
cells were predominantly CD8+ with a median of 62% of final cells NLV-specific. Nine 
patients were treated prophylactically, with an associated increase in NLV-specific T 
cells in six patients, although the increase was not maintained beyond several days to 
weeks. This lack of long term immunity provided by the transferred cells can be 
explained by the possible lack of CD4+ T cell help much like that observed in the early 
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studies of Riddell and Walter (Riddell et al, 1992; Walter et al, 1995). The use of 
overlapping pools of peptides spanning the entire CMVpp65 protein to pulse MoDC has 
been investigated, where polyclonal T cell lines containing both CD4+ and CD8+ 
CMV-T were successfully generated and capable of lysing CMV-infected targets 
(Trivedi et al, 2005). 
 
1.5.4.3 Multi-specific T cell lines 
 
Immunotherapeutic strategies to restore CMV immunity have also been examined 
through the use of T cells expanded against multiple viruses. In this system, EBV-
transformed B cells (EBV-LCLs) were genetically modified with a chimeric 
adenovirus-CMVpp65 vector (Ad5f35pp65) that generated CTLs specific for EBV, 
adenovirus and CMV in a single culture. In a proof of concept study (Leen et al, 2006), 
eleven patients received tri-specific CTLs prophylactically at a median of 62 days 
following HSCT with doses ranging from 5 x 10
6
 to 1 x 10
8
 cells/m
2
. Expansion of 
multi-specific CTLs was observed in vivo, with a concomitant reduction in the levels of 
all three viruses. Interestingly, the frequency of EBV- and CMV-specific T cells 
increased whether or not there was evidence of activation of the virus, whereas the 
expansion of adenovirus-specific T cells was only seen in those patients with a recent or 
concurrent adenoviral infection. Similar results were also observed after the infusion of 
T cell lines generated from co-culture with MoDC transduced with the same 
Ad5f35pp65 vector at a median of 54 days post HSCT at similar doses (Micklethwaite 
et al, 2008). One of the limiting factors in the generation of multi-virus specific T cells 
has been the complexity of the manufacturing process that requires infectious virus 
material, production of a clinical grade vector and long term culture (10-12 weeks). 
 
Leen and colleagues have built on these initial experiments to develop a system for the 
generation of multi-virus specific CTLs that extends the number of pathogens targeted 
to seven with the addition of specificity directed towards human herpes virus (HHV)-6, 
respiratory syncytial virus (RSV), influenza and the BK virus (Gerdemann et al, 2012). 
The system also reduces the culture time down to 10 days by a single stimulation of 
PBMCs with a peptide mixture spanning the target antigens and the addition of the 
cytokines IL4 and IL7. Two groups have shown that multi-virus specific T cells can be 
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generated through the activation-dependent expression of both CD154 (Khanna et al, 
2011) and CD25 (Lugthart et al, 2012) after peptide stimulation and magnetic isolation 
through the associated activation marker. However, none of these protocols has yet to 
be translated into clinical practice to allow for assessment of their efficacy and safety. 
 
1.5.4.4 Direct Selection 
 
The direct selection of CMV-T is made possible by the high frequency of CMV-reactive 
T cells in the majority of CMV seropositive individuals. This is an attractive option 
when considering the reduction in laboratory processing involved compared to the 
generation of T cell lines and clones. There are two strategies of direct selection that 
have seen adoptive transfer of CMV-T. The first is the use of HLA-peptide multimers 
where CMV-specific CD8+ T cells were magnetically enriched from donor PBMCs 
using varying HLA restriction and peptide specificities (Cobbold et al, 2005). Nine 
patients received cells with doses ranging from 1.2 x 10
4
 to 2 x 10
6
 cells/kg with a 
median purity of CMV-specific CTL of >95%. CTLs were shown to be functional after 
transfer: this was demonstrated most clearly in one patient in whom CMV reactivation 
was refractory to antiviral drugs but was controlled within eight days of adoptive 
transfer. One of the limitations of HLA-multimers is that they select only CD8+ T cells, 
and the lack of CD4+ T cell help might hinder their long term survival. In addition, the 
restriction of HLA-multimers to only several specificities means that not all patients 
would be eligible for such treatment. 
 
A second strategy for direct selection of CMV-T is based on the selection of interferon 
gamma (IFN-γ) secreting cells by magnetic enrichment (‘gamma catch’) in response to 
ex vivo priming by viral proteins or peptides (Assenmacher et al, 2002; Bissinger et al, 
2002). The adoptive transfer of CMV-reactive IFN-γ secreting cells has been 
demonstrated in clinical practice (Feuchtinger et al, 2010; Peggs et al, 2011). We used 
the ‘gamma catch’ strategy in the pre-emptive and prophylactic treatment of CMV 
infection in 18 patients who received a dose of 1 x10
4
 CD3+ T cells/kg which contained 
both CD4+and CD8+ T cells with a median of 43.9% IFN-γ secreting cells (Peggs et al, 
2011). Expansions in both CD4+ and CD8+ CMV-specific T cells was observed in 17 
patients within 2 weeks of transfer and offered protection from re-infection in the 
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majority of patients. Both strategies of direct selection are considered methodologies 
that allow widespread application of CMV-T immunotherapy due to their relative 
simplicity compared to T cell lines and T cell clones. 
 
1.5.4.5 TCR-Transgenic T cells  
 
The genetic modification of T cells using CMV-specific TCRs is an appealing strategy 
for adoptive transfer, but has yet to be translated into the clinic. TCR gene therapy for 
CMV is particularly promising when there is not the possibility of manufacturing CMV-
specific T cells using the methods already described above. This occurs mainly when 
the HSCT donor is CMV-seronegative and the recipient CMV-seropositive and 
therefore at risk to develop severe CMV-related disease. The manufacture of CMV-
specific TCRs involves the generation of CMV-specific T cell clones, before cloning 
retroviral vectors containing the CMV-specific TCR chain genes and subsequent 
retroviral TCR transfer into TCRαß-deficient cells. Several groups (Heemskerk et al, 
2007; van Lent et al, 2007; Schub et al, 2009) have explored this method of generation 
as a means for adoptive transfer and the first clinical trial is currently underway. 
 
1.5.5 Identification of anti-viral T cells through activation markers 
 
Identification of antigen specific T cells has also been attempted through the use of 
activation markers that are up-regulated after T cell activation. T cell activation markers 
offer an increased sensitivity over approaches such as IFN-γ secretion as they are 
independent of cytokine secretion and therefore could lead to the isolation of antigen-
specific T cells with an increased repertoire. Several T cell activation markers have been 
identified with differing temporal dynamics that allow for simultaneous detection and 
enrichment. 
 
1.5.5.1 CD25 
 
CD25 is the IL-2α receptor and its expression is a prerequisite for T cell proliferation. 
Cross linking of the antigen specific TCR is a key signal for CD25 expression, which 
makes it a potential target for the selection of CMV-T. It has been previously 
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demonstrated that virus-specific T cells can be purified through CD25 selection after 
peptide stimulation (Gallot et al, 2001) which also make CD25 a promising candidate 
for the generation of CMV-T. Identification of antigen-specific T cells through CD25 
expression can be confounded by the similar CD25 expression pattern exhibited by 
regulatory T cells (Tregs). Tregs are a subset of CD4+ T cells that are suppressive in 
nature and regulate responses towards tumour, foreign and allo-antigens that 
constitutively express CD25 (Sakaguchi et al, 1995; Sakaguchi, 2004). The 
transcription factor forkhead box P3 (FoxP3) has also been identified to play a role in 
the development and function of Tregs and is also used as a phenotypic marker of Tregs 
(Fontenot et al, 2003). Some groups have explored the removal of CD4+ CD25+ Tregs 
from starting populations to augment selectivity of antigen-specific T cells for adoptive 
immunotherapy (Powell, Jr. et al, 2005). However, it has also been demonstrated that 
the removal of this subset has an unpredictable impact on the yield of CMV-T after 
stimulation (Melenhorst et al, 2008a). CD25 has also been used as a target for the 
generation of multi-virus specific T cells to good manufacturing practice (GMP) grade 
(Lugthart et al, 2012). In this study, a proportion of CD25 enriched cells also expressed 
FoxP3 and were capable of suppressing T cell proliferation, demonstrating the presence 
of a functional subset of Tregs. 
 
1.5.5.2 CD69 
 
Although not directly shown to be a marker for the isolation of virus-specific T cells, 
CD69 offers itself as a prospective target for their enrichment due to its association as 
an early activation marker on T cells. CD69 is expressed as early as 2 hours post 
mitogenic stimulation, but is almost undetectable on resting T cells (Craston et al, 
1997). CD69 has also been used to detect antigen specific T cells following tetanus 
toxoid stimulation after as much as 48 hours (Mardiney, III et al, 1996) and at an 
optimal time point of 16 hours when stimulating with the superantigen Staphylococcal 
enterotoxin B (SEB) (Lindsey et al, 2007). 
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1.5.5.3 CD107a 
 
CD107a, also known as lysosomal associated membrane protein 1 (LAMP-1), is a 
vesicle membrane protein that becomes transiently mobilised to the cell surface during 
the process of cell killing in effector T cells. CD107a mobilisation has been 
demonstrated to be a viable marker for identifying antigen specific cells by flow 
cytometry (Betts et al, 2003) and has since been used to enrich a subset of EBV-specific 
T cells (Moor et al, 2007). Moor and colleagues were able to isolate CD8+ EBV-
specific T cells using CD107a mobilisation after 5-hour peptide stimulation and 
subsequent cell sorting. Sorted cells were also capable of in vitro expansion. The 
CD107a methodology requires stimulation of PBMCs in the presence of monensin to 
maintain CD107a surface expression. However, one limitation described by Moor and 
colleagues is that monensin compromises cell viability, which could be a drawback 
when trying to culture virus-specific T cells at numbers large enough for use as an 
immunotherapy. CD107a mobilisation has also been used to identify and isolate tumour 
specific T cells directed towards the melanoma antigen recognized by T cells (MART) 
or gp100. This allows for the generation of CD8+ T cell clones in short term culture 
(Rubio et al, 2003), demonstrating the potential of CD107a mobilisation in 
manufacturing cells for adoptive transfer.  
 
1.5.5.4 CD137 
 
CD137, also referred to as 4-1BB, is a member of the tumour necrosis factor (TNF) 
receptor superfamily and has been shown to have a low baseline expression level on 
resting T cells, is transiently upregulated on specific CD8+ T cells following alloantigen 
stimulation and is a target for selective allodepletion (Wehler et al, 2007). CD137 was 
subsequently shown to allow both identification and isolation of CD8+ T cells specific 
for both the Wilms tumour antigen 1 (WT-1) (Wolfl et al, 2007) which is overexpressed 
in various malignancies and also the HLA-A24-resticted CMVpp65 epitope (Watanabe 
et al, 2008). Both findings highlighted the potential for CD137 to act as a tool for the 
generation of T cell immunotherapies for adoptive transfer. Wehler and colleagues 
extended their findings, and also complemented the work of Watanbe and Wolf by 
demonstrating that CD137 is upregulated on both CD4+ and CD8+ T cells in response 
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to both CMV and EBV peptide antigens, allowing for the detection and enrichment of 
virus-specific T cells (Wehler et al, 2008).  
 
1.5.5.5 CD154 
 
CD154, otherwise known as CD40 ligand, binds to CD40 on B cells delivering 
activating signals and is transiently expressed on activated CD4+ T cells and to a lesser 
extent on CD8+ T cells after antigenic stimulation. CD154 has been shown to identify 
pathogen-specific T cells because of its high specificity and sensitivity (Chattopadhyay 
et al, 2005; Frentsch et al, 2005; Lane et al, 1992). Frentsch and colleagues showed that 
CD154 expression could be preserved at the cell surface after CMVpp65 stimulation 
through the addition of a CD40-specific blocking monoclonal antibody which allows 
direct access to CMV-T. More recently CD154 has been used as an activation marker 
for the generation of multi-pathogen specific T cells, including CMV that were cultured 
over 14 days and gave rise to both CD4+ and CD8+ T cell lines (Khanna et al, 2011). 
 
1.6 Granulocyte colony stimulating factor (G-CSF) 
 
Models of the generation of anti-viral T cell immunotherapies for clinical use have 
focused primarily on using PBMCs collected by leukapheresis from the original HSCT 
donor. The prospect of manufacturing anti-viral T cells from an aliquot of the original 
HSCT graft as an alternative PBMC source has yet to be investigated. HSC are 
mobilised from the bone marrow into the periphery through the administration of the G-
CSF. G-CSF is produced mainly by cells of monocyte/macrophage origin and binds to 
its receptor on precursor cells in the bone marrow, thereby initiating the proliferation 
and differentiation of HSCs into mature granulocytes. Thus, recombinant human G-CSF 
has been used clinically to accelerate neutrophil reconstitution following radiation or 
chemotherapy where myelosuppression occurs.  
  
1.6.1 G-CSF Mobilisation 
 
The early 1990s saw the first report of HSCs collected after G-CSF administration and 
used for allogeneic transplantation (Russell et al, 1993; Dreger et al, 1993). This was 
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followed by the first detailed publications confirming the feasibility of this approach 
(Schmitz et al, 1998). The use of G-CSF for HSC mobilisation is now widespread and 
has been adopted as an international standard. The recommended optimal dose of G-
CSF is 10µg/kg/day for five to six days followed by apheresis, which enables the 
collection of large numbers of CD34+ HSCs, significantly more than is achievable 
when harvesting bone marrow (Russell et al, 1996) . G-CSF is also used in combination 
with cylcophosphamide for the collection of HSCs used for autologous HSCT. The 
increase in numbers of CD34+ cells in PBSC grafts is considered to be the driving force 
behind the significantly faster engraftment of both neutrophils and platelets that is 
observed when using PBSCs compared to bone marrow, as described by Schmitz and 
colleagues. G-CSF mobilisation is associated with a significantly higher number of 
circulating lymphocytes (Hartung et al, 1999; Rutella et al, 1997; Sica et al, 1996) when 
compared to bone marrow harvests, and yet in several randomised studies the risk of 
acute GvHD grades II-IV were similar between PBSCs and bone marrow.  
 
1.6.2 Haematological effects of G-CSF  
 
G-CSF mobilisation is associated with a significantly higher number of circulating 
lymphocytes.(Hartung et al, 1999; Rutella et al, 1997; Sica et al, 1996)  Murine and 
human studies have suggested that G-CSF mobilisation induces alterations in the 
potential for type 1 cytokine production by T cells, through inhibition of secretion at a 
single cell level as well as reducing the fraction of cytokine secreting cells in the 
periphery (Tayebi et al, 2001; Arpinati et al, 2000; Pan et al, 1999). In contrast, it has 
been reported that the use of DLI obtained following G-CSF mobilisation for the 
treatment of relapse in advance myeloid malignancy compares favourably with other 
treatment approaches (Levine et al, 2002). This argues for maintenance of a GvL effect 
from within the lymphocyte population. What remains unclear is whether the anti-viral 
response in G-CSF mobilised PBMCs is retained. 
 
1.6.3 Mechanisms of stem cell mobilisation 
 
Successful mobilisation of HSCs from the bone marrow into the periphery requires the 
disruption of adhesion interaction in the bone marrow that keeps HSCs anchored to 
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bone marrow stromal cells. One of the many adhesion interactions that occurs within 
the bone marrow is the integrin very late antigen-4 (VLA-4) on the surface of HSCs 
which binds to its ligand vascular cell adhesion molecule-1 (VCAM-1) expressed by 
stromal cells. The disruption of this interaction through the use of anti-VLA-4 
antibodies prevents adhesion and promotes HSCs mobilisation (Papayannopoulou, 
2000). Furthermore, mobilised CD34+ HSCs have lower levels of VLA-4 compared 
with bone marrow HSCs (Graf et al, 2001). Another key interaction that influences 
mobilisation is that of the stromal derived factor-1 (SDF-1) with its receptor the 
chemokine receptor 4 (CXCR4). Disruption of this chemotactic interaction in the bone 
marrow during G-CSF mobilisation is induced through the cleavage of the N-terminus 
of CXCR4 on HSCs which results in the loss of chemotaxis in response to SDF-1, 
allowing HSC mobilisation into the periphery (Levesque et al, 2003). Just as with VLA-
4, mobilised CD34+ HSCs also express reduced levels of CXCR4, which correlates 
with improved mobilisation (Gazitt & Liu, 2001). The result of G-CSF mobilisation is a 
generalised peripheralisation of many different types of blood cells, including T cells, 
monocytes and neutrophils. 
 
1.7 Aims of This Thesis 
 
Infectious complications arising from CMV reactivation following HSCT is a 
significant cause of morbidity and mortality. A therapeutic option has been the 
manufacture of CMV-T for adoptive immunotherapy and proof of principle has been 
demonstrated in a small number of Phase I/II studies that vary in the CD4+ and CD8+ T 
cell content, and has been widely discussed in this chapter. To date, models for 
manufacturing CMV-T have focused on the use of PBMC collected after steady-state 
leukapheresis and from a single blood draw. In the case of related donors, procuring a 
second leukapheresate for CMV-T generation is inconvenient to the donor and is 
associated with some level of pain and discomfort. Obtaining a second apheresate from 
unrelated donors has proven more difficult, either due to donor refusal, registry refusal 
or simply scheduling difficulties. The aims of this thesis are to determine the feasibility 
of using an aliquot of the original HSCT obtained by leukapheresis after mobilisation by 
G-CSF as an alternative PBMC source for CMV-T generation. If this approach proves 
viable, a further aim is to investigate alternative methods of isolation of CMV-T using 
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activation-dependent expression of cell surface receptors and to determine their 
specificity and cytotoxicity after expansion in short term culture. The approach of using 
G-CSF mobilised PBMC for CMV-T generation will be directly compared to 
conventional non-mobilised PBMC to ascertain the feasibility of this methodology. 
 
1.7.1 Summary of Aims 
  
1. To examine the kinetics of CMV-induced expression of established activation 
markers and cytokine secretion in G-CSF mobilised PBMCs in response to 
CMV peptide stimulation compared with non-mobilised PBMCs. 
 
2. To test the hypothesis that CMV-reactive T cells can be isolated from  
G-CSF mobilised PBMCs through activation-induced antigen expression and 
compare to conventional methods using non-mobilised PBMCs. 
 
3. To expand CMV-reactive T cells isolated from G-CSF mobilised PBMCs in 
short term culture and demonstrate specificity through antigenic  
re-challenge. 
 
4. To demonstrate effective cytotoxicity of expanded CMV-reactive T cells from 
G-CSF mobilised PBMCs and compare with conventional non-mobilised 
expanded CMV-reactive T cells 
 
5. To develop a GMP compliant, clinical scale system for the isolation of 
functional CMV-reactive T cells from G-CSF mobilised PBMCs for the 
treatment of CMV disease post allogeneic HSCT. 
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Chapter 2  
 
General Materials and Methods 
 
2.1 Blood Donors 
 
Fresh blood samples were obtained from leukapheresis collections from both G-CSF 
mobilised and non-mobilised CMV-seropositive healthy donors, after a 3–5 hour 
collection on the COBE Spectra apheresis system (CardianBCT). This was performed 
on the Haematology Day Care Unit at The Royal Free Hospital, London. G-CSF 
(Filgrastim, Amgen) was administered over 4 days at a dose of 10µg/kg prior to HSC 
donation. Informed consent was obtained in accordance with the Declaration of Helsinki 
and the study was approved by the Royal Free NHS Trust Research and Development 
review board. Blood samples (500µl) were taken directly from the collection bags using 
needle and syringe by staff in the Laboratory of Cellular Therapeutics (LCT) at The 
Royal Free Hospital, London, and were aliquoted into 5ml tubes (Sterilin). In some 
cases, blood sample volumes of up to 10ml, obtained from non-mobilised leukapheresis 
collections that were due for discard, were dispensed into 50ml tubes (Nunc).  
 
2.2 Cell Culture Medium 
 
All cell cultures were performed in complete medium (CM) which consisted of Roswell 
Park Memorial Institute medium with L-glutamine (RPMI 1640, Life Technologies) 
supplemented with 10% human AB serum (Biosera) and 1% antibiotic (Life 
Technologies). For cultures involving the short term expansion of CMV-reactive T 
cells, complete medium was supplemented with 10ng/ml of IL-7 and 10ng/ml of IL-15 
(Cell Genix).  
 
2.3 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) 
 
Samples were transferred to 50ml tubes and diluted in Hank’s Balanced Salt Solution 
(HBSS, Life Technologies) to a volume of 50ml. PBMCs were isolated by 
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discontinuous density gradient separation. Diluted blood samples were layered onto an 
equal volume of Lymphoprep (Axis Shield Diagnostics) in 50ml tubes and centrifuged 
at 400g for 25 minutes at room temperature with no brake. PBMCs recovered at the 
interface using a sterile Pasteur pipette were transferred into new 50ml tubes, diluted to 
50ml with HBSS and centrifuged at room temperature for 10 minutes at 400g. The 
supernatant was discarded and the cell pellet gently disrupted using a sterile Pasteur 
pipette in 1-2ml of HBSS. The cell suspension was then diluted to 50ml in HBSS and 
centrifuged at 200g for 10 minutes at room temperature. The supernatant was discarded 
and the cell pellet resuspended in complete medium. 
 
2.4 Cell Counting and Viability Assessment 
 
A 10µl aliquot of PBMCs suspension was mixed with 10µl of 0.4% Trypan Blue 
solution (Sigma-Aldrich) and loaded onto a haemocytometer counting chamber 
(Hawksley). Cells were counted using a phase contrast microscope and the number of 
PBMCs determined, excluding non-viable cells that were blue in appearance. The 
number of cells in the central 25 squares were counted and the PBMCs concentration 
(x10
6
/ml) calculated by multiplying the total number of cells by 10,000. 
 
2.5 Cryopreservation of PBMCs 
 
For cryopreservation of PBMCs, cells were bought to a maximum concentration of 2 x 
10
7
/ml in complete medium and bought to 4°C by leaving on ice. Freezing medium was 
made up with 80% of 4.5% human serum albumin (HSA), (Bio Products Laboratory) 
and 20% dimethylsufoxide (DMSO, Wak Chemie). The cryopreserving solution was 
mixed drop by drop under mild agitation to an equal volume of cells, up to a maximum 
total volume of 1.5ml in Cryo-vials (Nunc) and placed in isoproponol freezing 
containers (Mr Frosty, Nalgene) at –80°C for 24 hours. The vials were then transferred 
for storage in liquid nitrogen at –196°C. 
 
For recovery of cryopreserved PBMCs, samples were removed from liquid nitrogen and 
transferred on ice to a 37°C waterbath. Vials were immersed halfway and gently 
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agitated to facilitate rapid thawing. Once the vial was partially thawed, samples were 
pipetted into a 20ml tube and pre-warmed complete medium at 37°C was added to the 
cells in a drop wise fashion, whilst gently swirling the tube. Cells were centrifuged at 
200g for 10 minutes at room temperature, resuspended in complete medium and 
centrifuged for a second time at 200g for 10 minutes. The final cell pellet was gently 
disrupted using a sterile Pasteur pipette in 1–2ml of complete medium for counting and 
cell viability assessment. 
 
2.6 In vitro Stimulation of PBMCs 
 
PBMCs isolated from G-CSF mobilised and non-mobilised donors were adjusted to a 
concentration of 1 x 10
7
/ml in complete medium and stimulations performed in either 6-
well plates (Nunc) with 5–6ml per well or 96-well plates (Nunc) with 150–200µl per 
well for between 1 and 24 hours at 37°C/5% CO2 dependent upon the experiment. 
PBMCs were stimulated with a CMVpp65 peptide pool, consisting mainly of 15-mer 
sequences with an 11 amino acid overlap spanning the entire pp65 protein of the human 
CMV AD169 strain (CMVpp65 Peptivator, Miltenyi Biotec). The stock concentration 
of CMVpp65 Peptivator was 30nmol (approximately 50µg) of each peptide per ml, with 
20µl added per ml of cell suspension, giving a final concentration in all cultures of 
0.6nmol (approximately 1µg) of each peptide per ml. In time course experiments, 
PBMCs were also stimulated with the superantigen Staphylococcus Enterotoxin B 
Fragment (SEB, Sigma-Aldrich) as a positive control. The stock concentration of SEB 
was at 1mg/ml, with 1µl/ml added to the cell suspension, giving a final concentration of 
1µg/ml. 
 
 
Chapter 2 
57 
 
2.7 Flow Cytometry 
 
2.7.1 Protocols for Antibody Cell Surface Staining of PBMC 
 
Cell surface staining of PBMCs was carried out in 12x75mm polystyrene tubes 
(Sarstedt). A total of 10
5
 cells were routinely used in a final volume of 100µl of HBSS. 
Between 2–5µl of fluorochrome conjugated antibodies were added to PBMCs (titration 
experiments confirmed adequate cell labelling) and incubated in the dark at room 
temperature for 10 minutes. Cells were then diluted in 2ml of HBSS and centrifuged at 
300g for 5 minutes at room temperature, and the cell pellet was resuspended in 
approximately 300µl of FACS Flow (Becton Dickenson). Samples were kept at 4°C and 
acquired within 8 hours of staining on a FACScan (Becton Dickenson/Cytek) using 
CellQuest Pro software for up to 5 parameters or on the MACSQuant (Miltenyi Biotec) 
for up to 8 parameters. A minimum of 50,000 CD3+ events were acquired after gating 
of viable cells using forward scatter (FSC) vs. side scatter (SSC) signals and data 
analysed using FlowJo v7.6 software (TreeStar). Appropriate controls matched for 
isotype, fluorochrome and manufacturer, as well as single stained and unstained 
samples were used to set voltages and compensation.  
 
Monoclonal antibodies used were conjugated to the following fluorochromes: 
1. Fluorescein isothiocyanate (FITC) 
2. Phycoerythrin (PE) 
3. Peridinin Chlorophyll Protein (PerCP) 
4. Phycoerythrin Cyanine-7 (PE Cy7) 
5. Peridinin Chlorophyll Protein Cyanine-5.5 (Percp Cy 5.5) 
6. Allophycocyanin (APC) 
7. Allophycocyanin Cyanine-7 (APC Cy7) 
8. VioBlue 
 
A summary of all monoclonal antibodies and their conjugates used in this study is 
shown in Table 2.1. 
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Monoclonal 
Antibody 
Fluorochrome Clone Manufacturer Catalogue 
Number 
 
CD3 
 
FITC 
 
SK7 
 
BD 
 
345763 
CD3 APC SK7 BD 345767 
CD4 PE-Cy7 SK3 BD 557852 
CD4 APC-Cy7 RPA-T4 BD 557871 
CD4 PerCP SK3 BD 345770 
CD4 FITC RPA-T4 BD 555346 
CD8 PerCP SK1 BD 345772 
CD8 FITC SK1 BD 345772 
CD25 PE M-A251 BD 555732 
CD25 PE 4E3 Miltenyi  Biotec 130-091-024 
CD25 APC-Cy7 M-A251 BD 560225 
CD25 FITC M-A251 BD 560990 
CD28 PerCP-Cy5.5 L293 BD 337181 
CD45RA FITC L48 BD 335039 
CD45RA V450 H100 BD 560362 
CD57 VioBlue TB03 Miltenyi Biotec 130-096-530 
CD69 PE FN50 BD 555531 
CD69 APC-Cy7 FN50 BD 557756 
CD137 PE 4B4-1 BD 555956 
CD152 PE BNI3 BD 555853 
CD154 PE TRAP1 BD 555700 
CD154 APC TRAP1 BD 560995 
CCR7 PE-Cy7 3d12 BD 557648 
FoxP3 Alexa 488 259D/C7 BD 560047 
IL-2 PE M01-17H12 BD 560902 
IL-10 PE JES3-19F1 BD 559330 
IFN-γ PE 25723.11 BD 340452 
IFN-γ PE 45-15 Miltenyi Biotec 130-091-653 
TNF-α PE 6401.111 BD 340512 
Granzyme B PE GB11 BD 561142 
CD178 APC NOK-1 Miltenyi Biotec 130-096-458 
HLA DR FITC L243 BD 555811 
Mouse IgG1 PE G18-145 BD 555787 
Mouse IgG1 FITC X40 BD 345815 
Mouse IgG1 
 
APC-Cy7 
 
X40 
 
BD 
 
348812 
 
 
Table 2.1 Summary of monoclonal antibodies 
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2.7.2 Basic Gating Strategy for Flow Cytometric Analysis 
 
A FSC versus SSC dot plot was always created for each sample and a gate drawn 
around the area of live lymphocytes. The live lymphocyte gate was projected onto a 
second dot plot of CD3 versus SSC and a second gate drawn to identify CD3+ T cells. 
For the assessment of activation markers (e.g. CD25) on CD3+ subsets, a new dot plot 
was constructed against CD4 or CD8 as illustrated in Figure 2.1. In some experiments a 
gate was drawn around the population of cells expressing the activation marker to 
construct a dot plot of CD45RA versus CCR7 for the assessment of memory phenotype 
using a quadrant gate. 
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Figure 2.1 Example of gating strategy used to calculate the frequency of antigen 
specific CD4+ T cells  
The frequency of CD154+ CD4+ cells is shown in the upper right quadrant of the 
bottom dot plot and is derived from the live lymphocyte gate (R1) in the FSC versus 
SSC dot plot and CD3+ T cells (R2) from the CD3 versus SSC dot plot.   
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2.8 TH1/TH2 Cytokine Analysis by Cytometric Bead Array 
 (CBA) 
 
The cytometric bead array (CBA, Becton Dickenson) is a flow cytometry based assay 
that allows the detection of six bead populations with distinct fluorescence intensities 
that have been coated with capture antibodies specific for IL-2, IL-4, IL-10, TNF and 
IFN-γ proteins (Figure 2.2). The six bead populations are mixed together to form the 
CBA that is resolved in the red channel (i.e. FL3 or FL4) of a flow cytometer, after 
labelling with PE-conjugated detection antibodies and then incubated with test samples 
or recombinant samples to form sandwich complexes. 
 
Figure 2.2 Histogram of the cytokine bead populations: 
The six cytokine bead populations are resolved in FL4 after gating on the bead 
population using a FSC versus SSC dot plot. 
 
Supernatants were collected from CMVpp65 stimulated and unstimulated cultures at 16 
hours from both G-CSF mobilised and non-mobilised donors and subsequently stored at 
–80°C. At the time of analysis, the cytokine bead standards were reconstituted with 2ml 
of assay diluent (top standard) in a 15ml conical tube (Becton Dickenson) and allowed 
to equilibrate for 15 minutes. Serial dilutions (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:32, 1:128 
and 1:256) of the reconstituted bead standard (500 pg/ml) were carried out with assay 
diluent (Becton Dickinson). A tube with assay diluent served as the negative control. A 
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10µl aliquot of each of the six capture beads was pooled into a single tube to prepare 
mixed capture beads. A 50µl aliquot of mixed capture beads was mixed with 50µl of PE 
detection reagent and either 50µl of thawed supernatant or 50µl of the cytokine standard 
dilutions. Assay tubes were incubated for 3 hours, washed in 1ml of wash buffer (All 
Becton Dickinson) and centrifuged at 200g for 5 minutes. The supernatant was removed 
and the bead pellet resuspended in 300µl of wash buffer. Samples were analysed on a 
FACS Aria (Becton Dickenson) flow cytometer with 3000 bead events acquired using a 
FSC versus SSC dot plot and data analysed using FCAP Array version 1.0.1 (SoftFlow, 
Inc). A standard curve was created for each cytokine using the mean fluorescence 
intensity (MFI) from each bead standard and the concentration of cytokine (pg/ml) for 
each test sample calculated (Figure 2.3). Representative FACS plots of cytokine 
standards used to construct the standard curves are shown in Figure 2.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
63 
 
 
 
Figure 2.3 Standard Curves constructed to quantify cytokine concentration 
(pg/ml) in CMVpp65 stimulated G-CSF mobilised and non-mobilised PBMCs 
 
 
 
 
Figure 2.4 Cytometric Bead Array (CBA) Assay Standards 
Representative FACS plots of 4 cytokine standards from one experiment used to construct the 
standard curves. 
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2.9 Time course Assay 
 
Activation induced expression of cell surface antigen was assessed in a 24 hour time 
course assay. PBMCs were plated in 96-well flat bottom plates at a concentration of 10 
x 10
6
/ml (200µl/well) and stimulated with either CMVpp65 peptides, SEB or left 
untouched. Samples were removed at 1, 4, 6, 16 and 24 hours, centrifuged in 2ml of 
HBSS at 300g for 5 minutes, the supernatant removed and cell pellets resuspended in 
600µl of HBSS. Cells were stained with CD3-APC, CD4-FITC, CD8-PerCP and either 
CD25-PE, CD69-PE, CD137-PE, CD152-PE, CD154-PE or Mouse IgG-PE (all BD 
Biosciences) and analysed on the BD/Cytek FACScan flow cytometer. 
 
In some experiments PBMCs were stimulated for 4 and 6 hours in the presence and 
absence of 1µg/ml of purified anti-CD40 antibody (Clone G28.5; BioLegend) and 
samples stained as described but with only CD154-PE or Mouse IgG1-PE antibodies. 
As a control, PBMCs were left untouched and incubated with anti-CD40 alone. 
 
2.10 Magnetic Bead Cell Sorting  
 
Sterile cell sorting was performed using MACS technology (Miltenyi Biotec) that is 
based on three components. The first component is microbeads which are 50nm 
superparamagnetic particles conjugated with monoclonal mouse anti-PE antibodies 
(anti-PE microbeads) or conjugated to a monoclonal antibody against a particular 
antigen on the cell surface. The second component are columns, which contain a matrix 
composed of ferromagnetic spheres. The third component, cell separators, which are 
strong permanent magnets, cause the spheres in the columns to amplify the magnetic 
field by 10,000-fold and allow for labelled cells to be held in suspension on the column 
and unlabelled cells to flow through the column. 
 
2.10.1 Enrichment using Anti-PE Microbeads 
 
For positive selection, cells were stained in 15ml conical tubes with 10µl of PE-
conjugated monoclonal antibody/10
7 
total cells after resuspending the cell pellet at a 
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concentration of 10
7
 cells/100µl of CliniMACS PBS/EDTA buffer (Miltenyi Biotec) 
and incubating for 10 minutes at 4–8°C in the dark. Cells were diluted to 15ml with 
CliniMACS buffer and centrifuged at 300g for 10 minutes at room temparature. The 
supernatant was removed and the cell pellet resuspended at 10
7
 cells/80µl in 
CliniMACS buffer, labelled with 20µl anti-PE Microbeads/10
7
 cells and incubated for 
15 minutes at 4–8°C in the dark. Cells were diluted to 15ml with CliniMACS buffer, 
centrifuged at 300g for 10 minutes at room temparature, the supernatant removed and 
the cell pellet resuspended in 500µl of CliniMACS buffer. MS columns were used for 
positive selection, which have the capacity for enrichment of 1 x 10
7
 labelled cells from 
up to 2 x 10
8
 total cells. The column was placed in the magnetic field of a MiniMACS 
separator and the column rinsed with 500µl of CliniMACS buffer. The cell suspension 
was then applied to the column and the unlabelled fraction collected in sterile 
polystyrene 12x75mm tubes (Becton Dickenson). The column was washed three times 
with 500µl of CliniMACS buffer. Once the column reservoir was empty the column 
was removed from the MiniMACS separator and the column flushed with 1ml of 
CliniMACS buffer and the positive fraction collected in sterile polystyrene 12x75mm 
tubes. 
 
2.10.2 Separation using CD25-Microbeads 
 
CD25-Microbeads (Miltenyi Biotec) were used for both the isolation and depletion of 
CD25+ cells dependent upon the experiment being performed. For depletion of CD25 
expressing cells, cell pellets were resuspended in 10
7
 cells/80µl of CliniMACS buffer, 
labelled with CD25-Microbeads at 10
7
 cells/20µl and incubated at 4–8°C in the dark for 
15 minutes. Cells were diluted in 15ml of CliniMACS buffer, centrifuged at 300g for 10 
minutes at room temperature, the supernatant removed and the cell pellet resuspended in 
500µl of CliniMACS buffer. LD columns were used for depletion, which have the 
capacity for depletion of up to 1 x 10
8
 labelled cells from up to 5 x 10
8 
total cells. LD 
columns were placed in the magnetic field of a VarioMACS separator and the column 
rinsed with 2ml of CliniMACS buffer. The cell suspension was applied to the column 
and the unlabelled cells collected into 15ml round bottom tubes. The column was 
washed twice with 1ml of CliniMACS buffer. In some experiments, the CD25-positive 
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fraction was retrieved by removing the column from the separator and flushing with 1ml 
of CliniMACS buffer before collection into 15ml round bottom tubes. 
For positive selection of CD25 expressing cells, cell pellets were resuspended in 10
7
 
cells/90µl of CliniMACS buffer, labelled with CD25-microbeads at 10
7
 cells/10µl and 
incubated at 4–8°C in the dark for 15 minutes. Cells were diluted in 15ml of 
CliniMACS buffer, centrifuged at 300g for 10 minutes at room temperature, the 
supernatant removed and the cell pellet resuspended in 500µl of CliniMACS buffer. MS 
columns were used for positive selection on the MiniMACS separator as previously 
described. 
 
2.11 IFN-γ Secretion Assay 
 
In principle the IFN-γ secretion assay (Miltenyi Biotec) allows for the detection and 
isolation of antigen-specific T cells after short term stimulation. PBMCs are labelled 
with a catch reagent, a bi-specific antibody that binds to CD45 on all leukocytes and is 
specific for IFN-γ. After a short incubation period, secreted IFN-γ binds to the catch 
reagent and can be detected with a second IFN-γ specific antibody that is conjugated to 
PE, allowing detection by flow cytometry (Figure 2.3). IFN-γ secreting cells can then be 
labelled with using Anti-PE Microbeads and enriched using MS columns placed on a 
MiniMACS separator. 
 
Up to 50 x 10
6
 PBMCs, at a concentration of 10 x 10
6
/ml,
 
were stimulated with 
CMVpp65 peptides or left untouched as a negative control and were incubated in 6-well 
plates for 16 hours at 37°C/5% CO2. PBMCs were washed in cold CliniMACS buffer 
and centrifuged at 300g for 10 minutes at 4–8°C. The supernatant was removed and the 
cell pellet resuspended in 10
7 
cells/80µl of cold complete medium and then incubated 
with 10
7
 cells/20µl of IFN-γ catch reagent on ice for 5 minutes. Cells were diluted to a 
concentration of 1 x 10
6
/ml with culture medium pre-warmed to 37°C and incubated for 
45 minutes at 37°C/5% CO2 under slow rotation using a MACSMix (Miltenyi Biotec) to 
allow IFN-γ secretion. Cells were then washed with cold CliniMACS buffer and 
centrifuged at 300g for 10 minutes at 4–8°C, the supernatant removed and the cell pellet 
resuspended in 10
7 
cells/80µl of cold CliniMACS buffer and then incubated with 10
7
 
cells/20µl of IFN-γ PE Detection Antibody on ice for 10 minutes. Cells were washed 
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once more with cold CliniMACS buffer and centrifuged at 300g for 10 minutes at 4–
8°C, the supernatant removed and the cell pellet resuspended in 10
7 
cells/80µl of cold 
CliniMACS buffer and then incubated with 10
7
 cells/20µl of Anti-PE Microbeads at 4–
8°C for 15 minutes. Cells were then washed in cold CliniMACS buffer and centrifuged 
at 300g for 10 minutes at 4–8°C, the supernatant removed and the cell pellet 
resuspended in 500µl cold CliniMACS buffer. MS columns were used for positive 
selection on the MiniMACS separator as previously described. 
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IFN-γ Catch Matrix Reagent 
Cytokine Secretion and capture 
IFN-γ Enrichment Reagent 
 
 
Figure 2.5 The principle of the IFN-γ Secretion Assay (reproduced from Miltenyi 
Biotec) 
Following CMVpp65 
stimulation PBMCs are 
labelled with the catch 
reagent, a bi-specific 
antibody that binds to CD45 
and is specific for IFN-γ 
 
 
 
Antigen-specific T cells 
secrete cytokine during a 45 
minute incubation, where 
IFN-γ is captured on the cell 
surface 
 
 
 
 
 
Cells are labelled with a 
second antibody specific for 
IFN-γ and conjugated to PE 
to allow detection. Labelling 
with anti-PE microbeads 
allows for positive selection 
of IFN-γ secreting cells 
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2.12 Intracellular Antigen Staining 
 
The detection of intracellular antigens, such as cytokines, was performed using fixation 
and permeabilisation reagents (Intrastain, Dako Cytomation) that leaves the cellular 
structure, morphology scatter and cell surface immunoreactivity intact. Brefeldin A 
(Sigma-Aldrich) was added to PBMC cultures at a final concentration of 5µg/ml after 2 
hours to inhibit protein transport from the Golgi apparatus to the endoplasmic reticulum, 
leading to the accumulation of protein that can be detected by flow cytometry. 
 
PBMCs were adjusted to a concentration of 1 x 10
6
/ml and 100µl of the cell suspension 
was stained with 3-5µl of CD3-APC, CD4 or CD8-PerCP and CD69 APC-Cy7 
antibodies (all BD Biosciences) and incubated in the dark for 15 minutes. Samples were 
fixed with 100µl of Intrastain Reagent A and incubated at room temperature for 15 
minutes in the dark, then washed with 2ml of HBSS at 300g for 5 minutes at room 
temperature and the supernatant removed. The cell pellet was resuspended in the 
residual volume, 100µl of Intrastain Reagent B added for cell permeabilisation, and 5µl 
of IL-2 PE, IL-10 PE, TNF-α-PE, Granzyme B-PE (all BD Biosciences) or IFN-γ-PE 
(Miltenyi Biotec) added for intracellular staining. Cells were incubated for 15 minutes 
in the dark and washed as previously described. Cell pellets were resuspended in 
FACSFlow and samples acquired on the FACScan flow cytometer with a minimum of 
50,000 CD3+ events recorded. 
 
2.13 Identification of T regulatory cells by FoxP3 Staining 
 
PBMCs were diluted to a concentration of 10 x 10
6
/ml in HBSS for the intracellular 
staining of the transcription factor FoxP3 using a fixation and permeabilisation assay 
(BD Biosciences). Buffers were prepared according to manufacturer instructions, but in 
brief, FoxP3 Buffer A (10X concentrate) was diluted 1:10 with room temperature 
deionised water and a working solution of Buffer C was prepared by diluting FoxP3 
Buffer B into 1X Buffer A at a ratio of 1:50. Working buffers were stored at room 
temperature in the dark. In polystyrene tubes, 100µl of PBMCs (1 x 10
6
) were stained 
with 3µl of CD3-APC and 5µl of CD25-PE, CD4-APC Cy7 and CD8-PerCP (all BD 
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Biosciences) and incubated at room temperature in the dark for 20 minutes. Cells were 
washed in 2ml HBSS at 250g for 10 minutes at room temperature, the supernatant 
removed and the cell pellet resuspended in 2ml of the fixation buffer, FoxP3 Buffer A, 
and incubated at room temperature in the dark for 10 minutes. The cells were 
centrifuged at 500g for 5 minutes and the supernatant removed by pipette and washed 
again in 2ml of HBSS at 500g for 5 minutes at room temperature. The supernatant was 
then removed and the cell pellet resuspended in 0.5ml of permeabilisation buffer 
(FoxP3 Buffer C) and incubated for 30 minutes at room temperature in the dark. Cells 
were washed twice as previously described and 5µl of FoxP3-Alexa Fluor 488 (BD 
Biosciences) antibody added, the cell pellet resuspended and incubated for 30 minutes 
at room temperature in the dark. In control samples, 5µl of Mouse IgG1-FITC antibody 
was added. Post incubation, two wash steps were performed as previously described and 
the final cell pellet resuspended in 300µl of FACSFlow. Samples were acquired on the 
FACScan flow cytometer with a minimum of 50,000 CD4+ events recorded. 
 
2.14 CFSE Based Suppression Assay  
 
2.14.1 CFSE labelling 
 
The stable incorporation of the intracellular dye carboxyfluorecein diacetate 
succinimidyl ester (CFSE) into lymphocytes allows the in vitro monitoring of cell 
division, using flow cytometry, through the sequential halving of fluorescence as the 
dye is inherited by daughter cells after cell division (Figure 2.4). One 50µg vial of 
CFSE (CellTrace CFSE, Invitrogen) stored at –20°C was reconstituted in 18µl of 
DMSO (Invitrogen) to give a 5mM stock solution as per the manufacturer’s 
instructions. PBMCs for staining were adjusted to a concentration of 1 x 10
6
/ml in 
RPMI (Invitrogen) without serum, up to a maximum volume of 10ml in 20ml plastic 
tubes. PBMCs were labelled with 2µl of 5mM stock CFSE for a final working 
concentration of 1µM and incubated at 37°C for 10 minutes. Following incubation, 1ml 
of Human AB Serum was added, the cells incubated at 4–8°C for 5 minutes and then 
topped up with complete medium to 20ml and centrifuged at 300g for 10 minutes at 
room temperature. The supernatant was removed and the cell pellet resuspended in 
 
Chapter 2 
71 
 
20ml of complete medium, and centrifuged at 300g for 10 minutes at room temperature. 
The supernatant was removed and the cell pellet resuspended in 1ml of complete 
medium. An aliquot of the cell suspension was analysed using a FACScan flow 
cytometer for assessment of successful CFSE labelling. 
 
PBMCs are labelled with CFSE and subsequently stimulated with a T cell mitogen such 
as phytohaemagglutinin (PHA) or with a specific antigen. Cell division results in the 
halving of fluorescence in daughter cells which is detected by a decrease in signal 
observed in FL1 by flow cytometry (Figure 2.6). 
 
Figure 2.6 Principle of CFSE labelling to monitor cell proliferation 
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2.14.2 Suppression Assay 
 
The CFSE based suppression assay was used to compare the suppressive capacity of 
CMV-specific T cells (CMV-T), isolated through the activation marker CD25 after a 
16-hour stimulation with CMVpp65 peptides, and compared directly with conventional 
CD4+ CD25+ T regulatory cells. CFSE labelled responder PBMCs were cultured in 
round bottom 96-well plates (Nunc) at 2 x 10
4
 cells/well with 1 x 10
5
 irradiated 
autologous PBMCs as feeder cells. Depending on the number of effector cells available, 
CD4+ CD25+ and CD25+ CMV-T were added to the cultures at a ratio of 1:1 (2 x 10
4
 
cells/well) and 1:2.5 (5 x 10
4
 cells/well) of responders to effectors. Cell cultures were 
stimulated with 2µg/ml of purified anti-CD3 antibody (Clone HIT3a, BioLegend) or 
1µg/ml of SEB (Sigma-Aldrich). In control experiments, CFSE labelled and unlabelled 
PBMCs were cultured alone. Cultures were incubated for 5 days at 37°C/5% CO2 
before harvesting, and cells stained with CD3-APC and CD69-APC Cy7 antibodies 
(both BD Biosciences). Samples were acquired on the FACScan flow cytometer and a 
minimum of 5,000 CD3+ CFSE+ events recorded. The frequency of suppression was 
analysed by gating on the CFSE
low 
population determined by the CFSE labelled and 
unlabelled PBMC control samples, as shown in Figure 2.5. Suppression was defined as: 
[100 - (%CFSE
low
 of CD3+ in presence of effectors/%CFSE
low
 of CD3+ in absence of 
effectors) x 100] 
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   Figure 2.7 CD3+ T cell proliferation using CFSE labelling: 
   Strategy for gating of CFSE
low
 population to determine proliferation  
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2.15 γ-irradiation of Feeder Cells 
 
All feeder cells were exposed to a γ-irradiation dose of approximately 50Gy by 
irradiation for 10 minutes in a Gammacel 3000 ELAN irradiator (Nordion International 
Inc) which emits approximately 500 rads per minute (5Gy per minute). Cells were 
irradiated at a concentration of 1–3 x 106/ml in 20ml of complete medium in plastic 
tubes. 
 
2.16 CMV-specific T cell lines 
 
2.16.1 Expansion of CMV-specific T cell lines 
 
CMV-specific T cells isolated by magnetic bead enrichment through activation-
dependent expression of both CD25 and CD154 were expanded in short term culture 
and re-challenged with CMV peptides as outlined in Figure 2.6. Isolated cells were 
adjusted to a concentration of 0.25 x 10
6
/ml in complete medium, and 1ml of the cell 
suspension was cultured in the presence of 1ml of γ-irradiated autologous PBMCs at a 
concentration of 12.5 x 10
6
/ml (50:1) to act as feeder cells. Expansions were performed 
in 24-well plates (Nunc) at a final concentration of 6.37 x 10
6
/ml. Cultures were 
supplemented with IL-7 and IL-15 (Cell Genix) to final concentrations of 10ng/ml. 
Cultures were replenished with IL-7 and IL-15 every 2–3 days and split when cell 
counts were greater than 3 x 10
6
/ml.  Every 5–7 days, cultures were phenotyped for 
CD3-APC, CD4-FITC, CD8-PerCP, CD69 APC-Cy7 and either CD25-PE or CD154-
PE (all BD Biosciences) antibodies and samples acquired on the FACScan flow 
cytometer with a  minimum of 30,000 CD3+ events recorded. Cells were expanded up 
to a maximum of 23 days before harvesting. 
 
2.16.2 Re-stimulation of Expanded CMV-specific T cell lines 
 
Cryopreserved autologous PBMCs were thawed and washed as described in section 2.5 
before labelling with CFSE as outlined in section 2.11.1. Cells were resuspended at 3 x 
10
6
/ml and incubated at 37°C/5% CO2 in 24-well plates (2ml/well) for 16 hours in the 
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presence and absence of CMVpp65 peptides and CMV IE-1 peptides (PepMIX HCMV 
IE1, JPT) at 1µg of each peptide/ml. Following peptide loading, cells were washed in 
complete medium at 300g for 10 minutes at room temperature and resuspended at 10 x 
10
6
/ml. Expanded cells were harvested, centrifuged at 300g for 10 minutes at room 
temperature and resuspended at 10 x 10
6
/ml, and incubated with CFSE PBMCs with 
and without peptides at a ratio of 5:1 (loaded cells: expanded cells) in 48- well plates for 
5-6 hours. In some experiments where CFSE PBMCs numbers were low, the ratio was 
reduced to 2.5:1. For analysis of intracellular cytokines and antigens, cells were 
incubated in the presence of anti-CD28 antibody (BD Bioscience) for 2 hours, followed 
by the addition of 1µg/ml of Brefeldin A (Sigma-Aldrich). Cells were stained for 
intracellular antigens as described in section 2.9 and analysed by flow cytometry. The 
schematic in Figure 2.8 illustrates the method of expansion and re-challenge of CMV-T. 
Expanded cells were also stained for CD45RA-Vioblue, CCR7-PE Cy7, CD69 APC 
Cy7 and either CD154 or CD25 PE (all BD Biosciences) and CD57-Vioblue (Miltenyi 
Biotec) following re-challenge. 
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Figure 2.8 Schematic representation of the expansion and re-challenge of expanded CMV-T isolated through CD25 or CD154  
activation-dependent expression. ICS indicates intracellular cytokine staining 
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2.17 Calcein-AM Cytotoxicity Assay 
 
Target cells were labelled with a cell-permeant dye calcein-acetoxymethyl (Calcein-
AM, Invitrogen), that is converted to a green-fluorescent calcein after acetoxymethyl 
ester hydrolysis in live cells by intracellular esterases. Release of calcein into the 
supernatants from cytoxicity assays is measured by fluorimetry. 
  
2.17.1 Calcein-AM labelling of PHA Blasts  
 
Autologous PBMCs were thawed as described in section 2.5 and resuspended at a 
concentration of 1 x 10
6
/ml in complete medium. Cells were incubated at 37°C/5%CO2 
in 24-well plates (2ml/well) in the presence of 3µg/ml of PHA (Sigma) for 24 hours. 
After 24 hours, 20U/ml of IL-2 (Miltenyi Biotec) was added to each well and cultures 
incubated for a further 72 hours. PHA blasts were loaded with CMVpp65 peptides for 
16 hours or left untouched. Cells were harvested and resuspended at 1 x 10
6
/ml in 
phenol-red free RPMI (Invitrogen) supplemented with 10% Human AB serum and a 
maximum of 1 x 10
6
 cells labelled with Calcein-AM to a final concentration of 10µM 
and incubated for 1 hour at 37°C in a water bath. Cells were centrifuged at 400g for 5 
minutes at room temperature, the supernatant removed and the cell pellet resuspended in 
2ml of phenol-red free RPMI supplemented with 10% Human AB serum.  The wash 
procedure was repeated 5 times and cells resuspended in phenol-red free RPMI 
supplemented with 10% Human AB serum at a final concentration of 7 x 10
4
/ml. 
 
2.17.2 Cytotoxicity Assay 
 
Expanded CMV-T cells isolated through both CD25 and CD154 were used as effector 
cells. After harvesting, cells were washed in 2ml of phenol-red free RPMI 
supplemented with 10% Human AB serum at 400g for 5 minutes at room temperature 
and resuspended in medium at a concentration of 1.4 x 10
6
/ml. The Calcein-AM killing 
assay was set up in triplicate with effector:target ratios of 20:1, 10:1, 5:1, 2.5:1 and 
0.5:1 in round bottom 96-well plates (Corning). A minimum of 7 x 10
3
 Calcein-AM-
labelled target cells were added to all effector cells, plates centrifuged at 400g for 5 
minutes at room temperature and incubated for 4–5 hours at 37°C/5% CO2. In some 
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experiments, Calcein-AM-labelled targets loaded with CMVpp65 peptides were 
incubated with either purified anti-HLA ABC (eBioscience) or purified anti-HLA DP 
DQ DR antibodies (AbD Serotec). Briefly, 0.5 x 10
6
 cells in 100µl of medium were 
incubated with 10µg/ml of anti-HLA ABC or anti-HLA DP DQ DR for 15 minutes at 
room temperature in the dark, centrifuged in 2ml of medium, the supernatant removed 
and cell pellets resuspended at a final concentration of  7 x 10
4
/ml. Control plates were 
also prepared with medium alone, medium plus 2% Triton-X100 (Fisher Scientific), 
target cells alone (spontaneous release) and target cells plus 2% Triton-X100 (maximal 
release) incubated under the same conditions as previously described. Following 
incubation, plates were centrifuged at 400g for 5 minutes at room temperature and 
100µl of supernatant removed from each well and transferred into flat bottom 96-well 
plates (Nunc). Supernatant fluorescence was measured on the FLUOstar Galaxy 
microplate fluorescence spectrophotometer (MTX Lab Systems) with excitation filter 
485 ± 9nm and band-pass filter 530 ± 9nm and data were expressed as arbitrary 
fluorescent units (AFU). Background fluorescence measured for medium alone was 
subtracted from all measured effector:target values and from spontaneous release 
values, and background fluorescence measured for medium plus 2% Triton-X100 was 
subtracted from maximal release values. Specific target killing was calculated as the 
[(test release-spontaneous release/maximal release-spontaneous release) x 100] for each 
ratio. 
 
2.18 Statistics 
 
Statistical analyses were conducted using GraphPad Prism v4.0 (GraphPad Software). 
The paired and unpaired two-tailed Student’s t-test was used for pairwise tests of 
differences between datasets which have a normal distribution and equal variances. The 
Mann-Whitney test was used for non-parametric data sets. Differences between data 
sets were tested for statistical significance at  = 0.05. 
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Chapter 3 
 
Analysis of Activation Markers and Cytokine Profile in CMVpp65-
Stimulated G-CSF-Mobilised PBMCs 
 
3.1 Introduction 
 
Several strategies have been employed in the manufacture of CMV-reactive T cells 
(CMV-T) for clinical use in the treatment of CMV disease in patients at high risk of 
reactivation, including the use of HLA peptide tetramers, the generation of T cell lines 
in short term culture and IFN-γ catch technology. To date, models for generating CMV-
T have focused primarily on using peripheral blood mononuclear cells (PBMCs) 
collected by an additional leukapheresis from the original HSCT donor. In the case of 
related donors, procuring a second apheresate for CMV-T generation is inconvenient to 
the donor and is associated with some level of pain, discomfort and risk. Obtaining a 
second apheresate from unrelated donors has proven to be even more problematic, due 
to donor refusal, registry refusal or simply scheduling difficulties. The prospect of 
manufacturing antigen-specific T cells from an aliquot of the original HSCT obtained 
by leukapheresis after mobilisation with recombinant human G-CSF is attractive but has 
yet to be fully investigated. The successful isolation from G-CSF-mobilised donors of 
γδ T cells that synthesise immunomodulatory cytokines, such as IFN-γ and TNF-α, and 
retain a strong tumoricidal activity (Otto et al, 2005), effectively demonstrated the 
potential for the identification and isolation of anti-viral T cells from the original 
apheresate starting material. G-CSF mobilisation is associated with a significant 
increase in the numbers of circulating lymphocytes (Hartung et al, 1999; Rutella et al, 
1997; Sica et al, 1996). It has been reported that the use of donor lymphocyte 
collections (DLI) obtained following G-CSF mobilisation for the treatment of relapse in 
advanced myeloid malignancy compares favourably with other treatment approaches 
(Levine et al, 2002), suggesting maintenance of a graft versus leukaemia (GvL) effect 
mediated by functional T cells within the lymphocyte population. However, murine and 
human studies have suggested that G-CSF mobilisation inhibits type 1 cytokine 
production by T cells, through inhibition of secretion at a single cell level as well as 
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reducing the fraction of cytokine secreting cells in the periphery, arguing against the use 
of these cells for adoptive immunotherapy (Tayebi et al, 2001; Arpinati et al, 2000; Pan 
et al, 1999). What remains unclear is the degree of functionality of the T cell 
compartment of G-CSF-mobilised PBMCs, in terms of their anti-viral response; and 
how these CMV-T compare against conventional non-mobilised T cells that are 
traditionally used for adoptive transfer of CMV immunity post allogeneic HSCT. The 
objective of the experiments described in this Chapter was to obtain data that enable 
these questions to be addressed. 
 
3.2 Aims of Experiments Described in this Chapter 
 
The initial aims of this Chapter were to test whether CMV-T could be identified in G-
CSF-mobilised PBMCs though IFN-γ secretion, and whether CMV-T could be isolated 
by magnetic bead enrichment using the IFN-γ catch assay. We began by investigating 
the cytokine profile of CMVpp65- stimulated G-CSF-mobilised PBMCs using a 
Cytometric Bead Array (CBA) to establish whether there was polarization of the T cell 
response towards a TH2 phenotype, through the inhibition of TH1 cytokines. Cytokine 
secretion in G-CSF-mobilised PBMCs was compared directly with non-mobilised 
PBMCs to ascertain the feasibility of using the IFN-γ secretion assay in future 
experiments.  
 
CMV-T have also been identified through a number of T cell surface markers that are 
up-regulated after activation, including CD25, CD69, CD137 and CD154 
(Chattopadhyay et al, 2005; Frentsch et al, 2005; Gallot et al, 2001; Watanabe et al, 
2008; Wehler et al, 2008; Wolfl et al, 2007). We therefore investigated the feasibility of 
identifying CMV-T based on activation markers in G-CSF-mobilised PBMCs as an 
alternative option to identification based on IFN-γ secretion.  
 
Samples were taken from both non-mobilised and G-CSF-mobilised PBMCs apheresis 
collections and stimulated with CMVpp65 Peptivator for investigating both IFN-γ 
secretion and activation-induced expression of surface markers. CMVpp65 Peptivator is 
a peptide pool consisting mainly of 15-mer sequences with 11 amino acid overlap 
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spanning the entire pp65 protein. Experiments focused on the T cell response to 
CMVpp65, as it is generally accepted that the cytotoxic T lymphocyte (CTL) response 
is dominated by this protein (Harcourt et al, 2006;Wills et al, 1996). 
The experimental aims of the Chapter were as follows: 
 
1. To compare the profile of cytokines secreted in response to CMVpp65 stimulation 
between G-CSF-mobilised and non-mobilised PBMCs. 
 
2. To compare the efficacy of IFN-γ-based identification and enrichment of CMV-
reactive T cells in G-CSF-mobilised and non-mobilised PBMCs. 
 
3. To examine the temporal kinetics of activation-induced antigen expression in G-
CSF-mobilised PBMCs after CMVpp65 peptide stimulation over 24 hours. 
 
4. To compare the temporal kinetics of activation-induced antigen expression with 
conventional non-mobilised PBMCs. 
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3.3 Materials and Methods 
 
Fresh samples were obtained from the leukapheresis collections from both G-CSF-
mobilised and non-mobilised consenting CMV-seropositive healthy donors, and 
PBMCs were isolated by density gradient centrifugation. Cultures from both 
CMVpp65-stimulated (1µg/peptide/ml) and non-stimulated PBMCs from G-CSF-
mobilised and non-mobilised donors (n=6) were incubated at a concentration of 10
7
/ml 
in 6-well plates, with 50 x 10
6
 cells added to each well. Supernatants were subsequently 
collected and stored at –80°C. The assessment of cytokine secretion was performed 
using the stored supernatants which were thawed at room temperature before incubation 
of 50µl for 3 hours with 50µl of mixed capture beads capable of identifying the 
cytokines IL-2, IL-4, IL-5, IL-10, IFN-γ and TNF-α, together with 50µl of PE-
conjugated detection antibody. Following incubation, samples were centrifuged at 200g 
for 10 minutes at room temperature and resuspended in 300µl of FACS Flow for flow 
cytometric analysis. Known quantities of cytokine were used as standards for the 
construction of a standard curve that was used to quantify concentration (pg/ml) of each 
cytokine in the supernatant samples. Samples were analysed using FCAP Array v1.0.1 
 
For the identification and enrichment of CMV-reactive T cells in G-CSF-mobilised and 
non-mobilised PBMCs, an IFN-γ-secretion assay was performed. PBMCs were 
stimulated with CMVpp65 peptides in a 16 hour culture, and labelled with an IFN-γ 
catch reagent before an IFN-γ secretion step of 45 minutes at 37°C/5%CO2, as 
described in section 2.11. Cells were then labelled with an IFN-γ PE detection antibody 
prior to labelling with anti-PE microbeads before enrichment on a MiniMACS using 
MS columns. Counts were performed pre- and post-enrichment and analysis of IFN-γ+ 
CD4+ and IFN-γ+ CD8+ subsets performed by flow cytometry to assess both yield and 
purity of CMV-reactive T cells between G-CSF-mobilised and non-mobilised PBMCs. 
 
To analyse activation marker expression, PBMCs were isolated from G-CSF-mobilised 
and non-mobilised apheresis, prior to the incubation of 2 x 10
6
 cells per well in 96-well 
flat bottom plates at a concentration of 10
7
/ml in complete medium. Cells were 
stimulated with either 1µg/ml SEB (positive control) or 1µg/peptide/ml CMVpp65 
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peptide pool or left untouched to act as a negative control. Cultures were then incubated 
at 37°C/5% CO2 and samples taken at 1, 4, 6, 16 and 24 hour time points for the 
assessment of cell surface expression of CD25, CD69, CD137, CD152 and CD154 
amongst CD3+ T cells. After the culture periods, cells were incubated with the 
following panels of monoclonal antibodies and analysed by flow cytometry (Table 3.1) 
using the staining procedure described in Chapter 2, section 2.7.1. 
 
Panel/Fluorochrome FITC PE PerCP APC 
1 CD4 IgG1 CD8 CD3 
2 CD4 CD25 CD8 CD3 
3 CD4 CD69 CD8 CD3 
4 CD4 CD137 CD8 CD3 
5 CD4 CD152 CD8 CD3 
6 CD4 CD154 CD8 CD3 
 
Table 3.1 Antibody panels used to assess temporal dynamics of activator marker 
expression in CMVpp65 stimulated PBMC isolated from G-CSF mobilised and 
non-mobilised PBMC  
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3.4 Results 
 
3.4.1 Cytokine profile of CMVpp65 stimulated G-CSF-mobilised and non-
 mobilised PBMCs 
 
Supernatants from G-CSF mobilised and non-mobilised PBMC cultures with and 
without CMVpp65 peptide stimulation were assessed for the secretion of the cytokines 
IL-2, IL-4, IL-5, IL-10, TNF-α and IFN-γ after 16 hours. Following acquisition of a 
minimum of 3,000 events on a FACS Aria flow cytometer, a region was drawn on a 
FSC vs. SSC dot plot around the bead population. The bead populations coated with 
capture antibodies specific for the cytokines are resolved in the FL3 channel based on 
their distinct fluorescence intensity and then reported in the FL2 channel using a PE-
conjugated detection antibody. Figure 3.1 illustrates a representative result from non-
stimulated (negative control) and CMVpp65 stimulated G-CSF mobilised PBMC 
sample.  
 
 
 
 
 
 
 
 
 
Figure 3.1 Cytometric bead array (CBA) Assay – G-CSF Mobilised PBMC:  
Representative FACS plots from one experiment using supernatant from G-CSF mobilised 
PBMC stimulated with CMVpp65 or left untouched (negative control).  
 
When comparing CMVpp65 stimulated with non-stimulated cultures, significant levels 
of IFN-γ, TNF-α and IL-2 were seen in both G-CSF mobilised and non-mobilised 
donors (p<0.005). On analysis of IL-10, IL-4 and IL-5 secretion we observed low to 
undetectable levels in the supernatants of both G-CSF mobilised and non-mobilised 
cultures, which after statistical analysis were shown to be not significant when 
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compared to non-stimulated cultures. Table 3.2 shows the calculated concentration of 
cytokine (pg/ml) secreted after flow cytometric analysis in PBMC from a G-CSF 
mobilised and non-mobilised donor which is representative of 6 donors that were 
analysed in both settings. 
 
Comparison of the cytokine profile of G-CSF-mobilised and non-mobilised PBMCs 
after CMVpp65 stimulation is shown in Figure 3.2. There was no significant difference 
between the donor groups in the concentration of the pro-inflammatory cytokines IL-2, 
IFN-γ and TNF-α, although a trend towards an increase in TNF-α and IFN-γ levels was 
observed in non-mobilised PBMC cultures. We observed a significant increase in IL-10 
secretion (p=0.01) and a trend towards an increase in levels of IL-4 and IL-5 from non-
mobilised PBMC cultures. It must be noted, however, that no significant increase in IL-
4, IL-5 or IL-10 levels was seen in CMVpp65-stimulated vs. non-stimulated PBMC 
cultures for both the G-CSF-mobilised and non-mobilised groups. Therefore, the 
significant increase in IL-10 secretion in non-mobilised PBMCs is probably not due to 
CMVpp65 stimulation, but to higher baseline levels of IL-10. 
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G-CSF Mobilised  
 
 IL-2 TNF-α IFN-γ IL-10 IL-4 IL-5 
 CMV Neg CMV Neg CMV Neg CMV Neg CMV Neg CMV Neg 
 
Event Number 394 449 540 494 438 423 518 496 455 537 558 478 
MFI 834.4 2.7 49.9 1.8 473 0.43 7.3 9.7 3.2 1.3 1.9 1.0 
CV% (MFI) 30.8 86.7 26.7 112.8 24.4 426.2 36.2 36.7 59.0 136.1 85.8 183.8 
Calculated CC 
(pg/ml) 
1328 0.0 118.1 3.0 1196 0.0 11.7 15.7 3.2 0.0 1.8 0.0 
 
Non- Mobilised  
 
 IL-2 TNF-α IFN-γ IL-10 IL-4 IL-5 
 CMV Neg CMV Neg CMV Neg CMV Neg CMV Neg CMV Neg 
 
Event Number 483 440 462 485 502 461 472 503 528 549 459 437 
MFI 309.6 4.2 541.5 54.2 963.7 5.6 10.8 3.4 5.8 1.8 3.3 0.7 
CV% (MFI) 27.4 57.6 25.9 31.0 26.6 49.3 33.8 68.9 128.3 107.0 85.9 239.5 
Calculated CC 
(pg/ml) 
453 2.9 1507 129 2645 9.5 17.5 5.2 7.1 0.0 3.1 0.0 
             
Table 3.2 Example of cytokine secretion (pg/ml) from G-CSF-mobilised and non-mobilised PBMCs after CMVpp65 stimulation by 
cytometric bead array: 
Cytokine secretion was evaluated in the supernatant of cultures stimulated with CMVpp65 peptide pools or left untouched (negative control) by flow cytometry 
using a cytometric bead array assay from G-CSF-mobilised (top table) and non-mobilised (bottom table) PBMCs. Cultures were incubated for 16 hours at a 
concentration of 10
7
/ml. MFI: median of fluorescence intensity, CV: coefficient of variance, CC: concentration calculated from the standard curve 
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Figure 3.2 Cytokine profile in G-CSF-mobilised (n=6) and non-mobilised (n=6) PBMCs after CMVpp65 stimulation: 
Quantitative assessment of IL-2, TNF-α, IFN-γ, IL-10, IL-4 and IL-5 in the supernatant of cultures after 16 hour stimulation with CMVpp65 peptide pools. Bars 
represent the mean (  SD) cytokine concentration (pg/ml) from non-mobilised (blue bars) and G-CSF-mobilised (red bars) PBMCs after subtraction of the 
negative control (no peptide). *p<0.05 in a non-paired t test. 
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3.4.2 Identification of IFN-γ-secreting CMV-specific T cells in G-CSF-mobilised 
 PBMCs 
 
In the previous section, significant levels of IFN-γ were detected in the supernatant of 
CMVpp65-stimulated G-CSF-mobilised PBMC cultures. This prompted the question of 
whether CMV-T could be identified and isolated from the supernatant of PBMC 
cultures. The identification and isolation of CMV-T utilised the IFN-γ catch assay and 
magnetic bead enrichment, as this system had been used previously for the manufacture 
of clinically efficacious CMV-T from non-mobilised PBMCs (Harcourt et al, 2006; 
Peggs et al, 2011; Wills et al, 1996). IFN-γ was measured before and after magnetic 
enrichment to assess purity and yield in mobilised and non-mobilised PBMCs. As 
illustrated in Figure 3.3, the mean proportion of IFN-γ-secreting cells was reduced in G-
CSF-mobilised PBMCs (1.42% ± 0.35) compared with non-mobilised PBMCs (2.50% ± 
0.63). Analysis of the CD3+ T cell compartment of IFN-γ-secreting cells showed that in 
non-mobilised donors the ratio of CD4+ to CD8+ T cells was evenly split (44% vs. 
56%) whereas in G-CSF-mobilised donors the ratio was shifted towards a more 
predominantly CD4+ T cell response (69% vs. 31%) which was statistically significant 
(p=0.04).  
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Figure 3.3 Identification of IFN-γ secreting antigen-specific T cells in unpaired G-
CSF-mobilised (n=6) and non-mobilised (n=6) donors: 
Samples from G-CSF-mobilised and non-mobilised apheresis were stimulated with CMVpp65 
peptide pools or left untouched (Nil) for 16 hours and the frequency of IFN-γ-secreting cells 
analysed amongst CD3+ T cells. CD3+ IFN-γ+ populations were further sub-divided into CD8+ 
(red bars) and CD4+ (blue bars). Bars represent mean (  SD) percentage of CD3+ IFN-γ+ cells. 
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3.4.3 Enrichment of IFN-γ-secreting CMV-reactive T cells in G-CSF-mobilised 
 PBMCs 
 
Following stimulation with CMVpp65 peptides, IFN-γ-secreting cells were isolated by 
magnetic bead enrichment as previously described. Enrichment of IFN-γ+ CMV-T was 
performed from G-CSF-mobilised (n=6) and non-mobilised (n=6) PBMC donors and 
the experimental results are summarised in Table 3.3. The mean lymphocyte percentage 
of PBMCs was significantly decreased in G-CSF-mobilised vs. non-mobilised PBMCs 
both pre- (14.04% vs. 53.96%, respectively; p<0.0001) and post-enrichment (4.24% vs. 
19.95%, respectively; p=0.04) but the percentage of CD3+ T cells within the 
lymphocyte population was comparable between the two donor groups pre- (69.1% vs. 
59.0%, respectively; p=0.24) and post-enrichment (43.1% vs. 63.1%, respectively; 
p=0.24). Table 3.3 also illustrates a significant reduction in the total number of IFN-γ 
secreting CD3+ T cells in G-CSF-mobilised PBMCs (p=0.04) as discussed in section 
3.4.2.  
 
The mean purity of IFN-γ+ CMV-T after magnetic enrichment was shown to be 
decreased in G-CSF-mobilised PBMCs (35.68% ± 13.18) compared with non-mobilised 
PBMCs (51.82% ± 10.66). However this observation proved not to be statistically 
significant (p=0.21).The yield of IFN-γ+ CMV-T was calculated by dividing the 
absolute number of IFN-γ+ CD3+ in the IFN-γ positive fractions after enrichment by 
the absolute number of IFN-γ+ CD3+ cells before enrichment, then multiplied by 100 to 
give a percentage. Combined results from 6 separate enrichments showed that the mean 
yield of IFN-γ+ CMV-T was decreased in G-CSF-mobilised PBMCs (6.61% ± 2.22) 
compared with non-mobilised PBMCs (18.07% ± 11.09), although no statistically 
significance was observed This result is reflected in the marked reduction seen in the 
absolute number of cells in the positive fractions of G-CSF-mobilised (0.23 x 10
6
) 
relative to non-mobilised (1.62 x 10
6
) PBMCs after enrichment, even though the 
absolute number of cells prior to enrichment was equivalent (135.6 vs. 132.8 x 10
6
) 
between the two groups. The ratio of CD4+ to CD8+ IFN-γ+ secreting cells post-
enrichment was comparable between G-CSF-mobilised (44.3% vs. 55.7%) and non-
mobilised (43.6% vs. 56.4%) PBMCs.  
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Representative staining for IFN-γ secretion from G-CSF-mobilised and non-mobilised 
PBMCs is shown in Figure 3.4 which highlights the reduced proportion of IFN-γ+ 
CD3+ T cells in G-CSF-mobilised vs. non-mobilised PBMCs before  and after 
enrichment. The efficiency of isolation of IFN-γ-secreting cells is summarised in Figure 
3.5, which illustrates a trend towards a reduction in G-CSF-mobilised PBMCs vs. non-
mobilised PBMCs in both purity and yield of IFN-γ-secreting CMV-T. 
 
In summary PBMC from G-CSF mobilised PBMC are capable of secreting IFN-γ and 
other effector cytokines at a level similar to non mobilised PBMC as shown in section 
3.4.1, but isolation and detection after CMVpp65 stimulation on a per cell basis appears 
to be impaired. These results are in line with previously published data suggesting that 
G-CSF mobilisation impairs the potential for IFN-γ production at a single cell level 
(Tayebi et al, 2001)
 
which could result in reduced detection of CMV-T using this 
method and ultimately in the efficiency of magnetic bead enrichment. 
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   Pre Enrichment  Post Enrichment 
        
   Non-Mobilised G-CSF Mobilised  Non-Mobilised G-CSF Mobilised 
        
Cell Number (x10
5
) 132.8 (105-177) 135.6 (44-186)  1.6 (0.3-3.9) 0.2 (0.04-0.6) 
Lymphocyte (% of PBMC) 54.0 (45.0-63.3) 14.0 (9.0-19.6)  20.0 (1.2-32.8) 4.2 (1.5-6.3) 
CD3 (% of lymphocytes) 59.0 (49.2-63.2) 69.1 (43.5-84.6)  56.1 (29.1-80.7) 43.1 (29.8-66.2) 
CD3+ IFN-γ+ (% of lymphocytes) 2.50 (0.8-3.4) 1.4 (0.8-2.7)  51.8 (12.7-76.0) 35.7 (12.1-86.3) 
CD4+ (% of CD3+ IFN-γ+) 42.6 (35.0-57.0) 59.5 (50.7-63.7)  42.7 (39.6-52.8) 44.3 (12.5-80.2) 
CD8+ (% of CD3+ IFN-γ+) 55.4 (45.7-65.0) 40.5 (36.6 – 49.3)  55.1 (46.0-64.0) 55.7 (19.8-87.5) 
CD3+ IFN-γ+ Cell Number (x105) 1.0 (0.5-1.7) 0.2 (0.1-0.9)  0.2 (0.01-0.8) 0.01 (0.001-0.04) 
 
 
 
Table 3.3 Summary of enrichment of CMV-reactive T cells through IFN-γ secretion in non-mobilised (n=6) and G-CSF-mobilised (n=6) 
PBMCs: 
The mean and range of G-CSF-mobilised and non-mobilised IFN-γ enrichment experiments (n=5, both) using PBMCs from CMV seropositive donors after 16 
hour culture with CMVpp65 peptide pools as determined by flow cytometry. Magnetic enrichments were performed on the MiniMACS using MS columns after 
labelling of IFN-γ+ cells using PE-microbeads 
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Figure 3.4 Comparison of IFN-γ secretion and enrichment after CMVpp65 
stimulation between a G-CSF-mobilised and non-mobilised donor: 
PBMCs were stained with CD3-APC, IFN-γ-PE and either CD4-FITC or CD8-FITC conjugated 
antibodies and analysed by flow cytometry. Samples were gated on live lymphocytes as side 
scatter (SSC) versus forward scatter (FSC) followed by gating on SSC
low 
CD3+ T cells in both 
(A) non-mobilised and (B) G-CSF-mobilised PBMCs. (C) IFN-γ+ cells were analysed in the 
negative control (no peptide), CMVpp65-stimulated and IFN-γ positive and negative fractions 
after magnetic enrichment. 
(Fra, fraction; Mob, mobilised; Neg, negative; Stim, stimulated) 
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Figure 3.5 Isolation of IFN-γ-secreting antigen-specific T cells in unpaired G-CSF-
mobilised (n=6) and non-mobilised (n=6) donors: 
G-CSF-mobilised (red bars) and non-mobilised (blue bars) PBMCs were stimulated with 
CMVpp65 peptide pools for 16 hours and IFN-γ-secreting cells isolated by magnetic bead 
enrichment on a MiniMACS with MS columns after labelling using the IFN-γ catch assay. Bars 
represent mean (  SD) percentage of purity and yield of IFN-γ+ cells from within the CD3+ 
population. 
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3.4.4 Temporal dynamics of activation marker expression on CD3+ T cells after 
 CMVpp65 peptide stimulation in G-CSF-mobilised and non-mobilised 
 PBMCs 
 
The kinetics of activation-induced CD25, CD69, CD137, CD152 and CD154 expression 
on CMV-reactive T cells in G-CSF-mobilised PBMCs was investigated over a 24 hour 
period to determine the optimal duration of stimulation and compared directly to that of 
non-mobilised PBMCs. PBMCs were stimulated with CMVpp65 peptides and the 
superantigen SEB as a positive control. Expression of activation markers were 
quantified as the percentage of positive cells within the CD3+ population after 
subtraction of the negative control (non-stimulated PBMCs). Results show experiments 
from 5 G-CSF-mobilised and 5 non-mobilised PBMCs donors. 
 
3.4.4.1 Baseline expression  
 
Baseline expression of all activation markers, assessed in resting PBMCs prior to 
stimulation, was comparable between G-CSF-mobilised and non-mobilised PBMCs 
(Figure 3.6). Mean baseline CD25 expression was shown to be elevated in both G-CSF-
mobilised (4.5%  0.59) and non-mobilised (4.3%  0.85) PBMCs when compared with 
CD69, CD137, CD152 and CD154, which showed mean expression levels of 0.73%-
1.19% (G-CSF-mobilised) and 0.38%-1.59% (non-mobilised)]. The elevation in CD25 
expression in comparison with other activation markers can be explained by the 
presence of naturally occurring T regulatory cells (Tregs) that also express the marker 
CD25, and is explored further in Chapter 4. 
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Figure 3.6 Comparison of T cell activation markers between G-CSF-mobilised 
(n=5) and non-mobilised (n=5) PBMCs at rest: 
Freshly isolated PBMCs were stained for activation markers CD25, CD69, CD137, CD152 and 
CD154 in resting G-CSF-mobilised (red bars) and non-mobilised (blue bars) PBMCs to assess 
baseline expression. Bars represent the mean (+SD) percentage of the CD3+ T cell population 
after gating on live lymphocytes by flow cytometry. 
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3.4.4.2 Activation marker expression after SEB stimulation  
 
Activation marker expression on CD3+ T cells were analysed at 1, 4, 6, 16 and 24 hours 
after SEB stimulation by flow cytometry. PBMCs from G-CSF-mobilised donors were 
stimulated with the superantigen SEB to compare the activation status with non-
mobilised PBMCs and to assess whether the kinetics of antigen expression were 
comparable between the two donor groups. As summarised in Table 3.4, SEB induced a 
similar expression profile over 24 hours in all activation markers with a trend towards 
higher expression in G-CSF-mobilised PBMCs after 24 hours. 
 
 CD25% CD69% CD137% CD152% CD154% 
           
 NM MOB NM MOB NM MOB NM MOB NM MOB 
1hr 4.14 3.05 0.83 6.26 0.92 1.45 0.46 4.17 1.22 2.37 
           
4hr 2.67 3.39 8.71 9.73 0.93 4.40 0.82 5.72 4.70 6.27 
           
6hr 4.09 5.95 10.4 11.4 2.84 5.07 0.73 2.44 4.49 3.68 
           
16hr 12.2 11.5 11.4 9.92 4.98 4.42 0.84 1.72 1.91 2.55 
           
24hr 11.7 18.3 10.3 11.9 4.00 6.12 0.93 3.57 1.45 3.96 
 
Table 3.4 Activation marker expression after SEB stimulation 
SEB stimulation at 1, 4, 6, 16 and 24 hours in G-CSF-mobilised (MOB; n=3) and non-mobilised 
(NM; n=5) PBMCs within the CD3+ T cell population. Data are mean percentage of the CD3+ 
T cell population after subtraction of the negative control 
 
Figure 3.7 illustrates a representative staining pattern of the activation markers CD25, 
CD69, CD37, CD152 and CD154 after SEB stimulation on CD3+ CD8+ in a G-CSF-
mobilised donor at all time points.  
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Figure 3.7 Analysis of activation markers after SEB stimulation at 1, 4, 6, 16 and 
24 hours in G-CSF-mobilised PBMCs: 
Freshly isolated PBMCs from a G-CSF-mobilised donor were stimulated in 96-well plates with 
SEB and samples removed at 1, 4, 6, 16 and 24 hours for the assessment of the expression of 
activation markers CD25, CD69, CD137, CD152 and CD154. Samples were gated on live 
lymphocytes as side scatter (SSC) versus forward scatter (FSC) followed by gating on SSC
low 
CD3+ T cells (A) CD3+ populations when then analysed or activation marker expression versus 
CD8 (B) Antigen dependent expression of CD25 was maximal at 16 hours 
A 
B 
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3.4.4.3 Activation marker expression after CMVpp65 stimulation  
 
The kinetics of activation-induced CD25, CD69, CD154 and CD137 expression on 
CMVpp65 specific T cells in G-CSF-mobilised PBMCs was investigated to determine 
both the optimal target and the optimal time for maximal expression and to compare 
these results directly with non-mobilised PBMCs. PBMCs were stimulated over a 24 
hour period with CMVpp65 peptides, removed from cultures at 1, 6, 16 and 24 hours, 
and analysed for surface expression of activation markers by flow cytometry. Figure 3.8 
shows activation marker expression against time in a G-CSF-mobilised donor in 
CMVpp65-stimulated, SEB-stimulated and non-stimulated PBMCs and illustrates the 
optimal time point for maximal expression. The results comparing mean expression of 
the activation markers CD25, CD69, CD137, CD152 and CD154 in G-CSF-mobilised 
(n=5) and non-mobilised donors (n=5) are shown in Figure 3.10. The mean antigen-
dependent expression of CD25 was maximal at 16 hours in G-CSF-mobilised PBMCs 
(3.19% ± 1.43) and was increased compared with non-mobilised PBMCs (1.73% ± 
0.63). Mean CD69 expression in G-CSF-mobilised PBMCs (1.32% ± 0.51) peaked at 
16 hours and was higher than that seen in non-mobilised PBMCs (0.33% ± 0.21) which 
peaked at 6 hours. CD137 reached peak expression at 24 hours after CMVpp65 
stimulation and was comparable in intensity between G-CSF-mobilised (0.88% ± 0.45) 
and non-mobilised (0.56% ± 0.16) PBMCs. CD154 expression in G-CSF-mobilised 
PBMCs was maximal at 6 hours (0.95% ± 0.44) and was increased compared with non-
mobilised PBMCs (0.16% ± 0.15). Analysis of CD152 expression showed a maximal 
time of expression at 16 hours with a trend (p=0.05) towards increased expression in G-
CSF-mobilised PBMCs (1.37% ± 0.46) compared with non-mobilised PBMCs (0.18% ± 
0.07). The results comparing mean expression of CD25, CD69, CD137, CD152 and 
CD154 in five G-CSF-mobilised and five non-mobilised donors are illustrated in Figure 
3.9, indicating the time point of maximal expression for each activation marker. 
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Figure 3.8 Analysis of activation markers after CMVpp65 stimulation at 1, 4, 6, 16 and 24 hours in G-CSF-mobilised PBMCs: 
PBMCs isolated from G-CSF-mobilised apheresis were stimulated with a CMVpp65 peptide pool and samples taken at 1, 4, 6, 16 and 24 hours for the assessment 
of activation dependent expression of the cell surface markers (A) CD25, (B) CD69, (C) CD152, (D) CD137 and (E) CD154 from within the CD3+ T cell 
population. Cells were also stimulated with SEB (1µg/ml) as a positive control and left untouched as a negative control. 
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Figure 3.9 Temporal dynamics of activation marker expression after CMVpp65 peptide stimulation in G-CSF-mobilised (n=5) and non-
mobilised (n=5) PBMCs: 
PBMCs isolated from G-CSF-mobilised (red bars) and non-mobilised (blue bars) apheresis were stimulated with a CMVpp65 peptide pool and analysed for the 
expression of (A) CD25, (B) CD69, (C) CD137, (D) CD152 and (E) CD154 at 1, 6, 16 and 24 hours. Bars represent the mean percentage (+SD) in the CD3+ T 
cell population after subtraction of the negative control (no peptide).  
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3.4.5 Assessment of CD154 activation-induced expression in G-CSF-Mobilised 
 PBMCs after blocking CD40-CD154 interaction 
 
Previously published data have demonstrated that CD154 is a suitable marker for the 
detection and isolation of CMV-specific T cells (Chattopadhyay et al, 2005; Frentsch et 
al, 2005; Khanna et al, 2011) from conventional non-mobilised PBMCs in the presence 
of CD40 blockade. Effective blocking of CD40 and CD154 ligation leads to the 
preservation of CD154 expression at the cell surface (Frentsch et al, 2005), although the 
effect of G-CSF mobilisation on this procedure was unknown. PBMCs were stimulated 
with either SEB or CMVpp65 peptides for 4 and 6 hours in the presence or absence of 
CD40-specific antibody, and then analysed for CD154 expression amongst the CD4+ T 
cell population. Figure 3.10 shows representative FACS plots from a G-CSF-mobilised 
and non-mobilised donor, illustrating the effect of CD40 blockade on CD154 expression 
after CMVpp65 stimulation. Results from G-CSF-mobilised and non-mobilised PBMCs 
donors (n=5, both) are shown in Figure 3.12. We found low background CD154 
expression in resting CD4+ T cells that was comparable between the two donor groups 
(G-CSF-mobilised: 0.30% ± 0.14; non-mobilised: 0.22% ± 0.06). Mean CD154 
expression in the presence of CD40-specific antibody at the optimal time point of 6 
hours, showed no significant difference between G-CSF-mobilised PBMCs (1.86% ± 
0.59) and non-mobilised PBMCs (1.22% ± 0.13). CD40 blocking significantly 
increased CD154 expression in CMVpp65 stimulated G-CSF-mobilised (p=0.0033) and 
non-mobilised (p=0.0008) PBMCs. In both donor groups, CD40 blocking antibody 
alone showed no significant effect on CD154 expression. The results from 5 G-CSF 
mobilised and 5 non-mobilised PBMC donors are summarised in Figure 3.11. 
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Figure 3.10 Direct comparison of CD154 surface expression at 4 and 6 hours between a G-CSF-mobilised and non-mobilised donor after 
CD40 blocking:  
PBMCs were stimulated with either CMVpp65 peptides or SEB in the presence or absence of CD40-specific antibody (1µg/ml) and with CD40-specific antibody 
alone. Cells are gated on CD3+ CD4+ T cells. (aCD40, CD40 antibody; SEB, staphylococcal enterotoxin B)
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Figure 3.11 Comparison of CD154 expression in non-mobilised (n=5) and G-CSF-
mobilised (n=5) donors at 4 and 6 hours.  
*P<0.05, ** P<0.01, *** P<0.001 in a paired t test. 
(Pre, pre stimulation; No stim, no stimulation; aCD40, CD40 antibody) 
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3.5 Discussion 
 
The manufacture of clinical grade CMV-T for adoptive immunotherapy has been 
successfully demonstrated in conventional non-mobilised through IFN-γ secretion 
(Peggs et al, 2011). This has been achieved through a short culture period in which cells 
were stimulated with either the CMVpp65 protein or overlapping CMVpp65 peptides 
covering the whole of the CMVpp65 protein.  This method of direct selection is 
consistent with clinical grade manufacture due to the short stimulation period of 6-16 
hours without the necessity for long term culture. In this Chapter, we investigated the 
feasibility of using G-CSF-mobilised PBMCs rather than conventional non-mobilised 
PBMCs to identify and isolate CMV-T. Initial experiments assessed the cytokine profile 
of G-CSF-mobilised PBMCs after stimulation with CMVpp65 peptides using a cytokine 
bead array (CBA) assay and subsequently to compare cytokine secretion directly against 
non-mobilised PBMCs. Following cytokine profiling, we identified CMV-T in G-CSF-
mobilised PBMCs based on IFN-γ secretion and subsequently isolated these cells using 
magnetic bead enrichment. In the final section of this Chapter, we investigated a panel 
of activation markers that have previously been shown to be upregulated after 
CMVpp65 stimulation in non-mobilised PBMCs (Chattopadhyay et al, 2005; Frentsch 
et al, 2005; Gallot et al, 2001; Peggs et al, 2011; Watanabe et al, 2008; Wehler et al, 
2008; Wolfl et al, 2007)  and assessed their candidacy for targeting the identification of 
CMV-T in G-CSF-mobilised PBMCs. 
 
Cytokine profiling by CBA showed that G-CSF mobilisation was not associated with a 
significant decrease in secretion of the inflammatory or anti-viral cytokines IL-2, TNF-α 
and IFN-γ in response to CMVpp65 stimulation compared with conventional non-
mobilised PBMCs. Similar low levels of secretion of IL-4 and IL-5 were observed in G-
CSF-mobilised and non-mobilised PBMCs, both of which are associated with a TH2 
phenotype. This result suggests that G-CSF mobilisation does not appear to 
significantly alter the potential for type 1 cytokine production observed when the whole 
PBMC population is studied. However, previous studies have reported inhibition of type 
1 cytokine production by T cells at a single cell level in G-CSF-mobilised PBMCs 
(Arpinati et al, 2000; Pan et al, 1999; Tayebi et al, 2001). The finding that IL-10 
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secretion was significantly decreased in G-CSF-mobilised PBMCs (p=0.01) is an 
interesting one, as it argues against evidence from previous studies that G-CSF 
augments the generation of IL-10-producing Tregs (Morris et al, 2004; Rutella et al, 
2002; Tayebi et al, 2001). However, these findings were observed in an early immune 
response whereas the administration of G-CSF to HSCT donors occurs every day for 5 
days leading up to the collection of HSCs. The reduction in IL-10 secretion seen in G-
CSF-mobilised PBMCs could be explained by the potential exhausting effect that 
administration of G-CSF over a five day period could have on the level of IL-10 
secretion. Furthermore IL-10 release has been shown to be induced in antigen 
presenting cells (APCs) after lipopolysaccharide (LPS) stimulation (Byrne & Reen, 
2002). If antigen uptake by APCs is less efficient in G-CSF-mobilised PBMCs, this 
could result in a decrease in IL-10 secretion when compared with non-mobilised 
PBMCs, although I have no data to support this hypothesis.  
 
Having observed that the level of IFN-γ secretion was equivalent between G-CSF-
mobilised and non-mobilised PBMCs after CMVpp65 stimulation determined by CBA, 
we evaluated the suitability of using IFN-γ secretion to both identify and isolate CMV-
T. Although not significant, the mean proportion of IFN-γ-secreting cells was found to 
be reduced in G-CSF-mobilised PBMCs compared with non-mobilised PBMCs (1.42% 
vs. 2.50%), which was reflected in a decrease in both purity and yield after isolation. 
The reduction in identification and isolation of CMV-T using the IFN-γ catch method 
from G-CSF-mobilised PBMCs suggests that G-CSF mobilisation does have a 
inhibitory effect upon IFN-γ production, in line with previous findings (Arpinati et al, 
2000; Pan et al, 1999; Tayebi et al, 2001). It must also be noted that the reduction in 
absolute IFN-γ secretion by CD3+ T cells observed here might be attributed to the 
significant reduction in the percentage of lymphocytes from within the PBMC pool in 
G-CSF-mobilised vs. non-mobilised donors (p<0.0001). G-CSF mobilisation is 
associated with a significant increase in the number of circulating lymphocytes 
(Hartung et al, 1999; Rutella et al, 1997; Sica et al, 1996). However, the reduction in 
lymphocyte percentage, partly due to the high percentage of granulocytes mobilised into 
the periphery, could result in a reduction in the absolute number of T cells capable of 
secreting IFN-γ after CMVpp65 stimulation from within a fixed number of PBMCs. 
Another hypothesis to explain the decrease in IFN-γ secretion seen from the T cell pool, 
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is that G-CSF mobilises a population of immature or non-functional T cells that are not 
capable of responding to antigenic stimulation, which would also dilute the pool of IFN-
γ-secreting CMV-T. 
 
It remains unclear whether the use of individual CMVpp65 peptides based upon donor 
HLA type or the use of CMV IE-1 peptides would result in a more efficient system for 
the identification and isolation of CMV-T (Gratama et al, 2008; Zandvliet et al, 2010; 
Slezak et al, 2007) as the kinetics for IFN-γ secretion in G-CSF-mobilised PBMCs may 
differ between epitopes at different peptide concentrations. This provides the basis for 
possible future experiments to ascertain the nature of IFN-γ secretion to individual 
HLA-matched CMV peptides in G-CSF-mobilised PBMCs. 
 
The next aim of this chapter was to investigate the temporal dynamics of a panel of 
activation markers after both SEB and CMVpp65 stimulation in GSF-mobilised and 
non-mobilised PBMCs. Samples from 5 non-mobilised and 5 G-CSF mobilised 
apheresis collections were stimulated over a 24 hour time period to assess activation 
induced expression of CD25, CD69, CD137, CD152 and CD154. No significant 
difference was observed in the baseline expression levels of CD25, CD69, CD137, 
CD152 and CD154 between G-CSF-mobilised and non-mobilised PBMCs, although 
CD25 expression was consistently 2- to 3-fold higher than the other makers, due to the 
pool of naturally circulating Tregs that also express CD25. SEB stimulation of G-CSF-
mobilised PBMCs provided the basis to assess whether T cells maintained the same 
level of maximal activation as non-mobilised PBMCs, which would establish evidence 
for continuing experiments with CMVpp65 stimulation. SEB-stimulated G-CSF-
mobilised PBMCs maintained similar expression levels of CD25, CD69, CD137 and 
CD154 as in non-mobilised PBMCs but showed an increase in expression of CD152. 
Stimulation with CMVpp65 showed no significant differences in the level of expression 
of CD25, CD69, CD137, CD152 and CD154 between non-mobilised and G-CSF-
mobilised PBMCs, although we did identify a trend towards increased expression of 
activation markers in G-CSF-mobilised PBMCs. CD25 was upregulated on a larger 
proportion of T cells after CMVpp65 stimulation, after the subtraction of CD25 
expression in non-stimulated T cells, when compared with other activation markers. 
Previous studies have explored the benefit of depleting naturally expressing CD25+ 
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cells from the PBMC pool prior to CMVpp65 stimulation (Gallot et al, 2001; 
Melenhorst et al, 2008b), which suggests the idea of using CD25 as a potential marker 
for the isolation of CMV-T from G-CSF-mobilised PBMCs. It is tempting to observe 
that the optimal time of CD25 expression, at 16 hours, fits within a convenient, 
logistical time frame for the clinical grade manufacture of CMV-T.  
 
Analysis of CD154 as a target antigen for isolation of CMV-T from G-CSF-mobilised 
PBMCs was optimal at a time point of 6 hours, which like the 16 hour time point for 
optimal CD25 expression, makes it a suitable marker for clinical grade manufacture. 
The short period of stimulation needed for CD154 activated expression together with 
the low to undetectable levels of background CD154 expression also make this antigen 
an optimal target. In line with published results in non-mobilised PBMCs, 
(Chattopadhyay et al, 2005; Frentsch et al, 2005) we have shown that after CMVpp65 
peptide stimulation, CD154 expression in G-CSF-mobilised PBMCs was preserved at 
the cell surface through CD40 blockade which prevented ligation of CD154. We also 
observed a trend towards greater mean expression of CD154 in G-CSF-mobilised 
PBMCs (1.86% ± 0.59) compared with non-mobilised PBMCs (1.22 ± 0.13%).  
 
In terms of their potential utility as activation markers for the isolation of CMV-T, 
CD25 and CD154 show equivalent expression kinetics in G-CSF-mobilised and non-
mobilised PBMCs, and both CD25 (Lugthart et al, 2012) and CD154 (Khanna et al, 
2011) have previously been demonstrated to be viable markers for the clinical scale 
production of virus-specific T cells. 
 
In conclusion, the results presented in this Chapter provide supporting evidence for the 
further investigation of CD25, at an optimal time of 16 hours and CD154 at an optimal 
time of 6 hours, as activation markers for the isolation of CMV-T from G-CSF-
mobilised PBMCs. 
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Chapter 4 
 
Isolation of CMV-T from G-CSF-Mobilised PBMCs Through CD25 
and CD154 Activation-Induced Expression 
 
4.1 Introduction 
 
Data presented in Chapter 3 indicated that both CD25 and CD154 are promising 
activation markers for the isolation of CMV-T in G-CSF-mobilised PBMCs. 
Furthermore CD25 and CD154 reveal maximal expression after CMVpp65 stimulation 
at 16 and 6 hours respectively, which has the potential to translate into clinical grade 
manufacture.  CD25 is up-regulated after CMVpp65 peptide stimulation in conventional 
non-mobilised PBMCs (Gallot et al, 2001) and allows for CMV-T isolation using 
magnetic enrichment. Lugthart and colleagues (2012) (Lugthart et al, 2012) recently 
demonstrated that CD25 can be used as a target for isolating multivirus-specific T cells 
to clinical scale. In this study, normal donor PBMCs were stimulated with CMVpp65, 
EBV and AdV peptides, cultured for 3 days, and then CD25+ cells were enriched using 
anti-CD25 magnetic beads sorted on the CliniMACS plus system. This method for 
generating CMV-T is made attractive by the commercial availability of clinical grade 
CD25 antibodies and a manufacturing system that allows for their magnetic enrichment 
or depletion (CliniMACS, Miltenyi Biotec). Indeed the feasibility of using magnetic 
enrichment with CD25 GMP grade antibodies to clinical scale in non-mobilised  has 
been demonstrated (Powell et al, 2005).  
 
Two groups have examined the depletion of contaminating expressing cells already 
present in PBMCs prior to CMV stimulation (Gallot et al, 2001;Melenhorst et al, 
2008a) in order to remove T regulatory cells (Tregs) which constitutively express 
CD25. However, in both studies, the purity and yield of CMV-T after CD25 enrichment 
were found to be highly variable between donors.  
 
CD4+CD25+ Tregs, which occur naturally in the peripheral blood and originate from 
the thymus (Jordan et al, 2001), have been the subject of intensive research over the last 
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three decades. Tregs express the transcription factor FoxP3, which is generally accepted 
as being the hallmark for the identification of Tregs. They have been show to contribute 
to peripheral self-tolerance in humans (Dieckmann et al, 2001; Jonuleit et al, 2001). 
The importance of naturally occurring CD4+CD25+FoxP3+ Tregs as mediators of self-
tolerance, through suppression of T cell function, is highlighted by humans who lack a 
functional FoxP3 gene. This results in a deficiency of Tregs and patients suffer from 
immune dysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX), an 
often fatal disorder of early childhood characterised by an overactive immune system 
caused by the proliferation of autoaggressive T cells and autoantibody-producing B 
cells (Bennett et al, 2001). 
 
Curiel and colleagues have shown that Tregs can contribute to the growth of human 
tumours in vivo by suppressing tumour-specific T cell immunity in ovarian cancer 
(Curiel et al, 2004). Thus, the removal of Tregs may be important for maximising the 
virus-specific content of CMV-T isolated through CD25. However, as discussed by 
Lugthart and colleagues (2012), there may be some benefit in a virus-specific T cell 
immunotherapy containing a population of Tregs, especially in the HSCT setting where 
patients are also susceptible to some degree of GvHD concomitant with CMV 
reactivation. GvHD can lead to skin, gut and liver disease that can be fatal, and Tregs 
have been successfully demonstrated to prevent GvHD when administered at the time of 
HSCT (Di et al, 2011). Therefore, a population of Tregs contained within a formulated 
dose of CMV-T could suppress the alloreactivity associated with GvHD.. However, it 
should be noted that this theory has yet to be fully elucidated and, furthermore, the 
alloreactivity of virus-specific T cells with the capability of inducing GvHD is an 
intense area of debate. Alloreactivity of virus-specific T cells was first illustrated by 
demonstrating that EBV-specific HLA-B8 restricted T cells cross-react with HLA-B44 
(Burrows et al, 1994), and it has also been suggested in the studies of Amir and 
colleagues that CMV-T cells have the ability to exert allo-HLA reactivity (Amir et al, 
2010). The true risk of GvHD associated with CMV-T immunotherapy is not yet clearly 
defined, but of the studies published to date there has been no excess incidence of 
GvHD  
 
. 
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4.2 Aims of Experiments Described in this Chapter 
 
In this Chapter, the level of contaminating CD25+ Tregs in G-CSF-mobilised PBMCs is 
investigated pre- and post-CMVpp65 stimulation, and following CD25 enrichment 
through assay of FoxP3 expression. The suppressive capacity of CD25–enriched CMV-
T is also investigated using a CFSE-based assay measuring proliferation of PBMCs co-
incubated with CD25+ CMV-T. Tregs have been shown to suppress proliferation of 
CD4+ CD25– (Shevach et al, 2001) and CD8+ T cells (Camara et al, 2003) as well as 
suppressing proliferation of virus-specific CD8+ T cells during chronic hepatitis C 
infection (Boettler et al, 2005). Therefore, the isolation of CMV-T from G-CSF-
mobilised PBMCs through CD25 expression requires the investigation of a possible 
suppressive capacity to determine whether CMV-T manufactured in this way are 
suitable for use in CMV immunotherapy.  
 
In addition to CD25, CD154 has also been shown to be a promising candidate for the 
identification and isolation of virus-specific T cells (Frentsch et al, 2005; Cohen et al, 
2005) and has recently been used as a marker to generate a functional population of 
multivirus-specific T cells (Khanna et al, 2011). Therefore, CMV-T isolation through 
CD154 activation-induced expression is also assessed in this Chapter. CD154+ CMV-T 
from G-CSF-mobilised PBMCs was isolated with magnetic-bead enrichment and 
compared to CD154+ CMV-T from conventional non-mobilised PBMCs to determine 
whether this method is a viable option for clinical grade manufacture of CMV-T. 
Furthermore, comparison with CD25–based isolation will reveal which of the two 
activation markers is the more promising candidate for the identification of CMV-T in 
G-CSF-mobilised PBMCs. 
 
Chapter 4 
 
112 
 
The experimental aims of the Chapter were as follows: 
 
1. To examine the efficiency of magnetic based enrichment of CMV-T from G-
CSF-mobilised PBMCs through CD25 and CD154 and compare directly with 
non-mobilised PBMCs. 
 
2. To identify the level of Treg enrichment and suppressive activity in  
CMV-T isolated through CD25 from G-CSF-mobilised and non-mobilised 
PBMCs. 
 
3. To investigate the impact of depletion of naturally occurring CD25+ T cells 
prior to CMVpp65 stimulation on the generation of CMV-T through CD25 
expression in both G-CSF-mobilised and non-mobilised PBMCs. 
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4.3 Materials and Methods 
 
PBMCs isolated from G-CSF-mobilised and non-mobilised CMV-seropositive healthy 
donors were stimulated with CMVpp65 peptides as outlined in Section 2.6. Cultures 
were stimulated for either 16 hours for the isolation of CMV-T through CD25 
expression or 6 hours for the isolation of CMV-T through CD154 expression. For the 
isolation of CMV-T through CD154, cultures were incubated in the presence of anti-
CD40 antibody (1µg/ml) to prevent ligation of CD154 and preserve its expression at the 
cell surface. Following CMVpp65 stimulation, CD25 or CD154 expressing cells were 
magnetically sorted with anti-PE microbeads conjugated to either CD25– PE or CD154-
PE using MS columns on a MiniMACS device. Counts were performed pre- and post-
enrichment and analysis of CD25+ or CD154+ T cell subsets performed by flow 
cytometry to assess both yield and purity of CMV-T in G-CSF-mobilised and non-
mobilised PBMCs. In some experiments, co-expression of CD25, CD154 and CD69 
was investigated both pre- and post-magnetic enrichment. 
 
CMV-T identified and isolated through CD25 expression were stained for the 
transcription factor FoxP3, which, along with CD4+CD25+ expression, is associated 
with a Treg phenotype. Intracellular staining of FoxP3 was performed using a fixation 
and permeabilisation protocol as described in Section 2.3. FoxP3 expression was 
investigated pre-stimulation, post-stimulation and post-enrichment in G-CSF-mobilised 
(n = 5) and non-mobilised (n = 5) PBMC donors. The suppressive nature of CMV-T 
isolated through CD25 in both G-CSF-mobilised and non-mobilised PBMCs was also 
investigated using a CFSE-based suppression assay. The suppression assay was 
performed as described in Section 2.14.2 by labelling autologous PBMCs with CFSE 
and stimulating them in culture with either SEB or anti-CD3 antibody in the presence of 
either CD25+ or CD25– cells obtained following magnetic enrichment after CMVpp65 
stimulation. The negative controls were unstimulated CFSE-labelled PBMCs and 
unlabelled autologous PBMCs. Conventional CD25+ Tregs isolated from resting G-
CSF-mobilised and non-mobilised PBMCs were also used as a positive control to 
demonstrate effective suppression. Cells were incubated for five days in 96-well round 
bottom plates before harvesting, staining with anti-CD3 APC and acquiring on a 
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FACScan flow cytometer. A minimum of 5,000 CD3+ CFSE+ events were recorded 
and the frequency of expression determined by the percentage of CFSE
high
 CD3+ T cells 
of all CFSE+ CD3+ T cells. Suppression experiments with CD25+ CMV-T were 
performed with cells isolated from G-CSF-mobilised (n = 4) and non-mobilised (n = 4) 
PBMC donors. 
 
The effect of depleting contaminating CD25-expressing cells prior to antigenic 
stimulation was investigated by comparing non-depleted PBMCs with CD25- depleted 
PBMCs in G-CSF-mobilised (n = 3) and non-mobilised (n = 3) donors. For the 
depletion of CD25-expressing cells, PBMCs were incubated with anti-CD25 
microbeads and passed through LD columns placed in the magnetic field of a 
VarioMACS separator (Section 2.10.2). Unlabelled (CD25-depleted) cells were 
collected and stimulated for 16 hours with CMVpp65 peptides along with non-depleted 
PBMCs from the same donor. CD25 expression, following CMV stimulation, was 
assessed by flow cytometry, before enrichment of CD25+ CMV-T as previously 
described. Counts were performed pre- and post- enrichment and analysis of CD25+ T 
cell subsets performed by flow cytometry to assess both the yield and purity of CMV-T 
in non-depleted and CD25-depleted PBMCs. 
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4.4 Results 
 
4.4.1 Isolation of CMV-T through CD25 and CD154 activation-
 induced expression 
 
The efficiency of magnetic enrichment of CMV-T through CD25 and CD154 
activation-induced expression in G-CSF-mobilised PBMCs was compared with non-
mobilised PBMCs (Table 4.1). No significant differences were observed in purity and 
yield of CMV-T between G-CSF-mobilised and non-mobilised PBMCs, although the 
data did show a trend (p=0.11) towards a reduction in CD25 yield with non-mobilised 
PBMCs. Mean purity was shown to be significantly higher in CD25+ compared with 
CD154+ cells (89.9% vs. 48.9%, respectively; p=0.01) in G-CSF-mobilised PBMCs. A 
similar pattern was observed in non-mobilised PBMCs but the difference was not 
significant (82.5% vs. 64.7%; p=0.38). Analysis of CD25+ and CD154+ enriched cells 
also showed that in both G-CSF-mobilised and non-mobilised PBMCs, CD3+ T cells 
were predominantly (>90%) CD4+ (Figure 4.1). 
 
Representative staining for CD25 and CD154 expression from a G-CSF-mobilised and 
non-mobilised PBMC donor is illustrated in Figure 4.2. This highlights the low 
background level of CD154 expression seen in both G-CSF-mobilised (0.31% ± 0.11) 
and non-mobilised PBMCs (0.29% ± 0.11) prior to CMVpp65 stimulation. In 
comparison CD25 expression at rest was significantly elevated (p=0.03) when 
compared with CD154 expression, in both G-CSF mobilised (mean, 3.39% ± 1.34) and 
non-mobilised (mean, 4.69% ± 1.71) PBMCs, thus confirming previous results from 
section 3.4.4.1. Following CMVpp65 stimulation, CD25 expression was significantly 
elevated compared with CD154 expression in both G-CSF-mobilised (6.41% ± 0.63 vs. 
1.97% ± 0.45, respectively; p=0.0004) and non-mobilised (7.50% ± 1.70 vs. 1.35% ± 
0.33, respectively; p=0.007) PBMCs, which could explain the improved purity observed 
in CD25-enriched CMV-T compared to CD154-based enrichment. 
Co-staining for CD25 and CD154 after CMVpp65 stimulation and CD154 enrichment 
showed that expression of both activation markers was mutually exclusive, with low co-
expression observed. This was not the case when looking at co-expression of CD69 and 
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CD154. FACS plots from a G-CSF-mobilised donor (Figure 4.3) show that CD25 was 
minimal following CD154 enrichment (3% of CD154+) at 6 hours, whereas the 
majority of CD154+ cells  co-expressed CD69 (>99%). In comparison co-expression of 
CD25 and CD69 was minimal following CD25 enrichment (9.3% of CD25+) at 16 
hours (Figure 4.4). Given that CD69 is a marker of T-cell activation (Craston et al, 
1997)  this suggested that CD154 might be a more reliable marker of functional CMV-T 
than CD25.  
 
 
   
 Non Mobilised G-CSF Mobilised 
   
CD25 Yield (%) 11.3% (0.1-34.75) 26.12% (3.3-52.7) 
CD25 Purity (%CD25+CD3+) 82.5% (43.0-95.9) 89.9% (85.1-96.5) 
Proportion of CD25+CD4+ (% of CD3+) 75.9% (91.8) 87.7% (97.5) 
Proportion of CD25+CD8+ (% of CD3+) 6.6% (8.2) 2.2% (2.5) 
   
CD154 Yield (%) 28.4% (5.9-44.5) 30.8% (4.0-48.2) 
CD154 Purity (%CD154+CD3+) 64.7% (10.6-91.2) 48.9% (9.6-78.7) 
Proportion of CD154+CD4+ (% of CD3+) 59.9% (92.6) 45.3% (92.6) 
Proportion of CD154+CD8+ (% of CD3+) 4.8% (7.4) 3.6% (7.4) 
 
 
Table 4.1 Comparison of CMV-T cell enrichment through CD25 and CD154 
activation-induced expression in G-CSF-mobilised and non-mobilised PBMCs:  
The mean and range of yield and purity of CD154+ (n = 5) and CD25+ (n = 5) enrichments in 
both G-CSF-mobilised and non-mobilised PBMCs after stimulation with CMVpp65 peptides. 
The mean purity is further dissected to show CD4+ and CD8+ frequencies within the CD3+ 
populations of positively enriched fractions. 
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Figure 4.1 Summary of isolation of CMV-T through CD25 and CD154 in non-
mobilised (n=5) and G-CSF-mobilised (n=5) donors:  
CD154+ and CD25+ fractions after magnetic enrichment were measured for purity and the 
CD8+ and CD4+ T cell populations assessed. 
*P<0.05 
Mob, mobilised 
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Figure 4.2 Isolation of CMV-T through CD154 and CD25 activation-induced 
expression.  
PBMCs isolated from non-mobilised and G-CSF-mobilised donors were stimulated with 
CMVpp65 peptides for either 6 hours for CD154 isolation (A) or 16 hours for CD25 isolation 
(B) and antigen expression measured amongst CD3+ lymphocytes, before stimulation, after 
stimulation and after magnetic enrichment. 
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Figure 4.3 Co-expression of activation markers in CD154 CMV-T in G-CSF-
mobilised PBMCs:  
After a 6-hour CMVpp65 peptide stimulation and subsequent CD154 isolation by magnetic 
bead enrichment, CD3+ T cells were analysed for CD154, CD25 and CD69 co-expression for 
phenotypic assessment. 
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Figure 4.4 Co-expression of activation markers in CD25 CMV-T in G-CSF-
mobilised PBMCs: 
After a 16-hour CMVpp65 peptide stimulation and subsequent CD25 isolation by magnetic 
bead enrichment, CD3+ T cells were analysed for CD25 and CD69 co-expression for 
phenotypic assessment. 
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4.4.2 FoxP3 expression in CD25+ CMV-T 
 
To evaluate whether CD25 is a suitable target for the isolation of CMV-T, the level of 
Treg enrichment was determined by analysing the proportion of CD25+FoxP3+ cells 
amongst CD4+ T cells at three time points: (1) pre-CMVpp65 stimulation; (2) post-
CMVpp65 stimulation; and (3) post-CD25 enrichment. Figure 4.5 illustrates a 
representative experiment in both a G-CSF-mobilised and non-mobilised donor and 
shows two main findings; first that CMVpp65 stimulated G-CSF-mobilised PBMCs 
contain a higher proportion of CD25+ cells expressing FoxP3 and second that this trend 
was continued after enrichment.  
Figure 4.6 summarises experiments from G-CSF-mobilised and non-mobilised donors 
(n=5, both). In pre-stimulated cells, a trend towards a significant increase in the mean 
proportion of CD25+FoxP3+ cells was observed in G-CSF-mobilised (1.80% ± 0.32) 
vs. non-mobilised (0.94% ± 0.29) PBMCs (p=0.07), shown in Figure 4.6A. This was 
consistent with a significant decrease of CD25+FoxP3– cells (Figure 4.6B) in G-CSF-
mobilised (1.31% ± 0.42) vs. non-mobilised (4.82% ± 1.35) pre-stimulated PBMCs 
(p=0.03). Interestingly, no significant difference in CD25+FoxP3+ expression was 
observed post-CMVpp65 stimulation in G-CSF-mobilised (3.67% ± 0.62) and non-
mobilised (3.16% ± 1.09) PBMCs (p=0.69). However, the proportion of CD25+FoxP3+ 
cells after CD25 enrichment was shown to be significantly increased in G-CSF-
mobilised (64.24% ± 4.88) vs. non-mobilised (33.84% ± 7.17) PBMCs (p=0.008), and 
conversely with CD25-FoxP3- cells (21.19% ± 4.03 vs. 38.72% ± 2.70 respectively; 
p=0.006). 
 
Experiments were carried out to determine the absolute number of CD25+ and FoxP3+ 
cells per 10,000 CD4+ T cells. Figure 4.6 presents the data from CD25+ CMV-T 
isolation in G-CSF-mobilised and non-mobilised PBMCs. Analysis of mean FoxP3 
expression amongst CD25+CD4+ T cells highlights the increased FoxP3 expression in 
G-CSF-mobilised (41.35% ± 8.41) compared with non-mobilised (17.5% ± 6.5) PBMCs 
at rest (p=0.05). After CMVpp65 stimulation, a significant increase in mean FoxP3 
expression amongst CD25+CD4+ was observed in G-CSF-mobilised (42.79% ± 4.07) 
compared with non-mobilised (20.84% ± 5.46) PBMCs (p=0.012). Figure 4.7 illustrates 
the significantly increased expression of FoxP3 amongst CD25+CD4+ after CD25 
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enrichment in G-CSF-mobilised (73.64% ± 4.88) compared to non-mobilised (43.82% ± 
5.64) PBMCs (p=0.004). 
 
 
 
  
 
 
 
 
 
 
1
2
3 
C
h
a
p
ter 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Comparison of FoxP3 expression in CD4+ CD25+ T cells between a non-mobilised and a G-CSF-mobilised PBMC donor:  
FoxP3 expression was assessed in pre-stimulated cells, CMVpp65-stimulated cells, and in CD25+ fractions post enrichment. Plots are derived from gating on 
CD3+ CD4+ cells. 
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Figure 4.6 Evaluation of FoxP3 expression in G-CSF-mobilised and non-mobilised 
PBMCs: 
FoxP3 expression was analysed in CD25-expressing (A) and CD25 negative (B) CD4+ T cells 
in G-CSF-mobilised (n=5) and non-mobilised (n=5) donors pre-CMVpp65 stimulation, post-
CMVpp65 stimulation and post-CD25 enrichment.  
*P<0.05 and **P<0.01, in an unpaired t test 
Stim, stimulated; Fra, fraction;  
A 
A 
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Figure 4.7 Assessment of FoxP3 expression in non-mobilised (A) and G-CSF-
mobilised (B) PBMCs:  
CD25 and FoxP3 expression was assessed per 10,000 CD4+ T cells pre-CMVpp65 stimulation, 
post-CMVpp65 stimulation and post-CD25 enrichment. **P<0.01 in an unpaired t test 
comparing CD25+FoxP3+  expression  in the CD25+ fraction between G-CSF-mobilised and 
non-mobilised PBMCs
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4.4.3 Assessment of suppressive nature of CD25+ enriched CMV-T in 
 G-CSF-mobilised PBMCs 
 
Having demonstrated that CD25+ cells enriched after CMVpp65 stimulation from G-
CSF-mobilised PBMCs contain a significant proportion of FoxP3-expressing cells, their 
suppressive activity was assessed using a CFSE-based proliferation assay. Initial 
experiments aimed to establish whether conventional CD25+FoxP3+ Tregs isolated 
from G-CSF-mobilised PBMCs were capable of suppressing T cell proliferation in 
response to SEB stimulation. As illustrated in Figure 4.8 in a representative experiment, 
CD25+ conventional Tregs were able to suppress proliferation of CFSE-labelled 
PBMCs when cultured at a ratio of 1:1 (38% of undivided CD3+ T cells) compared with 
PBMCs alone (22.3% undivided CD3+ T cells). When CFSE-labelled PBMCs were 
cultured in the presence of CD25– cells, no suppression was evident (13.9% of 
undivided CD3+ T cells) compared to PBMCs alone. The elevated T cell proliferation 
compared with PBMCs alone could be explained by an improvement in culture 
conditions with CD25– cells acting as feeder cells for the CFSE-labelled PBMCs. 
 
Next we evaluated the suppressive capacity of CD25+ T cells enriched after CMVpp65 
stimulation in G-CSF-mobilised PBMCs and compared this with the CD25– fraction 
after magnetic enrichment. Both fractions were cultured at ratios of 1:1 and 2:1 and in 
some experiments at 5:1, with CFSE-labelled PBMCs. Suppression experiments were 
carried out with CD25+ enriched cells from G-CSF-mobilised and non-mobilised 
donors (n=4, both). Figure 4.8 illustrates two representative experiments from the four 
G-CSF-mobilised donors. T cell proliferation in the presence of CD25– cells was 
similar to PBMCs alone (18.4% undivided CD3+ T cells) at both 1:1 (25.6% undivided 
CD3+ T cells) and 2:1 (24.3% undivided CD3+ T cells) illustrated in Figure 4.9A. In 
contrast, T cell proliferation was greatly reduced when CFSE-labelled PBMCs were 
cultured in the presence of CD25+ CMV-T at both 1:1 (95% undivided CD3+ T cells) 
and 2:1 (96.3% undivided CD3+ T cells), highlighting a strong suppressive capacity. 
Figure 4.9B shows a similar result in terms of strong T cell suppression exerted by 
CD25+ CMV-T and is achieved at a ratio of 1:1 (28.5% CD3+ T cells undivided) and at 
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5:1 (34.6% CD3+ T cells undivided) compared to PBMCs alone after SEB stimulation 
(5.69% CD3+ T cells undivided).  
Suppression of T cell proliferation by CD25+ CMV-T from non-mobilised PBMCs was 
lower than that from G-CSF-mobilised PBMCs. Figure 4.10 shows representative 
experimental results from two donors. Proliferation of CFSE-labelled PBMCs in 
response to SEB was lower when cultured with CD25+ cells at both 1:1 (19.9% 
undivided CD3+ T cells) and 5:1 (27.7% undivided CD3+ T cells) ratios than with 
CD25– cells at ratios of both 1:1 (15.3% undivided CD3+ T cells) and 5:1 (14.1% 
undivided CD3+ T cells) (Fig 4.10A). However, when PBMCs were stimulated alone, 
27.9% of CD3+ T cells remained undivided, suggesting that no suppression occurred 
with CD25+ CMV-T from non-mobilised PBMCs. A probable explanation for this 
observation is the significant reduction in the proportion of FoxP3+ cells seen in the 
CD4+ CD25+ fraction from non-mobilised PBMCs compared with G-CSF-mobilised 
PBMCs after CMVpp65 stimulation. The reduction in the proportion of Tregs would be 
expected to reduce the suppressive activity of non-mobilised CD25+ CMV-T. Figure 
4.10B illustrates suppression of T cell proliferation by CD25+ CMV-T at a ratio of 1:1 
with CFSE-labelled PBMCs (39.2% CD3+ T cells undivided) compared with CD25– 
cells (14.7% CD3+ T cells undivided), but also at a reduced level than that seen with 
CD25+ CMV-T isolated from G-CSF-mobilised PBMCs. 
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Figure 4.8 Dose-dependent suppression of T cell proliferation by CD25+ T cells in G-CSF-mobilised PBMCs: CD25– and CD25+ T cells 
isolated by magnetic enrichment were cultured at a 1:1 ratio with autologous PBMCs in the presence of SEB. Unlabelled PBMCs, CFSE-labelled PBMCs 
alone (CFSE), and CFSE-labelled PBMCs in the presence of SEB were cultured as experimental controls. 
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Figure 4.9 CFSE Suppression assay in G-CSF-mobilised PBMCs in two donors (A-
B): Dose dependent suppression of T cell proliferation was assessed by CD25 positive and 
CD25 negative fractions after CMVpp65 stimulation and subsequent CD25 enrichment. CFSE-
labelled PBMCs were cultured at two ratios in the presence of SEB for 5 days. Unlabelled, 
PBMCs alone (CFSE) and PBMCs with SEB were cultured as experimental controls. 
A 
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Figure 4.10 CFSE Suppression assay in Non-Mobilised PBMCs in two donors (A-
B):  
Dose dependent suppression of T cell proliferation was assessed by CD25 positive and CD25 
negative fractions after CMVpp65 stimulation and subsequent CD25 enrichment. CFSE-
labelled PBMCs were cultured at two ratios in the presence of SEB for 5 days. Unlabelled, 
PBMCs alone (CFSE) and PBMCs with SEB were cultured as experimental controls. 
A 
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4.4.4 Depletion of CD25-expressing cells prior to CMV 
 stimulation 
 
4.4.4.1 Impact on CD25 activation-induced expression and   
 isolation 
 
Having found that CMV-T isolated from G- CSF-mobilised PBMCs- through CD25 
expression contain a significant proportion of FoxP3 expressing cells and exert a strong 
suppressive capacity, the aim of the next series of experiments was to determine the 
effect of removal of naturally expressing CD25 cells, prior to CMVpp65 stimulation, on 
the Treg content of isolated CD25+ CMV-T. Figure 4.11 shows the effect of CD25 
depletion compared with non-depleted PBMCs in a representative G-CSF-mobilised 
donor. CD25 expression post-CMVpp65 stimulation was dramatically reduced in 
‘CD25-depleted’ PBMCs as was background CD25 expression in the negative control 
(unstimulated) sample. CD25 depletion prior to CMVpp65 stimulation had a 
detrimental effect on the purity of the CD25+ fraction after magnetic enrichment 
compared with the non-depleted sample (17.92% vs. 74.24% respectively). Figure 4.12 
summarises the effect of CD25 depletion in G-CSF-mobilised (n=3) and non-mobilised 
(n=4) donors. Although not significant, results showed a trend towards reduced mean 
CD25+ expression amongst CD3+ T cells in both G-CSF-mobilised (2.87% ± 0.22 vs. 
1.58% ± 0.59; p=0.14) and non-mobilised (3.92% ± 1.39 vs. 1.13% ± 0.61; p=0.16) 
PBMCs after CD25 depletion prior to CMVpp65 stimulation. 
 
The effect of CD25 depletion on the purity and yield of CD25+ cells is shown in Figure 
4.13. In G-CSF-mobilised PBMCs, purity (88.91% ± 0.58 vs. 17.08% ± 12.78; p=0.03) 
was significantly reduced and a trend towards reduced yield (30.68% ± 0.88 vs. 11.26% 
± 7.80; p=0.11) was observed, whereas in non-mobilised PBMCs, both yield (28.27% ± 
9.69 vs. 19.01% ± 10.94; p=0.02) and purity (69.16% ± 11.29 vs. 25.68% ± 3.37; 
p=0.03) were significantly reduced in CD25-depleted PBMCs.  
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Figure 4.11 Effect of depletion of naturally occurring CD25+ cells in G-CSF-mobilised PBMCs on CD25 expression post-CMVpp65 
stimulation and post-CD25 enrichment: A Paired sample either non-depleted or CD25-depleted are shown from a G-CSF-mobilised donor. Plots are 
derived from CD3+ gated cells after gating on the live lymphocyte population using FSC vs. SSC 
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Figure 4.12 CD25+ expression after CMVpp65 stimulation in non-depleted and 
CD25-depleted non-mobilised and G-CSF-mobilised PBMCs:  
Paired samples from both G-CSF-mobilised (n=3) and non-mobilised (n=4) PBMCs donors 
were stimulated for 16 hours with CMVpp65 peptides and CD25 expression analysed amongst 
CD3+ T cells. Bars represent the mean (  SD) percentage after subtraction of the negative 
control (no peptide) 
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Figure 4.13 Comparison of isolation of CD25-expressing cells after CMVpp65 
stimulation between non-depleted and CD25-depleted PBMCs: G-CSF-mobilised 
PBMCs (A) and non-mobilised PBMCs (B) were depleted of CD25-expressing cells prior to 
stimulation or left non-depleted before CD25 enrichment. Bars represent mean (  SD) 
percentage of purity and yield of CD25+ cells from within the CD3+ population. *P<0.05 in a 
paired t test 
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4.4.4.2 Impact on FoxP3 expression 
 
The following experiments aimed to establish the level of FoxP3 expression in 
CD25+CD4+ cells after depletion of contaminating Tregs. Data presented in Section 
4.4.2 showed that after CMVpp65 stimulation of G-CSF-mobilised PBMCs the mean 
proportion of FoxP3+ cells amongst CD25+CD4+ T cells was 43% ± 4.0. This was 
significantly reduced to 8.5% ± 5.4 (p=0.001) in G-CSF-mobilised PBMCs that had 
been depleted of contaminating Tregs prior to CMVpp65 stimulation. Similarly, after 
CD25 enrichment, FoxP3 expression amongst depleted CD25+CD4+ T cells showed a 
mean of 28.4% ± 12.3 compared with 73.6% ± 4.9 (p=0.006) in non-depleted G-CSF-
mobilised PBMCs (Section 4.4.2). 
 
In non-mobilised PBMCs post-stimulation, there was no significant difference in mean 
FoxP3 expression between depleted and non-depleted CD25+ CD4+ T cells (19.6% ± 
9.4 vs. 20.8% ± 5.4, respectively; p=0.90). However, after magnetic enrichment of 
CD25+ CMV-T, a significant reduction in mean FoxP3 expression was observed in 
depleted vs. non-depleted PBMCs (14.6% ± 2.4 vs. 43.8% ± 5.6, p=0.009). The results 
from CD25 depletion experiments and the impact on FoxP3 expression is summarised 
in Figure 4.13, illustrating the proportion of CD25+ FoxP3 expressing cells amongst 
CD4+ T cells. Figure 4.14 also highlights the negative impact on the proportion of 
CD25+ cells after CMVpp65 stimulation and purity after CD25 enrichment. 
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Figure 4.14 Assessment of FoxP3 expression after depletion of naturally occurring 
CD25-expressing cells: CD25 and FoxP3 expression was assessed per 10,000 CD4+ T cells 
post-CMVpp65 stimulation and post-CD25 enrichment in non-mobilised (A) and G-CSF-
mobilised (B) PBMCs. 
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4.5 Discussion 
 
Initial experiments targeted at the identification and isolation of CMV-T from G-CSF 
mobilised PBMC had highlighted two activation markers, CD25 and CD154, as 
candidates for further investigation and also demonstrated the sub-optimal use of IFN-γ 
secretion as a tool for enrichment of CMV-T. The results described in this chapter 
follow the isolation of CMV-T from G-CSF-mobilised through CD25 and CD154 and 
the subsequent functional analysis of CD25 enriched cells with regard to Tregs, due 
their similar CD25 expression pattern. Experiments using G-CSF-mobilised PBMCs 
were compared directly to non-mobilised PBMCs to allow for any significant 
observations to be made. 
 
Isolation of CMV-T from G- CSF-mobilised PBMCs using both CD25 and CD154 
enrichment demonstrated equivalence with non-mobilised in terms of purity. CD25- and 
CD154-enriched CMV-T were predominantly CD4+ cells, which is in keeping with 
published literature on non-mobilised PBMCs (Frentsch et al, 2005; Gallot et al, 2001). 
The purity of CD25-enriched CMV-T was found to be significantly higher than CMV-T 
isolated through CD154 expression in G-CSF-mobilised PBMCs. This difference can be 
explained by the increased proportion of CD25-expressing T cells prior to enrichment 
compared with CD154+ cells, as the efficiency of magnetic enrichment increases with 
the total number of target cells to be isolated. Only by performing clinical scale sorting, 
where the number of cells being sorted are greatly increased from ~50 x 10
6
 to 1 x 10
9
 
cells, can the impact on purity of CD154 and CD25 be definitively evaluated.  
 
The co-expression of CD25 and CD154 after CD154 enrichment was also investigated 
as CD154 cells were predominantly CD4+, suggesting the hypothesis that CD154 
enrichment could reveal a population of Tregs. It has been shown relatively recently that 
antigen-specific CD154+ cells can be identified within a population of CD25+ Tregs 
after CMV stimulation, although the kinetics of CD154 expression in CD25+ Tregs 
differs from that in effector T cells where maximal expression is revealed at 6 hours 
compared with only minimal CD154+ expression in CD25+ Tregs at the same time 
point (Litjens et al, 2012). The results presented here show that in G-CSF-mobilised 
PBMCs, after a 6 hour stimulation with CMVpp65 peptides, CD154+ cells expressed 
 
Chapter 4 
 
 
138 
 
very little CD25 and this was continued following subsequent CD154 enrichment. In 
contrast, CD154 cells co-expressed CD69, demonstrating an effector T cell population, 
whereas CD25+ cells co-expressed minimal CD69 expression after CMVpp65 
stimulation and CD25+ enrichment.  
 
The next part of this chapter focussed on investigating the functionality of CD25 CMV-
T isolated from G-CSF-mobilised PBMCs, with reference to Tregs, which also express 
the CD25 molecule (Sakaguchi et al, 1995). CD25+ cells enriched from G-CSF-
mobilised PBMCs after CMV stimulation contained a high frequency (>65%) of 
expression of the transcription factor FoxP3, a key molecule for identification of 
suppressive function in Tregs (Fontenot et al, 2003). In comparison with G-CSF-
mobilised PBMCs, CD25+ cells enriched from non-mobilised PBMCs showed a 
significantly reduced frequency of FoxP3 expression (<35%; p<0.01). There are two 
main conclusions that can be drawn from these findings. First, that G-CSF mobilisation 
increases the number of naturally circulating CD25+ Tregs; and second, that G-CSF 
mobilisation increases the frequency of CMVpp65-reactive Tregs. Both points raise 
valid arguments about the feasibility of generating a CMV-T product for clinical use 
that contains such a high proportion of FoxP3-expressing Tregs. To address the first 
point, there are very little published data investigating the impact of G-CSF 
mobilisation on circulating Tregs. Tayebi and colleagues (Tayebi et al, 2001) observed 
that after G-CSF mobilisation, the percentage of CD3+CD25+ cells significantly 
decreased in normal healthy donors, contradictory to the results seen here, and, 
furthermore, did not examine FoxP3 expression. Studies in rhesus macaques, have 
shown that the immunostimulant AMD3100, used for the effective mobilisation of 
CD34+ cells, also efficiently mobilised CD4+CD25
high
FoxP3+ into the periphery 
significantly more than mobilisation with G-CSF (Kean et al, 2011). Another study that 
analysed Tregs after G-CSF mobilisation showed a 2-3 fold increase in CD25+ T cells 
that expressed high levels of FoxP3, but this investigation examined patients mobilised 
for autograft who were also administered with high-dose cyclophosphamide 
(Condomines et al, 2006). The cytotoxic effect of low-dose cyclophosphamide has been 
shown by several groups to result in the depletion of Tregs (Frentsch et al, 2005; 
Hoover et al, 1990; Ikezawa et al, 2005; Lutsiak et al, 2005). It has been reported in a 
murine study that high-dose cyclophosphamide had no effect on the absolute number of 
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Tregs but a reduced ratio of Tregs among CD4+ T cells (Hong et al, 2010). This would 
suggest that the increase in Treg numbers seen by Condomines and colleagues was as a 
result of G-CSF administration. More recently, studies investigating the impact of G-
CSF-mobilisation on Treg numbers and function, showed that the number of 
CD4+CD25
high
CD127- Tregs increased 1.6-fold following mobilisation and remained 
highly suppressive on the proliferation of effector T cells (Ukena et al, 2012). Although 
the frequency of CD25+FoxP3+ cells in non-stimulated G-CSF-mobilised PBMCs were 
not significantly increased when compared with non-mobilised PBMCs, the results 
presented here suggest a trend towards increased frequency that might attain statistical 
significance in a study of a larger cohort. Therefore, the hypothesis is that CD25 
enrichment after CMVpp65 stimulation favours selection of CD25+ cells with a Treg 
phenotype due to increased numbers of Tregs in circulation after G-CSF mobilisation.  
 
On the second point above, many studies have indicated the existence of CMV-reactive 
Tregs and indeed Ltjens and colleagues concluded that CD4+CD25+CD127-FoxP3+ 
Tregs contained antigen-specific T cells (Litjens et al, 2012), which is consistent with 
the results seen here. The effect of G-CSF mobilisation appears to elevate Treg numbers 
beyond that of non-mobilised PBMCs and would therefore account for the increased 
numbers of CD25+FoxP3+ cells observed after CMVpp65 stimulation and, more 
significantly, after CD25 enrichment. However, studies have also indicated that FoxP3 
expression can be induced in human CD4+ effector T cells after activation (Walker et 
al, 2005) albeit in CD4+ CD25– cells. This report built on this result with the finding 
that FoxP3 expression is a normal consequence of CD4+ T cell activation, bringing into 
doubt its validity as an exclusive marker of Tregs.  
In the next section of this Chapter, I investigated whether the increased numbers of 
CD25+FoxP3+ cells after CD25 enrichment in G-CSF mobilisation were able to 
function as Tregs in suppressing T cell proliferation. Initial experiments determined that 
naturally occurring CD25+ Tregs isolated from G-CSF-mobilised PBMCs were capable 
of suppressing T cell proliferation in the same manner as conventional Tregs isolated 
from non-mobilised PBMCs. This is an important result in view of the widespread 
interest in manufacturing Tregs for adoptive immunotherapy without the need for ex-
vivo expansion (Ukena et al, 2012). 
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Post-CMVpp65 stimulation, CD25-enriched CMV-T from G-CSF-mobilised PBMCs 
were assessed for their ability to suppress T cell proliferation. Results showed that at 
ratios of 1:1 and 2:1 CD25+ to CFSE-labelled PBMCs, CD25+ cells were capable of 
suppression, which was not seen with CD25– fractions. The level of suppression 
observed with CD25+ CMV-T enriched from G-CSF-mobilised PBMCs was elevated 
compared with that of non-mobilised PBMCs. The higher level of suppression mediated 
with CD25+ CMV-T enriched from G-CSF-mobilised PBMCs can be explained by the 
significantly higher number of CD25+FoxP3+ cells isolated from G-CSF-mobilised 
PBMCs after CMVpp65 stimulation compared with non-mobilised PBMCs. These 
results would suggest that CMVpp65 stimulation of G-CSF-mobilised PBMCs reveals a 
population of Tregs that are not present in non-mobilised PBMCs and are preferentially 
enriched. CMVpp65 stimulation in G-CSF-mobilised PBMCs could induce a population 
of CD25+ Tregs that have antigen specificities and are able to recognize CMVpp65 
peptides and possibly proliferate in response to engagement of their cognate antigen. 
Support for this hypothesis was obtained in a murine model of Leishmania infection, in 
which Tregs proliferated in response to recognition of parasite-derived antigen (Suffia 
et al, 2006). 
 
Very little published data exist regarding the emergence and generation of Tregs during 
CMVpp65 stimulation and certainly none with regard to G-CSF mobilisation. However, 
Melenhorst and colleagues (Melenhorst et al, 2008a)  have demonstrated the emergence 
of a significant population of FoxP3+CD4+ and FoxP3+CD8+ T cells after CMVpp65 
stimulation in non-mobilised PBMCs but failed to demonstrate any subsequent 
suppression. However, CD4+CD27-CD28- cells sorted from CMVpp65-stimulated 
PBMCs was shown to include a population of cells with the capacity to inhibit de novo 
CMV-specific proliferation of autologous PBMCs (Tovar-Salazar et al, 2010) which 
would support the hypothesis that adaptive Tregs may arise as a consequence of 
antigenic stimulation. 
 
The hypothesis that CMVpp65 stimulation of G-CSF-mobilised PBMCs results in the 
emergence of a population of CD25+FoxP3+ cells with a suppressive capacity clearly 
requires further experimental investigation. However, in the context of manufacturing 
CMV-T for adoptive immunotherapy, it highlights potential problems with targeting 
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CD25 as an activation marker. With this in mind, the experiments in the final Results 
section sought to investigate the impact of depleting CD25-expressing cells prior to 
CMVpp65 stimulation in order to eliminate the high level of CD25+FoxP3+ 
suppressive cells in the enriched fractions from G-CSF-mobilised PBMCs. Results 
showed a reduction in CD25 expression post-CMVpp65 stimulation in both G-CSF-
mobilised PBMCs and non-mobilised PBMCs, which had a negative impact on both 
purity and yield after CD25 enrichment. The reduction in CD25 expression is partly 
explained by the elimination of contaminating Tregs prior to CMVpp65 stimulation, as 
indeed was the aim, but could also be attributed to a population of CMV-T that are in an 
activated state and express CD25 prior to CMVpp65 stimulation in vitro. The 
significant decrease in purity post-CD25 enrichment observed in both G-CSF-mobilised 
and non-mobilised PBMCs can be explained firstly by the reduced proportion of CD25-
expressing cells and, secondly, by a possible reduction in the intensity of CD25 
expression which would negatively effect magnetic enrichment.  
 
The impact on FoxP3 expression in cells depleted of contaminating CD25+ Tregs was 
also investigated. Although a significant reduction in FoxP3 expression was observed in 
CD25-depleted PBMCs post-CMVpp65 stimulation, FoxP3 expression post-CD25 
enrichment was still detectable. These results suggest either the emergence of newly 
expressing FoxP3 cells or persistence of FoxP3+CD25– cells following the depletion 
step. These results observed with PBMCs isolated from G-CSF-mobilised donors is in 
keeping with the findings of Melenhorst and colleagues (Melenhorst et al, 2008a) , and 
suggests that removal of Tregs using CD25 depletion prior to CMVpp65 is not an 
effective strategy for boosting the purity of CMV-specific cells isolated through CD25 
expression. 
 
The results from this Chapter illustrate the feasibility of isolating CMV-T from G-CSF-
mobilised PBMCs through both CD154 and CD25, although the overwhelming Treg 
phenotype observed when using CD25 appears to rule out its use. However, Lugthart 
and colleagues (Lugthart et al, 2012), using non-mobilised PBMCs, demonstrated that 
multivirus-specific T cells isolated through CD25 expression contain a population of 
Tregs and yet secrete IFN-γ and lyse virally infected target cells. Furthermore, they 
argued that it is unlikely that infused Tregs will prevent proliferation of virus-specific T 
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cells; a hypothesis that was supported by studies in mice showing that co-infusion of 
Tregs and conventional T cells enhances virus-specific immune reconstitution in the 
HSCT setting (Nguyen et al, 2008). These findings encouraged the further investigation 
of the functional capacity of CD154+ and CD25+ CMV-T isolated from G-CSF-
mobilised PBMCs, which is described in the following Chapter. 
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Chapter 5  
 
Expansion of CD154+ and CD25+ CMV-T isolated from G-CSF-
mobilised PBMCs and assessment of cytotoxic effector function 
 
5.1 Introduction 
 
In order to manufacture CMV-T isolated from G-CSF-mobilised PBMCs as a 
therapeutic alternative to CMV-T isolated from non-mobilised PBMCs, the functional 
assessment of CD25+ and CD154+ CMV-T after short term culture is essential. The in 
vitro expansion of CMV-T isolated from G-CSF-mobilised PBMCs together with the 
retention of potent anti-viral properties, determined by cytokine secretion and cytotoxic 
capabilities, would demonstrate the feasibility of manufacturing CD25- and CD154-
selected CMV-T at a clinical scale for therapeutic use. 
 
It has yet to be successfully demonstrated that anti-viral T cells isolated from  
G-CSF-mobilised PBMCs are capable of either expansion in short term culture or 
cytotoxicity when re-challenged with CMV loaded target cells. However, clinical-scale 
isolation of γδ T cells from G-CSF-mobilised donors showed a level of cytotoxicity 
towards the target erythroleukaemic cell line K562 and the neuroblastoma line NB-
1691(Otto et al, 2005) that was comparable to γδ T cells isolated from non-mobilised 
PBMCs (Schilbach et al, 2001). Although there is limited published data comparing the 
efficacy and toxicity of G-CSF-mobilised DLI with non-mobilised DLI, G-CSF-
mobilised DLI are routinely used in several transplant centres for the successful 
resolution of mixed chimerism. A recent study comparing G-CSF-mobilised and non-
mobilised DLI therapy following allogeneic HSCT reported similar therapeutic activity 
and also a similar incidence of GvHD (Abbi et al, 2013), suggesting G-CSF-mobilised 
PBMCs retain a comparable functional capacity when compared with non-mobilised 
PBMCs. 
  
Several groups have shown that anti-viral T cells isolated from non-mobilised PBMCs 
through CD154 isolation are capable of expansion and reveal a high level of specificity 
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when re-challenged (Frentsch et al, 2005; Cohen et al, 2005; Kirchhoff et al, 2007; 
Khanna et al, 2011). Expansion of CD154 anti-viral T cells from non-mobilised PBMCs 
was shown to have a predominance of CD4+ T cells after enrichment. However, 
Khanna and colleagues (Khanna et al, 2011) showed that the low frequency of CD8+ 
anti-viral T cells in CD154 T cell lines did not hamper the effectiveness of target cell 
killing compared with isolated CD8+ T cells alone in adenovirus (AdV)- and EBV 
latent membrane protein 2 (LMP2)-specific lines. The study of Frentsch and colleagues 
(Frentsch et al, 2005) was the first publication to demonstrate in non-mobilised PBMCs 
that CD154-isolated CMV-T expanded in short term culture contained a population of 
cells capable of secreting high levels of IFN-γ upon antigenic re-challenge, thereby 
illustrating their potential cytotoxic nature. A comprehensive study of the cytokine 
profile secreted by CD154-expanded CMV-T has yet to be reported; this will be 
addressed in the current Chapter.  
 
The expansion of anti-viral T cells with cytolytic activity from non-mobilised PBMCs 
selected on the basis of CD25 expression has also been successfully demonstrated after 
isolation from non-mobilised PBMCs (Gallot et al, 2001; Lugthart et al, 2012). 
However, no studies have determined the survival of CD25+ FoxP3-expressing Tregs 
that are also enriched after antigenic stimulation. This consideration becomes more 
important when attempting to expand CD25+ CMV-T from G-CSF-mobilised PBMCs, 
as the results reported in Chapter 4 (section 4.4.2) revealed a significant increase in the 
proportion of FoxP3- expressing cells after CD25+ enrichment compared with non-
mobilised PBMCs. Co-infusion of Tregs and conventional T cells has been shown to 
enhance recovery of virus-specific immune reconstitution in murine models (Nguyen et 
al, 2008). However, the hypothesis that the adoptive transfer of CD25+ CMV-T that 
contained a proportion of Tregs would benefit the donor, in terms of GvHD prevention, 
without risk to restoration of cellular immunity has not been tested. A determination of 
the proportion of FoxP3+ Tregs retained in CD25 CMV-T cultures following isolation 
and expansion from G-CSF-mobilised PBMCs is vital in assessing the feasibility of 
manufacturing these cells for clinical use.  
 
Data presented in Chapter 4 showed that after CD25+ and CD154+ enrichment 
following CMVpp65 stimulation, CD4+ T cells are the predominant T cell subset. 
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CD4+ T cells are considered for the most part to be dedicated towards the orchestration 
of cytotoxicity, rather than being directly responsible for cytotoxic activity. The in vivo 
existence of CD4+ T cells capable of mediating killing has been the subject of much 
debate in the past and because observations of such cytotoxic activity had been 
restricted to CD4+T cell lines and clones, it had been considered by some to be an 
artefact (Fleischer, 1984). More recently, the identification and characterisation of 
CD4+ cytotoxic T lymphocytes (CTLs) has confirmed the existence of such a 
population of T cells through the study of perforin expression, a molecular mechanism 
of cytotoxicity (Appay et al, 2002b). The identification of a subset of CMV-specific 
CD4+ CTLs in the peripheral blood in response to CMV antigenaemia (Suni et al, 2001; 
van Leeuwen et al, 2004) has aided the emerging hypothesis of a role for CD4+ T cells 
as mediators of protection against viral infections. Indeed, this hypothesis is 
strengthened by the mechanism of immune evasion of viruses such as CMV, which 
impair the CD8+ T cell response of MHC class I antigen processing and presentation 
(Petersen et al, 2003), thus presenting a cytotoxic role for CD4+ T cells. Clinical trials 
using both CD4+ T cell clones (Perruccio et al, 2005) and CD4+ T cell lines (Einsele et 
al, 2002) manufactured from non-mobilised PBMCs have demonstrated effective 
control of CMV disease. Therefore, an assessment of the cytotoxic capacity of CD25+ 
and CD154+ CMV-T isolated from G-CSF-mobilised PBMCs, in which CD4+ cells are 
the predominant T cell subset, was a key objective of this Chapter. 
 
5.2 Aims of Experiments Described in this Chapter 
 
The initial aims of this Chapter were to expand both CD25+ and CD154+  
CMV-T in short term culture following magnetic enrichment, and subsequently to test 
the CMV specificity of expanded cells through antigenic re-challenge. Expansion was 
investigated in both G-CSF-mobilised and non-mobilised PBMCs to ascertain the 
impact G-CSF may have on the potential for CMV-T expansion. Following short term 
culture, expanded cells were re-challenged with autologous PBMCs loaded with 
CMVpp65 antigens to ascertain the specificity of expanded cells. The cytokine profile 
of expanded cells from G-CSF-mobilised PBMCs was investigated in response to 
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CMVpp65 re-challenge and compared directly against non-mobilised PBMCs, using 
both CBA and ICS. 
 
Expanded CD25+ CMV-T were tested to identify whether FoxP3 expressing Tregs were 
maintained in short term culture and if any suppressive capacity existed.  
 
I also aimed to identify the cytolytic activity of expanded CMV-T from both CD25+ 
and CD154+ enrichments using a calcein-based cytotoxicity assay. Comparisons 
between both CD154 and CD25 CMV-T isolated from non-mobilised and G-CSF-
mobilised PBMCs were made to ascertain any differences in functionality. In addition, 
cultures were monitored for CD57 expression, a marker associated with replicative 
senescence and activation-induced apoptotic death (Brenchley et al, 2003). It has been 
proposed in some studies that chronic stimulation of T cells, such as that which occurs 
with CMV, can result in a reduced capacity for cell division in both CD4+ (Fletcher et 
al, 2005) and CD8+ (Voehringer et al, 2001) T cell subsets. Determining the level of 
CD57 expression in expanded cells will indicate the potential capacity for replication in 
vivo, were they to be used in a clinical setting. 
 
A final aim of this Chapter was to identify which activation marker would be the best 
candidate for clinical scale manufacture of CMV-T after isolation from  
G-CSF-mobilised PBMCs. 
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The experimental aims of the Chapter were as follows: 
 
1. To expand CMV-T isolated from G-CSF-mobilised PBMCs through CD154 or 
CD25 and directly compare against expanded CMV-T isolated from non-
mobilised PBMCs. 
 
2. To establish the specificity of expanded CMV-T through antigenic re-challenge.  
 
3. To compare the functional profile of expanded CMV-T from G-CSF-mobilised 
PBMCs though cytokine profiling after re-challenge against that of non-
mobilised PBMCs. 
 
4. To compare the cytotoxic capability of expanded CMV-T from G-CSF-
mobilised PBMCs in response to co-culture with CMV-pulsed target cells 
against that of non-mobilised PBMCs. 
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5.3 Materials and Methods 
 
CD25 and CD154 expressing cells magnetically enriched following CMVpp65 peptide 
stimulation were counted and resuspended at a concentration of 0.25 x 10
6
/ml, and 
incubated in 24-well plates in the presence of irradiated autologous PBMCs at a ratio of 
50:1 (feeders:CMV-T) for up to 23 days. Cultures were supplemented with 10ng/ml of 
IL-7 and IL-15, and the medium changed every 3-4 days. Cultures were counted and the 
T cell phenotype assessed by flow cytometry every 3 days and cultures split when the 
concentration exceeded 3 x 10
6
/ml, usually around day 7–10. In cultures where the total 
cell number exceeded 30 x 10
6
, cells were transferred from 24-well plates into T-25 
culture flasks (Nunc). 
 
Expanded cells were harvested no later than day 23 for final phenotypic analysis, 
antigenic re-challenge and cytotoxicity assays. Autologous PBMCs, previously 
cryopreserved, were thawed prior to re-challenge and loaded with CMVpp65 peptides, 
or left untouched as a negative control. In some experiments, autologous PBMCs were 
loaded with CMV-IE peptides to allow the assessment of specificity. Re-challenge 
experiments consisted of co-culture of autologous PBMCs with expanded cells at a ratio 
of 2.5:1 to 5:1 (PBMCs:CMV-T), dependent upon availability of cell number, in 12-
well plates for 6 hours in the presence Brefeldin A (1µg/ml) to allow for ICS. Secretion 
of IL-2, TNF-α, IFN-γ, Granzyme B and, in the case of CD25-expanded CMV-T, IL-10 
were assessed by flow cytometry after antigenic re-challenge. Aliquots of supernatants 
from re-challenge cultures were frozen for subsequent use in a CBA assay for further 
determination of cytokine secretion. Surface expression of CD25 and CD154 was also 
assessed after re-challenge in the absence of Brefeldin A, after 6 hours. CD25-expanded 
cells were assessed for FoxP3 expression and their suppressive capacity determined 
using the CFSE suppression assay targeted towards SEB-stimulated autologous 
PBMCs, as previously described in Chapter 4 (section 4.4.3). 
 
Autologous PBMCs were stimulated with PHA (3µg/ml) for 24 hours, followed by 
20IU/ml of IL-2 for 72 hours to use as targets in a cytotoxicity assay. PHA blasts were 
then loaded with CMVpp65 peptides or left untouched before labelling with Calcein-
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AM (Neri et al, 2001) and incubating with CMV-T-expanded cells in 24-well plates for 
4 hours at E:T ratios ranging from 0.5:1 to 20:1. Lysis of target cells was determined by 
fluorescence using a microplate fluorescence spectrophotometer. In some experiments, 
target cells were blocked from engaging CD4+ or CD8+ T cells or both using purified 
HLA class I and class II antibodies after calcein labelling, to assess the T cell subset 
predominantly responsible for cytotoxicity. 
 
In both CD25 and CD154 expansions, experiments using G-CSF-mobilised PBMCs 
were compared directly with conventional non-mobilised PBMCs and any statistical 
difference determined using an unpaired t-test. 
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5.4 Results 
 
5.4.1 Expansion of CD154+ and CD25+ CMV-T 
 
Figure 5.1 illustrates the expansion of CMV-T after CD154 selection from  
G-CSF-mobilised donors (Figure 5a) and non-mobilised donors (Figure 5b). CD154+ 
CMV-T from G-CSF-mobilised PBMCs were cultured for up to 23 days and showed no 
significant difference (p=0.75) in their mean proliferative capacity (90.4-fold expansion 
± 25.6) compared with cells from non-mobilised PBMCs (104.4-fold expansion ± 37.4). 
Both G-CSF-mobilised and non-mobilised expanded cells were >90% CD3+ and were 
predominantly CD4+ (mean, 98%) in all cultures, although a small fraction of expanded 
cells expressed CD8 (mean, 2%). Representative staining for CD3, CD4 and CD8 over 
21 days expansion of CD154+ CMV-T from a G-CSF-mobilised donor is illustrated in 
Figure 5.2. This highlights the elevated lymphocyte purity of expanded cells and also 
the high CD3+ purity coupled with the predominance of CD4+ T cells. 
 
The mean proliferative capacity of CD25+ CMV-T expanded from G-CSF-mobilised 
PBMCs (90.3-fold expansion ± 30.0) was similar to that of CD154+ CMV-T. However, 
a trend (p=0.06) towards an increased mean proliferative capacity of CD25+ CMV-T 
was observed in non-mobilised PBMCs (175.2-fold expansion ± 21.0) vs. G-CSF-
mobilised PBMCs. In contrast to CD154+ CMV-T, CD25+ expanded cells were a 
mixture of both CD4+ and CD8+ T cells. G-CSF-mobilised CD25+ CMV-T revealed a 
higher mean proportion of CD4+ T cells compared with non-mobilised PBMCs 
(44.13% ± 17.04 vs. 13.7% ± 7.07; p=0.18); and a trend towards a significantly reduced 
proportion of CD8+ T cells compared with non-mobilised PBMCs (53.0% ± 17.31 vs. 
80.2% ± 11.18; p=0.06). Interestingly, in two of the five CD25 expansion experiments 
performed from G-CSF-mobilised donors, the CD8+ subset at day 22 accounted for 
>90% of CD3+ T cells compared with <5.5% CD4+, which was contradictory to the 
results seen in the remaining three CD25 expansions from G-CSF-mobilised donors. 
However, in both the predominantly CD8+ expanded cell lines, the CD25+ fractions 
isolated after magnetic enrichment were comparable to the CD25+ fractions from the 
other three expansions, with respect to having a predominantly CD4+ fraction. The 
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change of phenotype over short term culture, from predominantly CD4+ to 
predominantly CD8+, is illustrated in Figure 5.4 and will be discussed later in this 
Chapter.  
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Figure 5.1 Expansion of CD154+ CMV-T in short term culture 
CD154+ CMV-T were expanded in short term culture for up to 23 days in the presence of IL-7, 
IL-15 and 12.5 x 10
6
 irradiated autologous feeder cells from both G-CSF-mobilised (A) and 
non-mobilised (B) donors. 
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Figure 5.2 T cell phenotype of CD154+ CMV-T isolated from G-CSF-mobilised 
PBMCs cultured over 21 days 
Freshly isolated CMVpp65-stimulated CD154+ cells were expanded in short term culture over 
21 days in the presence of IL-7, IL-15 and irradiated feeder cells. Lymphocyte purity was 
assessed together with CD4+ and CD8+ T cell phenotype at 4 different time points. 
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Figure 5.3 Expansion of CD25+ CMV-T in short term culture 
CD154+ CMV-T were expanded in short term culture for up to 24 days in the presence of IL-7, 
IL-15 and 12.5 x 10
6
 irradiated autologous feeder cells from both G-CSF-mobilised (A) and 
non-mobilised (B) donors. 
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Figure 5.4 T cell phenotype of CD25+ CMV-T isolated from a G-CSF-mobilised donor cultured over 22 days 
Freshly isolated CMVpp65-stimulated CD25+ cells were expanded in short term culture over 22 days in the presence of IL-7, IL-15 and  
irradiated feeder cells. Lymphocyte purity was assessed together with CD4+ and CD8+ T cell phenotype at 6 different time points. 
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5.4.2 Antigenic re-challenge of expanded cells 
 
To determine the specificity of CD154 and CD25 expanded cells, the cytokine profile 
was examined in response to CMVpp65 peptide re-challenge together with Granzyme B 
secretion and co-expression of CD69. Where sufficient cells were available, expanded 
cells were re-challenged with an irrelevant CMV peptide to determine specificity to 
CMVpp65.  
 
5.4.2.1 CD154 
 
Figure 5.5 illustrates representative data showing the specificity of CD154+ expanded 
CMV-T after CMVpp65 re-challenge in one G-CSF-mobilised donor and one non-
mobilised donor. Experiments to determine the specificity of CD154+ T cells after 
CMVpp65 re-challenge of expanded cells are summarised in Figure 5.6. Mean levels of 
CD154+ CD69+ co-expression in both G-CSF-mobilised (83.3% ± 5.03) and non-
mobilised (60.96% ± 15.5) PBMCs, showed specificity for CMVpp65 upon re-
challenge with autologous PBMCs loaded with CMVpp65 peptides. Re-challenge of 
expanded cells with autologous PBMCs alone did not induce CD154 expression in 
either G-CSF-mobilised or non-mobilised PBMCs. Stimulation of expanded cells with 
autologous PBMCs loaded with CMV IE-1 peptides also revealed low mean levels of 
CD154 expression in both G-CSF-mobilised (4.24% ± 2.9) and non-mobilised (5.83% ± 
2.7) PBMCs.  
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Figure 5.5 Re-challenge of CD154+ CMV-T expanded from one G-CSF-mobilised 
and one non-mobilised donor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Summary of CD154 and CD69 expression after antigenic re-challenge 
0
10
20
30
40
50
60
70
80
90
100
G-CSF Mobilised (n=6)
Non-Mobilised (n=5)
CMVpp65      Nil Peptide     CMV IE-1
%
 C
D
1
5
4
+
  
C
D
6
9
+
 Chapter 5 
 
158 
 
Expanded cells were also re-challenged to assess the secretion of effector cytokines by 
ICS determined by flow cytometry. Figure 5.8 shows representative data comparing 
cytokine secretion in one G-CSF-mobilised and one non-mobilised donor after re-
challenge with CMVpp65 peptides. The combined assessment of IL-2, TNF-α, IFN-γ 
and Granzyme B after re-challenge is illustrated in Figure 5.7 using data generated from 
expanded cells in six G-CSF-mobilised and five non-mobilised donors. Expanded cells 
from both G-CSF-mobilised and non-mobilised PBMCs synthesised and secreted 
similar mean levels of IL-2 (25.3% of CD3+ ± 11.8 vs. 38.3% ± 12.1; p=0.47), TNF-α 
(24.4% ± 7.3 vs. 25.5% ± 8.1; p=0.93) and IFN-γ (69.5% ± 9.3 vs. 54.1% ± 14.3; 
p=0.37) with no significant differences observed. Expanded cells were also highly 
positive for Granzyme B both after re-challenge with CMVpp65 peptides, indicating 
that cells possessed the effector molecules necessary for cytotoxic activity. Comparison 
between mean Granzyme B expression in G-CSF-mobilised (79.4% ± 2.7) and non-
mobilised (83.5% ± 4.1) PBMCs also showed equivalence with no significant difference 
detected (p=0.53). In experiments where expanded cells were unstimulated or incubated 
with CMV-IE peptides, minimal cytokine secretion was observed. 
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Figure 5.7 Summary of cytokine secretion after antigenic re-challenge from 
CD154+ CMV-T 
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Figure 5.8 Cytokine secretion in re-challenged CD154+ CMV-T from one  
G-CSF-mobilised and one non-mobilised donor 
Histograms are generated after live cell gating on lymphocytes using FSC vs. SSC plots and 
after subsequent gating on CD3+SSC
low
 events. Open peaks represent matched isotype controls 
and filled peaks represent test samples. 
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Having demonstrated synthesis and secretion of effector molecules by CD154+ 
expanded cells using ICS, cytokine secretion was further assessed through the analysis 
of culture supernatants after re-challenge with CMVpp65 peptides. Cytokine 
concentration was measured for IL-2, TNF-α, IFN-γ, IL-4, IL-5 and IL-10 using the 
CBA assay and results are summarised in Figure 5.9. Cytokine levels were again 
comparable in expanded cells from G-CSF-mobilised and non-mobilised PBMCs, with 
no significant differences observed. Analysis of mean cytokine levels in expanded cells 
from G-CSF-mobilised PBMCs revealed a predominantly cytotoxic phenotype,with 
significant levels of TNF-α (26,960  8667 pg/ml),  IL-2 (7791  5400 pg/ml), and IFN-
γ (8091  1457 pg/ml;) secretion. Low levels of IL-5 (237  140 pg/ml) and IL-10 (35  
16 pg/ml) secretion were observed and interestingly a high concentration of IL-4 
secretion (14,759  7065 pg/ml).  
 
The CMVpp65 specificity of CD154+ expanded cells is evident when comparing 
cytokine levels in these cells against those in PBMCs following CMVpp65 stimulation, 
as reported in Chapter 3 (section 3.4.1). In CD154+ expanded CMV-T vs. G-CSF-
mobilised PBMCs (Table 5.1), mean IL-2 secretion increased 22-fold, mean IFN-γ 
secretion increased 15-fold, whilst mean TNF-α secretion increased by 88-fold. In 
CD154+ expanded CMV-T vs. non-mobilised PBMCs, mean IL-2 secretion also 
increased 22-fold, mean IFN-γ secretion increased 4.5-fold, and mean TNF-α secretion 
increased 23-fold. Most striking were the 5904-fold increase of IL-4 secretion in 
CD154+ expanded CMV-T vs. G-CSF-mobilised PBMCs, and the 659-fold increase of 
IL-4 secretion in CD154+ expanded CMV-T vs. non-mobilised PBMCs. 
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Figure 5.9 Cytokine secretion detected in culture supernatant of CD154+ expanded 
cells after CMVpp65 re-challenge 
Quantitative assessment of IL-2, IL-4, IL-5, IL-10, TNF-α and IFN-γ detected in the supernatant 
of cultures after a 6-hour re-challenge with autologous PBMCs loaded with CMVpp65 peptides. 
Performed by CBA in G-CSF-mobilised (n=5) and non-mobilised (n=4) donors 
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G-CSF-Mobilised 
     
 IL-2 TNF-α IFN-γ IL-4 
        
PBMC Exp PBMC Exp PBMC Exp PBMC Exp 
         
Mean Conc. 
(pg/ml) 
354 7791 306 26960 548 8091 3 14760 
         
Range 
(pg/ml) 
30 – 
1328 
607 – 
29165 
52 – 
1247 
4053 – 
48906 
140 – 
1195 
5572 – 
13540 
0 – 6 
80 – 
40839 
         
Fold 
Increase 
 22  88  15  5904 
 
 
 
 
Non-Mobilised 
 
 IL-2 TNF-α IFN-γ IL-4 
        
PBMC Exp PBMC Exp PBMC Exp PBMC Exp 
         
Mean Conc. 
(pg/ml) 
235 5178 1756 39604 2028 9137 13 8497 
         
Range 
(pg/ml) 
27 – 
450 
584 – 
14659 
37 – 
8129 
589 – 
61353 
497 – 
5753 
4143 – 
10721 
0 – 48 
683 – 
12090 
         
Fold 
Increase 
 22  23  4.5  659 
 
Table 5.1 Comparison of mean cytokine concentration between PBMCs and 
CD154+ expanded CMV-T (Exp) following CMVpp65 stimulation in both G-CSF-
mobilised PBMCs (A; n=5) and non-mobilised PBMCs (B; n=5) 
 
A 
B 
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5.4.2.2 CD25 
 
Expanded CD25+ CMV-T were re-challenged with autologous PBMCs loaded with 
CMVpp65 peptides to determine their CMV specificity and cytokine repertoire, as 
described for expanded CD154+ CMV-T. The results obtained were also compared 
directly with those of expanded CD154+ CMV-T to ascertain the suitability of CD25 as 
a target molecule for the effective manufacture of CMV-T. Figure 5.10 illustrates 
representative CD25+ CD69+ co-expression after antigenic re-challenge in expanded 
CD25+ CMV-T from one G-CSF-mobilised donor and one non-mobilised donor. Figure 
5.11 shows a summary of CD25+ CD69+ co-expression after re-challenge in all CD25 
CMV-T expansion experiments. Mean levels of CD25+ CD69+ co-expression in 
CD25+ expanded CMV-T from both G-CSF-mobilised (64.9% ± 15.7) and non-
mobilised (38.0% ± 8.0) PBMCs showed specificity for CMVpp65. The reduction in 
CD25+ CD69+ expression observed in CD25+ expanded CMV-T from non-mobilised 
vs. mobilised PBMCs was not statistically significant (p=0.23). Re-challenge with 
autologous PBMCs alone produced a low mean level of CD25+ CD69+ co-expression 
in CD25+ expanded CMV-T from G-CSF-mobilised (10.0% ± 4.9) and non-mobilised 
(3.7% ± 1.4) PBMCs. 
 
Determining the cytokine profile of CD25+ expanded CMV-T was achieved through 
ICS with the addition of IL-10 staining. The rationale for determining the level of IL-10 
secretion was based on results presented in Chapter 4 indicating that after magnetic 
enrichment following CMVpp65 stimulation, CD25-expressing cells contained a 
significant population of FoxP3-expressing Tregs. Tregs are associated with a 
suppressive function, which is achieved partly through IL-10 secretion (Groux et al, 
1997).  
 
Figure 5.12 illustrates representative data from one G-CSF-mobilised and one non-
mobilised donor after CMVpp65 re-challenge. The cumulative data from re-challenge 
of CD25+ expanded cells in five G-CSF-mobilised and four non-mobilised donors is 
summarised in Figure 5.13. CD25+ expanded CMV-T revealed low to undetectable 
mean levels of IL-10 secretion after CMVpp65 re-challenge from both G-CSF-
mobilised (0.11% ± 0.05) and non-mobilised PBMCs (0.41% ± 0.10). A trend towards 
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increased mean cytokine secretion in expanded CD25+ CMV-T from G-CSF-mobilised 
PBMCs vs. non-mobilised PBMCs was revealed for IL-2 (11.5% ± 4.5 vs. 4.7% ± 2.4, 
respectively; p=0.25) and TNF-α (36.0% ± 12.9 vs. 25.0% ± 7.6, respectively; p=0.51). 
This difference became significant (p=0.02) when comparing mean IFN-γ secretion 
between CD25+ expanded cells from G-CSF-mobilised (78.4% ± 5.2) and non-
mobilised (50.0% ± 9.1) PBMCs after CMVpp65 re-challenge. A comparison of mean 
Granzyme B expression in G-CSF-mobilised (66.8% ± 16.2) and non-mobilised (73.8% 
± 17.5) PBMCs revealed no significant difference (p=0.79). Similar to the results 
observed after CMVpp65 re-challenge of CD154+ expanded cells, CD25+ expanded 
cells exhibited minimal cytokine secretion when cells were unstimulated or incubated 
with CMV-IE peptides. 
 Chapter 5 
 
166 
 
 
Figure 5.10 Re-challenge of CD25+ CMV-T expanded from one G-CSF-mobilised 
and one non-mobilised donor 
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Figure 5.11 Summary of CD25 and CD69 expression after antigenic re-challenge 
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Figure 5.12 Cytokine secretion after CMVpp65 re-challenge in CD25+ CMV-T 
from both a G-CSF-mobilised donor and a non-mobilised donor 
Histograms are generated after live cell gating on lymphocytes using FSC vs. SSC plots and 
after subsequent gating on CD3+SSC
low
 events. Open peaks represent matched isotype controls 
and filled peaks represent test samples. 
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Figure 5.13 Summary of cytokine secretion after antigenic re-challenge in CD25+ 
CMV-T 
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The CBA assay was used to further determine the concentration of IL-2, IL-4, IL-5, IL-
10, TNF-α and IFN-γ secreted after re-challenge (Figure 5.14). In line with the results 
observed with CD154+ expanded cells, CD25+ expanded cells from G-CSF-mobilised 
PBMCs showed no statistical difference compared with non-mobilised PBMCs in the 
levels of any of the cytokines. Furthermore, analysis of CD25+ expanded CMV-T from 
G-CSF-mobilised PBMCs revealed a similar profile to that of CD154+ expanded CMV-
T, in mean concentration of TNF-α (27,430  12540 pg/ml),  IL-2 (5849  4866 pg/ml) 
and IFN-γ (12,620  859 pg/ml) secretion. The mean concentration of IL-4 levels 
(10,960  5974 pg/ml) from G-CSF-mobilised PBMCs was comparable to that of IL-2 
and IFN-γ, as was observed with CD154+ expanded CMV-T. IL-5 (48  30 pg/ml) and 
IL-10 (29  13 pg/ml) were both secreted at low levels compared with the other 
cytokines. Taken together, these findings support a polarisation towards a population of 
cytotoxic CMV-T and argue against the existence of a significant population of IL-10-
secreting Tregs. 
 
Table 5.2 compares cytokine levels in CMVpp65-stimulated PBMCs and CD25+ 
expanded cells from G-CSF-mobilised and non-mobilised PBMCs. Analysis showed a 
greater increase relative to PBMCs in CD25+ expanded cells from  
G-CSF-mobilised vs. non-mobilised PBMCs: IL-2 (16.2-fold vs. 6-fold, respectively), 
TNF-α (90-fold vs. 19-fold, respectively), IFN-γ (22-fold vs. 5-fold, respectively) and 
IL-4 (3935-fold vs. 65-fold, respectively).  
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Figure 5.14 Cytokine secretion detected in culture supernatant of CD25+ expanded 
cells after CMVpp65 re-challenge 
Quantitative assessment by CBA of IL-2, IL-4, IL-5, IL-10, TNF-α and IFN-γ detected in the 
supernatant of cultures after a 6-hour re-challenge with autologous PBMCs loaded with 
CMVpp65 peptide in G-CSF-mobilised (n=3) and non-mobilised (n=3) donors 
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G-CSF-Mobilised 
 
 IL-2 TNF-α IFN-γ IL-4 
        
PBMC Exp PBMC Exp PBMC Exp PBMC Exp 
         
Mean Conc. 
(pg/ml) 
354 5849 306 27430 548 12260 3 10960 
         
Range 
(pg/ml) 
30 – 
1328 
499 – 
15565 
52 – 
1247 
13134 – 
58625 
140 – 
1195 
11204 – 
14169 
0 – 6 
255 – 
26896 
         
Fold Increase  16.5  90  22  3935 
 
 
 
 
Non-Mobilised 
     
 IL-2 TNF-α IFN-γ IL-4 
        
PBMC Exp PBMC Exp PBMC Exp PBMC Exp 
         
Mean Conc. 
(pg/ml) 
235 1496 1756 33760 2028 9569 13 837 
         
Range 
(pg/ml) 
27 – 
450 
58 – 
3110 
37 – 
8129 
735 – 
24488 
497 – 
5753 
5619 – 
12211 
0 – 48 
146 – 
1284 
         
Fold Increase  6  19  5  65 
 
 
Table 5.2 Comparison of mean cytokine concentration between PBMCs and 
CD25+ expanded CMV-T (Exp) following CMVpp65 stimulation in both  
G-CSF-mobilised PBMCs (A; n=3) and non-mobilised PBMCs (B; n=3) 
 
A 
B 
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5.4.3 FoxP3 expression in CD25+ expanded CMV-T 
 
Data presented in Chapter 4 indicated that CD25+ cells enriched from G-CSF-mobilised 
PBMCs, following a 16-hour incubation with CMVpp65 peptides, contain a significant 
population of FoxP3 expressing cells. Therefore, FoxP3 expression was analysed 
amongst the CD4+ population of CD25+ expanded cells from four G-CSF-mobilised 
donors, after 14-21 days in culture. The mean CD25+ FoxP3+ expression was 4.28% ± 
1.92, a significant reduction compared with CD25+ FoxP3+ expression prior to 
expansion (64.24% ± 4.88; p<0.0001). Figure 5.15 illustrates the reduced frequency 
observed in FoxP3 expression in two representative experiments. 
 
 
 
Figure 5.15 FoxP3 expression in CD25+ expanded cells in two G-CSF-mobilised 
donors (A and B) 
Open peaks represent matched isotype controls and filled peaks represent test samples. 
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5.4.4 Cytotoxicity of expanded CMV-T 
 
Cytotoxicity was evaluated in CD154+ and CD25+ expanded CMV-T from both  
G-CSF-mobilised and non-mobilised PBMCs, using autologous PHA blasts loaded with 
CMVpp65 peptides and labelled with Calcein-AM dye as targets. Both CD154+ and 
CD25+ expanded cells from G-CSF-mobilised PBMCs effectively lysed CMVpp65 
loaded targets at all E:T ratios in a dose-dependent manner that was comparable with 
lysis by CD154 and CD25 CMV-T expanded from non-mobilised PBMCs (Figures 5.16 
and 5.17).  
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Figure 5.16 Lysis of CMVpp65 targets by CD154+ CMV-T expanded from G-CSF-mobilised PBMCs (A, B) and  
non-mobilised PBMCs (C, D) 
Graphs show the percentage of calcein released from target cells after normalisation in the supernatants of cultures measured by fluorescence 
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Figure 5.17 Lysis of CMVpp65 targets by CD25+ CMV-T Expanded from G-CSF-mobilised PBMCs (A, B) and  
non-mobilised PBMCs (C, D) 
Graphs show the percentage of calcein released from target cells after normalisation in the supernatants of cultures measured by fluorescence 
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5.4.5 Suppression by CD25+ expanded CMV-T from G-CSF-mobilised 
 PBMCs 
 
FoxP3 expression and IL-10 secretion were shown to be detected at very low levels in 
CD25+ expanded CMV-T from G-CSF-mobilised PBMCs, suggesting that Tregs 
present prior to expansion do not survive in short-term culture. To further elucidate 
whether this is indeed the case, CD25+ expanded CMV-T were co-cultured with 
autologous PBMCs in the presence of anti-CD3 antibody, to assess whether expanded 
CD25+ CMV-T exerted any suppressive capacity. Expanded CD25+ CMV-T from two 
experiments showed greater suppressive capacity than the negative control at all ratios. 
Following anti-CD3 antibody stimulation, undivided CD3+ T cells in the two 
experiments were 10.3% and 17.9%, respectively. In the presence of CD25+ CMV-T 
expanded from G-CSF-mobilised PBMCs at a ratio of 1:1 (PBMCs:CD25+ CMV-T), 
undivided CD3+ T cells were 44.4% and 54.5% respectively. At a ratio of 1:2, the 
proportion of undivided CD3+ T cells was 46.9% and 59.2% respectively. Figure 5.19A 
illustrates suppression of CD3+ T cells at a ratio of 1:4 (43.2% undivided), which was 
also evident at a ratio of 1:5 (63.5% undivided), as shown in Figure 5.19B. It can be 
considered a limitation of the suppression assays that comparator CD25-autologous 
PBMCs were not used due to the availability of cell numbers. This would have allowed 
the assessment of proliferation in co-culture with autologous PBMCs, in comparison 
with expanded CD25+ CMV-T. 
 
A comparison of mean suppression exerted by CD25+ enriched CMV-T (at a ratio of 
1:1) prior to expansion (59.8% undivided; Chapter 4.4.3) and CD25+ CMV-T post-
expansion (49.5% undivided) shows a trend towards a decrease in mean suppression 
exerted by expanded CD25+ CMV-T. The mean fold-increase, relative to autologous 
PBMCs, in the proportion of undivided CD3+ T cells alone (at ratios of 1:1 and 1:2) 
was 5.09 and 5.66, reectively, for CD25+ enriched CMV-T; compared with 3.65 and 
3.90 , respectively, for expanded CD25+ CMV-T. 
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Figure 5.18 Figure 4.9 Suppression of αCD3 stimulated autologous G-CSF-
mobilised PBMCs by CD25+ CMV-T in two donors (A and B):  
Dose-dependent suppression of T cell proliferation in CFSE-labelled PBMCs by expanded 
CD25+ CMV-T was assessed at 3 ratios in the presence of αCD3 antibody for 5 days. 
Unlabelled PBMCs, PBMCs alone (CFSE) and PBMCs with αCD3 were cultured as 
experimental controls.  
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5.4.6 CD57 expression in expanded CMV-T 
 
CD57 expression after expansion of CD154 and CD25 CMV-T from both  
G-CSF-mobilised and non-mobilised PBMCs was assessed in order to determine the 
level of replicative senescence of expanded cells. No significant difference was 
observed in baseline CD57 expression in resting G-CSF-mobilised (17.96% ± 7.05) vs. 
non-mobilised (12.21% ± 3.19) PBMCs prior to CMVpp65 stimulation and subsequent 
expansion (Figure 5.20). Further analysis showed CD57 expression to be comparable 
between G-CSF-mobilised and non-mobilised PBMCs in both CD4+ (3.94% ± 1.80 vs. 
2.53% ± 0.85; p=0.47) and CD8+ (14.06% ± 5.79 vs. 9.68% ± 2.90; p=0.49) T cell 
subsets. In both G-CSF-mobilised and non-mobilised PBMCs, a trend was identified 
towards increased CD57 expression in the CD8+ T cell subset compared with CD4+ 
(p=0.10 and p=0.05 respectively).  
 
As summarised in Figure 5.21, analysis of mean CD57 expression in CD154 expanded 
CMV-T from G-CSF-mobilised PBMCs (56.03% ± 4.04) showed a significant increase 
compared with non-mobilised CD154 CMV-T (18.67% ± 5.31; p=0.005). Analysis also 
revealed a significant increase of CD57 expression in CD154 expanded CMV-T from 
G-CSF-mobilised PBMCs compared with resting PBMCs (56.03% vs. 17.96%; 
p=0.008). Representative CD57 staining in expanded CMV-T is illustrated in Figure 
5.20. Comparison of CD57 expression between CD25 expanded CMV-T from G-CSF-
mobilised PBMCs (16.83% ± 8.17) showed no significant difference compared to non-
mobilised CD25 CMV-T (27.09% ± 10.71; p=0.49) 
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Figure 5.19 Mean CD57 expression in resting PBMCs from G-CSF-mobilised (n=5) 
and non-mobilised (n=6) donors 
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Figure 5.20 Mean CD57 expression post CMV-T expansion in CD25+ and CD154+ 
G-CSF-mobilised (n=3) and non-mobilised donors (n=3).  
*P<0.05; **P<0.01 
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Figure 5.21 Phenotypic analysis of CD57 expression after CD154 CMV-T 
expansion in a G-CSF-mobilised and non-mobilised donor.  
Plots are derived after gating on lymphocytes using a FSC vs. SSC plot and on CD3+ events. 
CD154 CMV-T are presented as CD57 vs. CD4 cell subset  
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5.4.7 Memory phenotype of G-CSF-mobilised expanded CMV-T 
 
CD25+ and CD154+ CMV-T expanded from G-CSF-mobilised PBMCs were assessed 
for memory phenotype using anti-CD45RA and anti-CCR7 antibodies to distinguish 
between effector memory (CCR7- CD45RA-), central memory (CCR7+CD45RA-) and 
naïve (CCR7+CD45RA+) subsets. The memory phenotype of both CD154+ and CD25+ 
CMV-T were predominantly effector memory (72.4% ± 7.98 and 73.63% ± 11.09 
respectively) and to a lesser extent, central memory (26.67% ± 7.73 and 24.20% ± 10.64 
respectively). Figure 5.23 shows the accumulative data analysing memory phenotype 
from four CD25+ CMV-T and three CD154+ expansions. Figure 5.24 shows 
representative staining from one CD25+ and one CD154+ expansion from G-CSF-
mobilised PBMCs.  
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Figure 5.22 Classification of memory phenotype of CD25+ (n=4) and CD154+ 
(n=3) CMV-T expanded from G-CSF-mobilised PBMCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23 Phenotypic analysis of memory phenotype in one CD154+ and one 
CD25+ CMV-T expansion from G-CSF-mobilised donor 
Plots were derived after gating on lymphocytes using a FSC vs. SSC plot and on CD3+ events. 
Matched isotype controls were used to enable gating and are shown on the left-hand side. 
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5.5 Discussion 
 
The initial aims of this chapter were to expand CD25+ and CD154+ CMV-T following 
magnetic enrichment in short term culture and then to re-challenge the expanded cells to 
demonstrate CMVpp65 specificity. Expansions were performed for CD25+ and 
CD154+ CMV-T isolated from G-CSF-mobilised PBMCs and compared directly 
against CMV-T from non-mobilised PBMCs. Cytotoxicity was examined in expanded 
cells to demonstrate and compare functionality in G-CSF-mobilised and non-mobilised 
PBMCs. Analysis of CD25+ enriched CMV-T from G-CSF-mobilised PBMCs in 
Chapter 4 had shown a significantly high level of FoxP3-expressing cells that were 
capable of suppressing T cell proliferation. Therefore, a further aim of this chapter was 
to assess FoxP3 expression and suppressive capacity of CD25+ CMV-T following 
expansion in G-CSF-mobilised PBMCs. 
 
The expansion of CD154+ CMV-T from G-CSF-mobilised PBMCs was shown to be 
comparable with that of non-mobilised PBMCs, demonstrating that G-CSF mobilisation 
had no detrimental effect on the proliferative capacity of CMV-T after enrichment 
through CD154 expression. The mean expansion of 54-fold from G-CSF-mobilised 
PBMCs and 60-fold from non-mobilised PBMCs after 14 days was comparable to the 
expansion of CD154+ CMV-T of 41-fold and 58-fold after 14 days reported by Khanna 
and colleagues (Khanna et al, 2011). However, the level of expansion reported here and 
by Khanna et al. are markedly lower than that of Frentcsh et al. (Frentsch et al, 2005) 
who reported expansion of at least 1,000-fold within 14 days. A possible explanation for 
this discrepancy is that the analysis of expansion by Fentsch et al. used CD154+ CD4+ 
T cells together with the absolute number of CD154+ cells that were isolated, whereas 
the analysis described here utilised CD154+ CD3+ T cells and the absolute number of 
cells isolated. The absolute number of cells would be significantly higher than that of 
CD154+ cells; and, given that the mean purity of CD154+ cells from G-CSF-mobilised 
PBMCs was 48.9%, would therefore be consistent with a reduced level of expansion 
relative to Frentcsh et al. (Frentsch et al, 2005). 
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Analysis of mean CD25+ CMV-T expansion, following a 3 week culture period, 
showed a trend (p=0.06) towards increased expansion in non-mobilised PBMCs 
compared with G-CSF-mobilised PBMCs (175-fold vs. 90-fold expansion respectively). 
Similar to the findings for CD154+ CMV-T, these levels of expansion are markedly 
lower than that in the published literature. Gallot and colleagues (Gallot et al, 2001) 
reported data from one non-mobilised donor, showing an amplification factor of 583-
fold in CD25+ CMV-T after 13 days in culture. It must be pointed out, however, that 
culture conditions were very different from that in the present study, as was the method 
of CMVpp65 stimulation, which makes comparisons between the two studies difficult 
to interpret.  
 
Following CD25+ enrichment, G-CSF-mobilised PBMCs contained significantly more 
FoxP3-expressing Tregs that demonstrated superior suppressive capacity than CD25+ 
enriched from non-mobilised PBMCs. The increased number of Tregs in CD25+ 
enriched T cells from G-CSF-mobilised PBMCs could account for the difference in 
expansion between G-CSF-mobilised and non-mobilised PBMCs. There are two 
possible hypotheses to consider here. Firstly, that the higher proportion and the superior 
suppressive capacity of Tregs in CD25+ enriched from G-CSF-mobilised PBMCs 
reduces the total number of non-Tregs (CD25+ CMV-T) and inhibits their expansion 
compared with non-mobilised PBMCs. Secondly, Tregs do not survive the culture 
process and therefore the number of CD25+ T cells capable of proliferating in the G-
CSF-mobilised setting is significantly lower than that of the non-mobilised setting. This 
second hypothesis is supported by the decrease in the mean proportion of CD4+ T cells 
from G-CSF-mobilised PBMCs following expansion (44.1%) compared with pre-
expansion (97.5%). FoxP3 expression and IL-10 secretion levels were both low to 
undetectable in CD25+ expanded CMV-T from G-CSF-mobilised PBMCs, also 
suggesting that Tregs present after CD25+ enrichment do not survive in long-term 
culture. However, expanded CD25+ CMV-T still demonstrated suppression of T cell 
proliferation after polyclonal activation, which is suggestive of a population of FoxP3– 
IL10– Tregs in the expanded cells.  
 
The finding, reported here, of an increased number of Tregs in G-CSF-mobilised 
PBMCs following CMVpp65 stimulation, is supported by the results of a recent study 
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by Ukena and colleagues (Ukena et al, 2012). In contrast, however, this study also 
reported that CD25+ enriched T cells from G-CSF-mobilised PBMCs were capable of a 
higher level of expansion than non-mobilised PBMCs after 14 days. In this regard, it 
should be noted that culture conditions were different from those reported here, and 
CD25+ enrichment was performed in the absence of antigenic stimulation prior to 
enrichment.  
 
Both CD25+ and CD154+ expanded cells from G-CSF-mobilised PBMCs showed 
functional specificity against CMVpp65, demonstrated by the high levels of IFN-γ, 
TNF-α and IL-2 secretion, which were statistically equivalent to those of non-mobilised 
PBMCs. Cytokine profiling by CBA supported these results, demonstrating a cytotoxic 
effector function in expanded CMV-T. The most striking result observed through 
cytokine profiling of expanded CD25+ and CD154+ CMV-T, was the highly significant 
increase in IL-4 secretion compared with both G-CSF-mobilised and non-mobilised 
PBMCs. Mean IL-4 secretion levels were 3935-fold higher in CD25+ CMV-T and 
5904-fold higher in CD154+ CMV-T from G-CSF-mobilised PBMCs compared with 
G-CSF-mobilised PBMCs prior to magnetic enrichment. IL-4 is recognized as a key 
pleiotropic cytokine promoting the development of the TH2 cell subset (Hsieh et al, 
1992; Swain et al, 1990) which, in contrast to TH1 cells, do not secret IFN-γ (Abbas et 
al, 1996). Both CD25+ and CD154+ expanded CMV-T secreted similar levels of IFN-γ, 
suggesting that expanded cells give rise to polarized differentiation, producing a 
mixture of TH1 and TH2 cells amongst the CD4+ T cell population. One study has 
described the down-regulation of CD8 expression induced by IL-4 secretion during in 
vitro activation, (Kienzle et al, 2005), which could explain the predominantly CD4+ 
phenotype of CD154+ expanded CMV-T, but not the CD25+ expanded CMV-T 
phenotype, which contained a proportionally more balanced population of CD4+ and 
CD8+ T cells. Future experiments investigating the expression of GATA3, a 
transcription factor associated with TH2 cells and necessary for IL-4 secretion (Zheng & 
Flavell, 1997), could determine the subset of CD4+ cells expanded in this culture 
system. 
 
CD25+ and CD154+ expanded CMV-T both contained high levels of Granzyme B, 
indicating a possible mechanism for cytotoxicity through the process of directed 
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exocytosis, resulting in apoptosis of the target cells (Adrain et al, 2005; Darmon et al, 
1995). The cytokine profile of expanded cells together with the identification of the lytic 
granule Granzyme B are in keeping with a population of anti-viral CD4+ cytotoxic T 
cells (CTLs) characterised in previous studies (Appay et al, 2002b) and reminiscent of 
anti-viral CD8+ T cells. Furthermore, cytotoxicity was directly demonstrated by using a 
Calcein-AM cytotoxicity assay (Neri et al, 2001) to show that both CD25+ and CD154+ 
CMV-T expanded from G-CSF-mobilised PBMCs can successfully lyse CMVpp65 
peptide pulsed target cells. The memory phenotype of CD154+ CMV-T expanded from 
G-CSF-mobilised PBMCs was predominantly effector memory and, to a lesser extent, 
central memory determined by staining for CD45RA and CCR7 by flow cytometry. The 
effector memory phenotype is consistent with previous findings that CCR7 is down 
regulated during prolonged culture (Zandvliet et al, 2009). The functional expansion of 
a population of anti-viral CD4+ CTLs could have been strengthened through the 
demonstration of enhanced cell lysis after effective blocking of HLA class I on target 
cells. Although experiments demonstrated ligation of HLA class I and HLA class II 
with anti-HLA DR,DP,DQ and anti-HLA A,B,C antibodies, lysis of target cells was not 
affected.  
 
In addition to direct cytotoxicity, the secretion by expanded CD154+ CMV-T of IFN-γ 
and TNF-α, cytokines that inhibit CMV replication (Hengel et al, 1994), further 
supports the existence of a predominant CD4+ CTL cell subset.  It is important to note 
that in various anti-viral immune responses, maintenance of CD8+ CTL depends greatly 
on CD4+ T cell function (Gallot et al, 2001; Komanduri et al, 2001), demonstrated by 
the increase of CD8+ CMV-T after adoptive transfer of CD4+ CMV-T in vivo (Einsele 
et al, 2002). In contrast, the expansion of CD25+ CMV-T in both G-CSF-mobilised and 
non-mobilised PBMCs contained a mixture of both CD4+ and CD8+ T cells. The use of 
CMV-T comprising a mixture of CD4+ and CD8+ T cells is in line with several studies 
which demonstrate the effective treatment of CMV disease after adoptive transfer of 
CMV-T (Peggs et al, 2003; Peggs et al, 2011; Rauser et al, 2004; Feuchtinger et al, 
2010).  
 
The expression of CD57 as a marker of replicative senescence in HIV-specific CD8+ T 
cells was demonstrated through an inability to proliferate after antigenic stimulation 
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(Brenchley et al, 2003). CD154+ CMV-T expanded from G-CSF-mobilised PBMCs 
expressed CD57 at significantly higher levels than CD154+ CMV-T from non-
mobilised PBMCs and CD25+ CMV-T from G-CSF-mobilised and non-mobilised 
PBMCs. Over half of CD154+ CMV-T expanded from G-CSF-mobilised PBMCs 
expressed the CD57 antigen (mean, 56%). However, expansion in CD154+ CMV-T 
from G-CSF-mobilised PBMCs was equivalent to that of CD154+ CMV-T from non-
mobilised PBMCs, indicating that their proliferative capacity is not effected. This could 
be attributed to the predominant CD4+ phenotype in CD154+ CMV-T, in contrast to the 
CD8+ subset studied by Brenchley and colleagues. Future experiments to sort CD57+ 
cells at the end of the culture period and assess their proliferation in response to 
antigenic challenge could allow further understanding of CD57 as a marker of 
replicative senescence in CD4+ CMV-T cells.  
 
An additional experimental idea is the investigation of telomere length, which is 
associated with the proportion of expanded cells that are non-functional and will 
become senescent or apoptotic (Verdun & Karlseder, 2007). Telomere length has been 
demonstrated to be reduced in CD8+ CD28– T cells, a population of cells associated 
with activation, compared with that of the naïve CD8+ CD28+ T cell subset (Batliwalla 
et al, 2000) and also after CMV infection (van de Berg et al, 2010). Investigating 
telomere length offers further understanding of the replicative capacity of expanded 
cells after adoptive transfer. 
 
The results presented in this Chapter illustrate that CMV-T isolated from  
G-CSF-mobilised PBMCs through both CD154+ and CD25+ activation-dependent 
expression are capable of expanding in short term culture at a comparable level to that 
of conventional non-mobilised PBMCs. Expanded cells secreted and synthesised 
cytokines associated with a cytotoxic function and were effective in lysing CMVpp65 
loaded target cells in a dose-dependent manner. CMV-T expanded from G-CSF-
mobilised PBMCs following CD25+ enrichment did not retain a Treg phenotype, as 
indicated by the loss of FoxP3 expression and the lack of IL-10 secretion, but were, 
nevertheless, capable of exerting a suppressive capacity on autologous PBMCs, as 
determined by a CFSE proliferation assay. In conclusion, these results suggest that 
manufacturing a CMV-T immunotherapy product from G-CSF-mobilised PBMCs to 
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clinical scale could be effective in the treatment of CMV disease following allogeneic 
HSCT. Clinical scale-up would allow for the rigorous assessment of the purity, yield 
and absolute numbers of CMV-T necessary for the successful translation of this 
approach as a routine therapy for patients with CMV disease. 
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Chapter 6 
 
Development of CD154-based Selection of CMV-T to Clinical Scale 
 
6.1 Introduction 
 
The development of a strategy for CD154-based selection of CMV-T from  
G-CSF-mobilised PBMCs requires process validation at a clinical scale in order for this 
methodology to be approved as a clinically applicable protocol. The direct selection of 
CMV-T for clinical use has relied primarily on the use of HLA-peptide multimers 
(Cobbold et al, 2005) or IFN-γ secretion (Feuchtinger et al, 2010; Peggs et al, 2011) in 
order to manufacture clinically relevant doses for adoptive transfer. Direct selection of 
CMV-T using the IFN-γ secretion protocol has also been used as a platform for the 
subsequent expansion of CMV-T, thereby demonstrating a second approach to the 
production of CMV-T that can be translated into clinical use (Rauser et al, 2004b). IFN-
γ secretion has also been utilised for the isolation and expansion of adenovirus-specific 
CD4+ and CD8+ T cells, which were safely administered to nine children with 
lymphopenia following HSCT (Feuchtinger et al, 2004). However none of these 
protocols resolves the complex issues surrounding successive donation following 
donation of the original HSC graft. 
 
Results reported in Chapter 3 showed that the IFN-γ secretion method for CMV-T 
isolation is sub-optimal when using G-CSF-mobilised PBMCs as a starting material. 
However, the use of G-CSF-mobilised PBMCs as a starting material for the generation 
of CMV-T to clinical scale has recently been reported in 11 donors (Clancy et al, 2013). 
In this study, seven patients received CMV-T lines expanded from an aliquot of the 
original HSCT graft. This study adopted the approach of using monocyte-derived APCs 
transfected with a clinical grade adenovirus vector (Ad5F35pp65) encoding the entire 
CMVpp65 protein in order to initiate CMV-T expansion from unmanipulated aliquots 
of G-CSF-mobilised PBMCs. This approach is labour-intensive, requires several weeks 
for the generation of a clinically relevant product, and would potentially require 
laboratories to hold both gene therapy and cell therapy licences, which from a 
 Chapter 6 
 
190 
 
regulatory standpoint is extremely difficult to achieve outside of an industrial setting. 
Therefore, the feasibility of this approach to CMV-T manufacture is not one that is 
easily applicable to the widespread cell therapy community and patient-directed 
therapies. An alternative method of direct selection, the isolation of CMV-T through 
cell surface activation markers, has been successfully demonstrated at a clinical scale 
using CD25-based selection (Lugthart et al, 2012). 
 
GMP-compliant magnetic isolation of cell subsets has been enhanced through the 
availability of instruments such as the CliniMACS (Miltenyi Biotec) and Isolex 300 
(Baxter Healthcare) devices. The CliniMACS device has now become a routine 
instrument in cellular therapy laboratories since its inception for the isolation of CD34+ 
cells from apheresis products (Schumm et al, 1999). Over the past decade its use in 
process development for the manufacture of novel cell therapies, including the 
generation of anti-viral T cells for adoptive transfer, has resulted in the CliniMACS 
becoming the primary device used in direct selection (Cobbold et al, 2005; Feuchtinger 
et al, 2004; Feuchtinger et al, 2010; Meij et al, 2012; Peggs et al, 2011; Rauser et al, 
2004a; Lugthart et al, 2012). Therefore, the CliniMACS lends itself to the process 
development of CD154-based enrichment of CMV-T and the potential translation of 
this methodology into routine clinical therapy. 
 
The manufacture of cell therapies, including CMV-T, has changed substantially over the 
past decade and as a consequence, EU legislation was laid down to govern such 
products. CMV-T manufactured by any process other than direct selection using 
multimers, are classified in Europe as advanced therapeutic medicinal products 
(ATMPs) as an amendment to the EU Directive 2001/83/EC, under the classification of 
a somatic cell therapy product (Annex 1, Part IV), defined in Regulation 1394/2007/EC. 
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) is the 
competent authority responsible for issuing manufacturing licences for ATMPs and 
subsequently accrediting laboratories to undertake such manufacturing. The 
manufacture of ATMPs must be in compliance with the principles of good 
manufacturing practice (GMP), as set out in Directive 2009/94/EC, which demands the 
use of validated procedures and processes with product definition, sterility testing, 
pharmaceutical-grade raw materials and records of reagents used (Dwenger et al, 2010; 
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Botta & Migliaccio, 2011). Currently there is no commercially available GMP-grade 
anti-CD154 antibody nor associated CD154 magnetic bead conjugate for use in clinical 
grade immunoselection. Neither is there a GMP-grade purified anti-CD40 antibody 
available. Using an anti-biotin bead conjugate is a potential solution to performing 
clinical scale enrichment of CD154+CMV-T, and is commercially available to GMP-
grade (Miltenyi Biotec). Although the remaining reagents needed for a GMP-compliant 
process validation are not available, the use of non-GMP-qualified reagents is not 
precluded once they have been subjected to suitable risk assessments (Lowdell et al, 
2012b). Process validation of CD154+ CMV-T manufacture, together with appropriate 
risk assessments of non-GMP-qualified reagents, is an important step in assessing the 
feasibility of both this approach to CMV-T manufacture and its successful transfer into 
routine clinically practice as an ATMP. 
 
6.2 Aims of Experiments Described in this Chapter 
 
The initial aim of this Chapter was the assessment of anti-biotin microbeads for the 
enrichment of CD154+ CMV-T following CMVpp65 peptide stimulation. This aim was 
assessed in three G-CSF-mobilised PBMC donors to investigate whether this approach 
was comparable with previous experiments using anti-PE microbeads and could, 
therefore, be used in a clinical scale experiment. Next, a G-CSF-mobilised PBMC donor 
was pre-screened for CD154 activation-induced expression after CMVpp65 peptide 
stimulation to assess whether previously cryopreserved PBMCs would be a feasible 
approach for use in the clinical scale-up.  
 
The secondary aim of this Chapter was the process development of a CD154-based 
selection strategy for isolation of CMV-T from a G-CSF-mobilised donor at a clinical 
scale. This process validation aimed to test current standard operating procedures 
(SOPs) for the stimulation, labelling and selection of anti-viral T cells that would allow 
the process to be translated into a “clean-room” laboratory for manufacture. The process 
validation allowed yield and purity at clinical scale to be tested and compared to current 
practice. In addition, total cell numbers were measured to ascertain whether clinically 
relevant doses of CMV-T can be manufactured in this system. CD154+ CMV-T were 
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also rested after selection and re-challenged with CMVpp65 peptides to assess the 
specificity of the product. Process validation is a critical step in testing novel therapies 
to ascertain the feasibility of translation to full GMP-compliance. The final aim of this 
Chapter was to ascertain what aspects of the protocol could be changed and improved in 
future clinical scale experiments to facilitate the development of the process and 
expedite translation to the clinic. 
 
The experimental aims of the Chapter were as follows: 
 
1. To optimise CD154+ CMV-T isolation from G-CSF-mobilised PBMCs using 
anti-biotin microbeads and compare against isolation using PE-microbeads 
 
2. To identify a suitable G-CSF-mobilised donor for clinical scale CD154+ CMV-
T manufacture. 
 
3. To assess yield, purity and cell numbers in clinical scale CD154+ CMV-T 
manufacture. 
 
4. To assess the functionality of CD154+ CMV-T following clinical scale 
manufacture. 
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6.3 Materials and Methods 
 
6.3.1 Anti-Biotin Microbeads for Small Scale Enrichment  
 
Optimisation of the biotin-based selection strategy was performed in three  
G-CSF mobilised donors. CMVpp65 peptide stimulation was performed as previously 
described for CD154 activation-induced expression at an optimal time point of 6 hours. 
Following a 6-hour stimulation, PBMCs were centrifuged at 300g for 10 minutes at 
room temperature and the cell pellet was resuspended at a concentration of 10
7
 
cells/100µl of CliniMACS PBS/EDTA buffer. PBMCs were labelled in 15ml conical 
tubes with 10µl of anti-CD154 Biotin (Miltenyi Biotec)/10
7
 total cells and incubated for 
10 minutes at 4–8°C in the dark. The supernatant was removed and the cell pellet 
resuspended at 10
7
 cells/80µl in CliniMACS buffer, labelled with 20µl of anti-Biotin 
microbeads (Miltenyi Biotec)/10
7
 cells and incubated for 15 minutes at 4–8°C in the 
dark. Cells were diluted to 15ml with CliniMACS buffer, centrifuged at 300g for 10 
minutes at room temperature, and enrichment performed using MS columns as 
previously described in Chapter 2.10.1. Following enrichment, samples from the 
positive, negative, and pre-sort fractions were labelled with anti-Biotin PE (Miltenyi 
Biotec) for assessment of CD154 purity and yield by flow cytometry, as described in 
Chapter 2.7.  
 
6.3.2 Preparation of PBMCs for Clinical Scale Enrichment  
 
A previously cryopreserved G-CSF-mobilised apheresis collection of 100ml, signed off 
for discard, was identified as starting material for the clinical scale-up experiment. Pre-
screening was performed on a cryopreserved aliquot from the identified donor, to 
determine CD154 expression in response to CMVpp65 stimulation. The cryopreserved 
sample was thawed at 37°C by gentle massage in a waterbath, before transferring into 
20 x 50ml falcon tubes with 5ml per tube. Thawed PBMCs were diluted to 50ml in pre-
warmed CM and centrifuged for 10 minutes at 200g. Supernatant was removed using a 
25ml pipette and cell pellets resuspended in 2-3ml of CM and passed through a cell 
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strainer (Becton Dickenson). Cells were diluted to a volume of 10ml in CM, before re-
combining all cells and transferring into a 600ml transfer bag (Baxter).  
 
6.3.3 Isolation of PBMCs for Clinical Scale Enrichment 
 
Isolation of PBMCs was performed on the COBE 2991 cell processor using a COBE 
processing set (both BCT Caridian). The cell suspension was layered onto an equal 
volume of Lymphoprep, using a peristaltic pump (Watson Marlow) and pump tube 
(Quest Biomedical) at a speed of 25rpm and subsequently centrifuged at 2000rpm for 
20 minutes. The mononuclear cell (MNC) fraction was collected and washed in 1 litre 
of buffer, consisting of 500ml HSA 4.5% and 500ml saline (Baxter), on the COBE 
2991. Washed cells were resuspended in wash buffer and transferred to a 50ml falcon 
tube and centrifuged for 10 minutes at 250g. Supernatant was removed and the cell 
pellet resuspended in CM at a concentration of 10
7
/ml, before transferring into a 100ml 
cell expansion bag (Miltenyi Biotec) and incubating overnight at 37°C/5%CO2. 
Following the overnight incubation, cells were transferred into four falcon tubes and 
washed in CM to remove any cell clumps. Supernatants were removed and cell pellets 
resuspended in CM, then re-combined and transferred into a cell expansion bag at a 
concentration of 10
7
/ml. 
 
6.3.4 In vitro Stimulation of PBMCs for Clinical Scale Enrichment 
 
G-CSF mobilised PBMCs were stimulated for 6 hours with CMVpp65 Peptivator at a 
final concentration of 0.6nmol (approximately 1µg) of each peptide per ml of cells, in 
the presence of 1µg/ml of anti-CD40 antibody. As a negative control,  
1 x 10
6
 PBMCs were incubated in one well of a 96-well plate in the presence of anti-
CD40 antibody only and incubated at 37°C/5%CO2. 
 
6.3.5 Clinical Scale CD154 Enrichment 
 
Following CMVpp65 stimulation PBMCs were transferred into 2 x 50ml Falcon tubes, 
washed in cold CliniMACS PBS/EDTA buffer (Miltenyi Biotec) supplemented with 
0.5% HSA at 300g for 10 minutes, the supernatants removed and the cell pellets 
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resuspended in 2ml of buffer and recombined. The cell suspension was sampled for 
counting and 1ml of anti CD154-Biotin antibody added before incubation at 4-8°C for 
10 minutes. PBMCs were diluted to 50ml in buffer, centrifuged at 300g for 10 minutes, 
the supernatant removed and the cell pellet resuspended in 2.5ml of buffer. PBMCs 
were incubated at 4-8°C for 15 minutes with 2ml of anti-biotin microbeads, then 
washed in 50ml of buffer and resuspended in a final volume of 100ml in buffer for 
selection. A sample was taken for pre-sort counting and immunophenotyping, before 
loading onto the CliniMACS
PLUS 
with 1 litre of CliniMACS PBS/EDTA buffer 
supplemented with 0.5% HSA using a CliniMACS tubing set (all Miltenyi Biotec). The 
Enrichment 2.1 programme was used for the selection of labelled cells with low antigen 
expression, and the positive fraction eluted into a 250ml collection bag (Miltenyi 
Biotec). CD154-positive and CD154-negative fractions were detached from the 
CliniMACS tubing set and their volumes recorded. Samples were taken from both 
fractions for counting and immunophenotyping in order to establish yield and purity. 
Both fractions were transferred to 50ml falcon tubes and centrifuged at 300g for 10 
minutes, the supernatant removed and cells resuspended in CM at 2 x 10
6
 cells/ml for 
culture.  
 
 
Table 6.1 shows a list of reagents and consumables used in the clinical scale CD154 
enrichment and Figure 6.1 (A–D) illustrate the instrumentation involved in clinical scale 
manufacture. Analysis of pre-stimulation, post-stimulation, CD154-positive and 
CD154-negative samples were analysed for viability using the carbocyanine monomer 
nucleic stain TO-PRO-3 Iodide (Life Technologies) as a dead cell indicator that was 
resolved in FL4 by flow cytometry. 
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Table 6.1 List of reagents and consumables used in clinical scale-up 
 
 Reagent/Consumable No. of 
units  
Lot Number Expiry 
Date 
Supplier 
Anti CD154 Biotin 1 5121128075 29/11/13 Miltenyi Biotec 
Anti Biotin Beads 1 130-090-485 17/08/13 Miltenyi Biotec 
CMVpp65 Peptivator 
(60nmol) 
1 130-093-435 29/11/14 Miltenyi Biotec 
5L RPMI + Glutamax 1 1156093 05/2013 Invitrogen 
100ml AB Serum 3 10169 06/2017 BioSera 
250ml Lymphoprep 1 12CK515 10/2013 Axis Shield 
Diagnostics 
Purified anti CD40 1 B147482 - BioLegend 
COBE processing set 3 06S15004 10/2014 Caridian BCT 
100ml cell expansion bag 3 6061009007 11/2013 Miltenyi Biotec 
1L CliniMACS 
PBS/EDTA buffer 
3 D0467 02/2014 Miltenyi Biotec 
CliniMACS Tubing Set 1 B1915 06/2015 Miltenyi Biotec 
Pre System Filter 1 219802 07/2017 Miltenyi Biotec 
150ml transfer bag 1 110721F2 06/2014 Miltenyi Biotec 
Leur/Spike interconnector 1 12A03V233 12/2016 Miltenyi Biotec 
Injection site coupler 5 FA11I10049 08/2016 Baxter 
500ml 4.5% HSA 1 ADAN9424 01/2015 BPL 
100ml 20% HSA 1 ABCN8943 09/2013 BPL 
500ml sodium chloride 1 12E03E42 04/2014 Baxter 
1L transfer bags 2 FA11H01115 08/2014 Fenwal Inc. 
600ml transfer set 4 1412020115 01/2015 Baxter 
50ml syringe 5 1211001 10/2017 Terumo 
pump tube 1 10G0379 07/2015 Quest Biomedical 
2 port to spike 2 H17014 10/2014 OriGen Biomedical 
10ml Sterile water ampoule 1 12266012 05/2015 Braun 
Air Inlet 2 12I04V725 08/2017 Baxter 
50ml Falcon tube 10 17812011AA - BD 
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Figure 6.1 Processing of CD154+ CMV-T from G-CSF-mobilised PBMCs 
G-CSF-mobilised PBMCs were loaded onto the COBE 2991 cell processor for washing 
following thawing and MNC preparation (A-B). The resulting MNC fraction was recovered (C) 
and, following labelling with anti-CD154 Biotin and anti-Biotin microbeads, was loaded onto 
the CliniMACS for CD154 selection (D). 
 
A B 
C D 
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6.3.6 Culture of CD154+ Fraction 
 
CD154-positive and negative fractions were immediately washed in CliniMACS 
PBS/EDTA buffer + 0.5% HSA following clinical scale enrichment then resuspended at 
2 x 10
6
/ml and sampled for flow cytometry. The remaining cells were rested for 6 days 
in 24-well plates in CM supplemented with 10ng/ml of IL-7 and IL-15. CD154+ cells 
were cultured in the presence of irradiated autologous feeder cells at a ratio of 1:1, 
before assessment of anti-CMV responses using intracellular cytokine staining and 
proliferation assays, as previously described in Chapter 2.  
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6.4 Results  
 
6.4.1 Small scale enrichment of CD154+ CMV-T using anti-biotin microbeads 
 
Three small scale enrichments of CD154+ CMV-T were performed in G-CSF-mobilised 
PBMCs, for assessment of the efficiency of the selection methodology and for 
comparison with CD154+ CMV-T enrichment using PE-microbeads reported in Chapter 
4. Figure 6.2 illustrates CD154+ enrichment in two donors using anti-biotin microbeads 
and Figure 6.3 summarises the comparative CD154+ enrichment data using PE- and 
anti-biotin microbeads. Anti-biotin enrichment technology showed an increased mean 
CD154+ purity vs. PE-microbeads (71.13% ± 12.64 vs. 48.94% ±12.80, respectively; 
p=0.29), but a decreased mean CD154+ yield was observed (20.87% ± 9.59 vs. 30.80% 
± 7.95, respectively; p=0.46). These changes were not statistically significant. Analysis 
of T cell subsets after CD154+ enrichment using anti-biotin microbeads showed no 
significant difference with PE-microbead enrichment when comparing CD4+ T cells 
(67.77% ± 13.42 vs. 45.38% ± 11.70, respectively; p=0.27) and CD8+ T cells (3.36% ± 
0.96 vs. 3.57% ± 1.59, respectively; p=0.93).  
 
 
 Chapter 6 
 
200 
 
 
 
Figure 6.2 Isolation of CD154+ CMV-T using anti-biotin microbeads in  
G-CSF-mobilised PBMCs 
PBMCs isolated from G-CSF-mobilised donors were stimulated for 6 hours in the presence of 
anti-CD40 antibody, labelled with CD154-biotin and anti-biotin microbeads prior to magnetic 
enrichment. Cells were assessed for phenotype using anti-biotin-PE for the detection of CD154+ 
cells. 
Fra, fraction; Neg, negative; Pos, Positive. 
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Figure 6.3 Comparison of CD154+ isolation using PE-microbead (n=5) and anti-
biotin (n=3) technology for the enrichment of CMV-T in G-CSF-mobilised PBMCs 
CD154+ purity was measured following magnetic enrichment and CD4+ and CD8+ T cell 
populations assessed. 
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6.4.2 CD154+ pre-screening of G-CSF-mobilised donor for clinical scale-up 
 
A CMV+ G-CSF-mobilised donor was selected from a bank of previously 
cryopreserved PBMCs to demonstrate an effective CD154+ T cell response to 
CMVpp65 peptide stimulation and establish suitability for clinical scale-up. CD154 
expression was analysed pre-CMVpp65 stimulation, post-stimulation and in response to 
the superantigen SEB. A negative control (non-stimulated) was also included to 
ascertain the specificity of the CMV response using CD154 detection. Figure 6.4 shows 
the results from the pre-screening experiment analysing the CD154 response to 
CMVpp65 peptide stimulation. Minimal background CD154 expression was observed 
pre-stimulation (0.29%) and in the non-stimulated negative control (0.27%). Following 
CMVpp65 peptide stimulation, CD154 expression was 2.47% (1.83% CD4+, 0.64% 
CD8+), demonstrating donor suitability suitable for use in a clinical scale-up 
experiment. CD154 expression after SEB stimulation in the same donor was 14.41% 
(CD4+, 13.0%, CD8+, 1.41%).  
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Figure 6.4 Pre-screening CD154 expression in a G-CSF-mobilised donor to 
ascertain suitability for clinical scale-up 
G-CSF-mobilised PBMCs were stimulated in a 96-well plate with SEB, CMVpp65 peptides or 
left untouched (non-stimulated) as a negative control before analysis of CD154 expression 
amongst the CD3+ T cell population. Background CD154 expression was analysed pre-
stimulation in order to ascertain CD154 CMV specificity. 
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6.4.3 Clinical scale enrichment of CD154+ CMV-T  
 
6.4.3.1 CD154+ Selection 
 
PBMCs from a previously cryopreserved G-CSF-mobilised CMV+ donor were thawed 
out for subsequent use in a clinical scale process for the isolation of CD154+ CMV-T. 
The target total cell number for stimulation in the clinical scale process run had been set 
at 1000 x 10
6
 as this was the figure reported in a previously published clinical scale 
manufacture of CMV-T using the IFN-γ catch method (Peggs et al, 2011). Table 6.2 
shows that our clinical scale process run did not achieve that threshold. The total 
number of cryopreserved cells was 6000 x 10
6
, but this decreased almost 10-fold to 678 
x 10
6 
prior to CMV peptide stimulation. Viability was also found to diminish during the 
process, stabilising at around 50% at pre-enrichment.  
 
 
 
Table 6.2 Cell recovery and viability during clinical scale enrichment of CD154+ 
CMV-T  
Viability and total cell number were recorded during each step of the process prior to 
enrichment. Viability was determined using TO-PRO cell dye for staining as a dead cell 
indicator and cell counts were performed on a haematology analyser. 
Cryo’d, cryopreserved; Fra, fraction; MNC, mononuclear cells; Neg, negative; O/N, overnight; 
prep, preparation; Pos, positive; Stim, stimulated; 
 
 
 Cryo’d Post- 
Thaw 
Post-
MNC 
prep  
Pre-Stim 
(Post O/N 
rest) 
Post-
Stim 
Pre-
Sort 
CD154 
Pos  
Fra 
CD154 
Neg  
Fra 
Viability 
(%) 
90 70 60.0 57.0 50.0 49.7 21.9 51.5 
Total Cell 
Number 
(x 10
6
) 
6000 3000 1340 678 310 275 29.5 132 
 Chapter 6 
 
205 
 
 
Following enrichment, the total cell number in the CD154+ fraction was calculated to 
be 0.21 x 10
6
, compared to 0.45 x 10
6 
in the pre-enrichment sample (Table 6.3). This 
represented a CD154+ cell yield of 46.6%. The total cell number of the CD154-negative 
fraction was calculated at 0.15 x 10
6
. CD154+ purity after enrichment was 54.55%, of 
which 45.3% (83% of total CD154+) were CD4+ and 9.25% (17% of total CD154+) 
were CD8+, as determined by flow cytometry. This was in keeping with the proportion 
of CD4+ (87.5% of total CD154+) and CD8+ (12.5% of total CD154+) T cells in the 
pre-enrichment sample. Viability diminished following enrichment from 49.7% to 
21.9% in the CD154 positive fraction, whereas viability in the negative fraction 
remained stable (51.5%). Both the lymphocyte population and CD3+ T cell content 
were reduced following enrichment when compared with pre-enrichment (36.6% vs. 
18.7% and 53.2% vs. 32.3% respectively). Figure 6.5 illustrates the results from the 
clinical scale process validation after flow cytometric analysis. 
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Table 6.3 Enumeration of post-magnetic enrichment of CD154+ CMV-T isolated 
from a single cryopreserved G-CSF-mobilised CMV+ donor 
Values were determined using a dual-platform method by flow cytometry and manual cell 
counts using a haematology analyser. Viability was determined using TO-PRO cell dye for 
staining as a dead cell indicator and gating on TO-PRO negative events prior to phenotypic 
analysis 
 
 Pre-CD154 
Enrichment 
CD154+ 
Fraction 
CD154– 
Fraction 
Cell concentration 5.5 x10
6
/ml 0.95 x10
6
/ml 0.44 x10
6
/ml 
Volume 50ml 31ml 300ml 
Total Cell Number 275 x10
6
 29.5 x10
6
 132 x10
6
 
Viability (%) 49.7 21.9 51.5 
Lymphocytes (%) 36.6 18.7 53.0 
CD3+ (%) 53.2 32.3 55.7 
Total CD3+ Cell 
Number 
26.6 x10
6
 0.39 x10
6
 20.1 x10
6
 
CD4+ CD154 (%) 1.48 45.3 0.59 
CD8+ CD154 (%) 0.21 9.25 0.17 
Total CD154 (%) 1.69 54.55 0.76 
Total CD154+ Cell 
Number 
0.45 x10
6
 0.21 x10
6
 0.15 x10
6
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Figure 6.5 Phenotypic analysis of clinical scale CD154 enrichment following 
CMVpp65 peptide stimulation in a G-CSF-mobilised donor 
CD154 analysis was performed by gating on TO-PRO negative events to exclude dead cells, 
prior to lymphocyte gating using FSC vs. SSC. 
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6.4.3.2 Functional analysis of CD154+ following clinical scale   
 enrichment 
 
Following enrichment of CD154+ CMV-T, the CD154+ positive fraction was cultured 
in the presence of irradiated negative feeders (1:1), 10ng/ml of IL-7 and IL-15, and 
rested for 6 days before carrying out the functional analysis. At day 6, CD154+ CMV-T 
cultures were 97.6% CD3+ T cells of which 98.1% were CD4+ and 0.57% CD8+, 
determined by flow cytometry. CD154+ CMV-T were re-challenged with CFSE-
labelled autologous PBMCs loaded with CMVpp65 peptides at a ratio of 1:2 (CD154+ 
CMV-T:autologous PBMCs) before analysis of cytokine secretion using both ICS and 
CBA. Re-challenge with CFSE-labelled autologous PBMCs without peptide was 
included as a negative control. ICS revealed a high level of Granzyme B secretion 
compared to the negative control (44.8% vs. 6.1%, respectively) and a low level of IFN-
γ secretion (8.3% vs. 0.7%, respectively). TNF-α secretion (1.8% vs. 0.7%) and IL-2 
secretion (0.6% vs. 0.5%) were both at low to undetectable levels after CMVpp65 
peptide re-challenge (Figure 6.6). CD69 analysis after re-challenge revealed an increase 
in surface expression from 39.2% in the negative control (PBMCs alone) to 75.5% after 
CMVpp65 peptide re-challenge.  
 
Supernatants were collected and analysed by CBA for quantification of cytokine 
secretion in response to CMVpp65 peptide re-challenge. Analysis revealed an increased 
secretion of IFN-γ and TNF-α compared with the negative control (1055 vs. 412 pg/ml; 
and 970 vs. 609 pg/ml respectively). Secretion levels of IL-2, IL-4, IL-5 and IL-10 were 
minimal and is summarised in Figure 6.7. 
 
Memory phenotype was performed following CD154+ enrichment on the CD3+ T cell 
population (Figure 6.8) and revealed a mixed population of naive CD45RA+CCR7+ 
(45.5%) and central memory CD45RA-CCR7+ (42.8%), with a small population of 
effector memory CD45RA-CCR7- (10.4%). Following 6 day rest in culture, CD154+ 
CMV-T were predominantly central memory (67.7%) and to a lesser extent effector 
memory (27.3%). 
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Figure 6.6 Cytokine profile of CMV-T after clinical scale CD154 enrichment 
CD154+ cells were co-incubated with autologous PBMCs with or without loaded CMVpp65 peptides for 6 hours and cytokine secretion 
measured using ICS by flow cytometry. 
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Figure 6.7 Cytokine profile of CMV-T by CBA following re-challenge 
CMV-T were co-incubated with autologous PBMC loaded with CMVpp65 peptides or PBMC 
alone. Supernatant was collected after 6 hour re-challenge for analysis of cytokine secretion by 
CBA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 Classification of memory phenotype after CD154+ enrichment and 
following 6 days rest in culture 
Plots were derived after gating on lymphocytes using a FSC vs. SSC plot and on CD3+ events. 
Matched isotype controls were used to enable gating and are shown on the left-hand side. 
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6.5 Discussion 
 
The main aims of this Chapter were to develop CD154-based magnetic selection of 
CMV-T from G-CSF-mobilised PBMCs at a clinical scale, and to assess whether this 
process yielded an immunotherapeutic product that was clinically relevant in terms of 
cell numbers and demonstrated CMV-specificity upon re-challenge. In common with 
the work described in Chapters 3, 4 and 5 of this thesis, all cell selections utilised the 
Miltenyi/MACS immunomagnetic enrichment system. Therefore, in order to test the 
feasibility of CD154-based enrichment of CMV-T at a clinical scale, the 
CliniMACS
PLUS
 device (Miltenyi Biotec) was used for the scale-up. Previous results 
reported in Chapter 4 showed that it was possible to enrich for CMV-T through CD154 
activation-induced expression from G-CSF-mobilised PBMCs. Mean CD154+ purity 
was 48.9%, mean yield 30.8% and the mean proportion of CD4+ and CD8+ T cells 
92.6% and 7.4% respectively. For the process validation of clinical scale enrichment of 
CD154+ CMV-T, the decision was taken to use anti-biotin microbeads rather than anti-
PE microbeads, due to their availability at GMP-grade. Small scale experiments using 
anti-biotin microbeads were performed to assess this option. Results showed that mean 
purity was increased using anti-biotin microbeads compared with anti-PE microbeads 
(71.13% ± 12.64 vs. 48.94% ± 12.80 respectively; p=0.29), but mean yield decreased 
(20.87% ± 9.59 vs. 30.80% ± 7.95; p=0.46). However, neither difference was 
statistically significant and therefore the decision to use anti-biotin microbeads in a 
clinical scale experiement was deemed to be an optimal approach.  
 
Clinical scale enrichment of CD154+ CMV-T was performed with previously 
cryopreserved material, which had a detrimental impact on both total cell number and 
viability throughout the course of the experiment. The target cell number for loading 
onto the CliniMACS for magnetic enrichment was deemed to be 1 x 10
9
 PBMCs 
(Feuchtinger et al, 2010; Peggs et al, 2011). Approximately 0.7 x 10
9
 PBMCs were 
available for CMVpp65 peptide stimulation, which represented a loss of 54% from a 
total of 1.3 x 10
9
 PBMCs left in culture overnight post MNC separation.. Following 
antibody and magnetic bead labelling only approximately 0.3 x 10
9
 PBMCs were loaded 
onto the CliniMACS for enrichment, equating to a loss of approximately 40% from 0.7 
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x 10
9
 PBMCs that were stimulated. The cumulative loss of PBMCs over the course of 
the experiment resulted in a total CD3+ cell number of 0.39 x 10
6
 in the CD154+ 
fraction. Assuming an average recipient weight of 75kg, this would equate to a 
therapeutic dose of 5.2 x 10
4
 CD3+/kg of which 54.55% were CD154+ (2.8 x 10
4
/kg). 
Even considering such significant cell loss throughout the process, 5.2 x 10
4
 CD3+/kg is 
still comparable to the cell numbers infused after direct selection using IFN-γ secretion 
(Feuchtinger et al, 2010; Peggs et al, 2011). In comparison, the CD3+ T cell dose 
achieved using CD154+ selection of CMV-T was greater than that achieved using 
HLA-peptide tetramers (Cobbold et al, 2005) where cells were returned at doses of 
1.23-1.33 x 10
3
/kg. It should be noted, however, that purity was very high using this 
approach, with a reported median T cell purity of 95.6%. In the present study, CD154+ 
purity after CD154 selection was 54.55% which is comparable to the purity achieved 
after IFN-γ selection in the studies of both Fuechtinger (65% ± 31) and Peggs (43.9%; 
range 1.4%–81.8%).  
 
In a similar clinical study utilising the CliniMACS IFN-γ capture system, CD8+ CMV-
T were generated after stimulation with the HLA-A*0201-restricted peptide 
NLVPMVATV (NLV) and HLA-B*0702-resticted peptide TPRVTGGGAM (TPR) 
(Meij et al, 2012). In this study, results showed cell numbers ranging from 0.25 to 14.4 
x 10
6 
cells and contained between 3% and 45% IFN-γ+ CD8+ T cells. Although only 
CD8+ T cells were isolated in the study of Meij and colleagues, these cell numbers 
compare favourably with the results shown here using CD154-based isolation of CMV-
T. Furthermore, isolated CD8+ CMV-T using IFN-γ catch technology were 
subsequently cultured and although no further increase in cell numbers was observed, 
further enrichment of CMV-T was observed with T cell lines containing 54% to 96% 
NLV-specific and/or TPR-specific T cells. This approach of short-term culture to 
further enrich isolated CMV-T was demonstrated in Chapter 5.  
 
The low cell viability following enrichment can be attributed firstly to the quality of the 
cryopreserved cells being used, as previously discussed, and secondly to the 
CliniMACS device itself, that generally yields a higher proportion of apoptotic cells in 
selected fractions (Watts et al, 2002) compared with other magnetic selection devices. 
Our experience when using the IFN-γ catch method for enrichment of CMV-T by 
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CliniMACS has shown yields of as much as 90% dead cells following selection, as 
determined by Propidium Iodide (PI) staining using flow cytometry (unpublished data). 
 
Although the CMV-T purity in this clinical scale experiment failed to reach the levels 
reported by Cobbold and colleagues (Cobbold et al, 2005), it should be noted that as a 
release criterion for clinical use, the purity of isolated cells would not be required to be 
>90%. Indeed, in the studies of Fuechtinger and colleagues (Feuchtinger et al, 2010), 
CMV-T products containing ≥10% IFN-γ+ cells were approved for clinical use. 
Furthermore, a Phase III randomised study (NCT01077908) to evaluate the clinical 
benefit of prophylactic CMV-T therapy following T-cell depleted allogeneic HSCT for 
reducing recurrent CMV reactivation has a similar release criterion of 1 x 10
3
 IFN-γ+ 
cells/kg. The total CD154+ cell numbers generated with the approach described here 
would therefore support the feasibility of adoptive transfer in a Phase I/II trial to assess 
the safety and efficacy of CD154+ CMV-T therapy for the prophylactic treatment of 
CMV disease. 
 
CD154-based selection revealed a yield of 46.6%, which illustrates an improvement 
when compared to small scale enrichment using both anti-biotin microbeads (20.8%) 
and PE-microbeads (30.8%). Furthermore, this result is comparable to CMV-T yield 
using IFN-γ secretion (41.7%) (Peggs et al, 2011). Clearly, the products generated in 
the studies of Cobbold, Fuechtinger and Peggs differ greatly in terms of cellular 
composition to the product generated through CD154+ CMV-T, where T cells were 
majority CD4+. However, these studies have shown that similar doses, in terms of cell 
numbers, to that achieved here with CD154-based selection, were capable of achieving 
in vivo expansion of CMV-T. Doses of CMV+ CD4+ T cell lines ranging between  
1 to 5 x 10
6
 resulted in a rapid anti-viral effect, cleared the virus in the majority of 
patients (5 of 7) and persisted in vivo at numbers comparable to healthy individuals 
(Einsele et al, 2002). The future use of fresh G-CSF-mobilised PBMCs in favour of 
cryopreserved PBMCs for CD154+ CMV-T generation could significantly improve 
both the viability and overall cell number, which would result in higher cell numbers for 
adoptive transfer, in line with that of Einsele and colleagues. Therefore, the manufacture 
of escalating doses of CMV-T generated through CD154+ selection remains feasible. 
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Large scale studies investigating enrichment of CMV-T using activation markers have 
yet to be carried out. However, comparison of CD154-based clinical grade enrichment 
of CMV-T with one such study using selection of CD25+ multi-virus specific T cells at 
clinical grade using the CliniMACS (Lugthart et al, 2012) was comparable in terms of 
purity (55% vs. 44% respectively). The median total CD25+ cell number was 6.8 x 10
6 
which represents a significantly higher yield when compared with CD154-based 
enrichment, although the CD25 study was targeted towards multiple viruses and 
cultured 3 days prior to enrichment. Experiments in Chapters 3 and 4 of this thesis 
showed increased expression of CD25 compared with CD154 after antigenic 
stimulation. CD154-based isolation was favoured over CD25 selection for the isolation 
of CMV-T in this clinical scale experiment due to the high frequency of Tregs present 
after CD25 selection, as reported in Chapter 4. Lugthart and colleagues report a median 
of 21% of CD4+ Treg cells in the enriched CD25+ fraction, in agreement with the 
CD25 selection data presented in Chapter 4. CD25-based enrichment resulted in a 
median yield of 50% (Lugthart et al, 2012) which is comparable with the 46.6% yield 
obtained using CD154-based enrichment.  
 
One of the main obstacles for process validation of new cellular therapy techniques is 
the procurement of sufficient starting material. Unfortunately, we were not able to 
obtain ethical approval to procure fresh G-CSF-mobilised PBMCs at a quantity 
sufficient for clinical scale-up. Without ethical approval to take a large enough sample 
for process validation from G-CSF-mobilised apheresis, the only remaining option was 
to use cryopreserved cells. Donor cells, whose intended recipient was deceased, were 
procured after the donor cells in storage had been released for discard and subsequently 
approved for use in research and development under ethical approval. Although G-CSF-
mobilised PBMCs are commercially available (Key Biologics; Hemacare) this is an 
expensive option and also requires shipping from overseas, which impacts on the 
quality of cells and in our experience renders them unsuitable. 
 
 The development of a CD154+ CMV-T cell therapy product clearly requires multiple 
process validation runs in order to quantify the feasibility of adopting this approach. 
Several published studies quote numbers of 2 (Powell et al, 2005), 5 (Albon et al, 
2013), 6 (Otto et al, 2005), and 7 (Lugthart et al, 2012) process validation runs with 
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leukapheresis collections in order to demonstrate feasibility at a clinical scale. 
Increasing the number of process runs would therefore be a requirement for CD154-
based CMV-T generation, if future plans for a small clinical trial were to be realised. 
 
To optimise detection of functional antiviral responses, CD154+ cells were rested for 6 
days after selection and before re-challenge. Immediately after the selection, the 
majority of cells were CD4+ (83% of CD3+) with a small proportion of CD8+ (17% of 
CD3+) T cells. During this rest period, the proportion of CD8+ T cells reduced 
dramatically (0.57% of CD3+). Although this observation is only in one clinical scale 
experiment, it is reflective of the small scale experiments discussed in Chapter 5 and 
suggestive that CD154+ CD8+ T enriched T cells do not survive in culture where the 
overwhelming subset is CD4+ and perhaps indicative of the elevated levels of IL-4 
secreted during culture as reported in Chapter 5 that would favour CD4+ T cells over 
CD8+ cells (Kienzle et al, 2005). However, the supernatant from the re-challenge of 
CD154+ CMV-T after clinical scale enrichment showed minimal secretion of IL-4, 
arguing against this idea. This minimal secretion could, however, be attributed to the 
short culture period of 6 days compared with 21–23 days in the small scale experiments. 
One limitation of this clinical scale experiment is the failure to extend the culture period 
to 21 days in order to allow re-challenge experiments to be performed that could have 
revealed a more pronounced anti-CMV response. CD154+ CMV-T from clinical scale 
enrichment also revealed low-level IFN-γ secretion and low to undetectable levels of 
TNF-α and IL-2, both associated with a cytotoxic function. However, Granzyme B 
secretion was detected at significant levels (44.8% of CD3+) after CMVpp65 peptide 
re-challenge demonstrating a functional anti-viral response. 
 
In conclusion, the results presented in this Chapter illustrate the successful development 
of a rapid and simple methodology for the enrichment of CMV-T from G-CSF-
mobilised PBMCs using CD154 activation-induced expression, to a clinical grade scale. 
The protocol is yet to achieve full GMP-compliance due to the non-availability of 
GMP-grade anti-CD154 and anti-CD40 antibodies, although the future use of non-GMP 
compliant reagents could be overcome by a comprehensive risk assessment of these 
reagents (Lowdell et al, 2012a). The selection method used (CliniMACS) is already in 
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widespread clinical use, which makes this approach of CMV-T isolation broadly 
applicable to many transplant centres.  
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Chapter 7 
 
General Discussion 
 
The generation of CMV-T for adoptive transfer from freshly isolated, non-G-CSF-
mobilised blood or apheresates has been successfully demonstrated using a variety of 
methods, resulting in products containing CD4+ T cells, CD8+ T cells or a mixture of 
both (Peggs, 2009). The widespread application of some of these methods has been 
limited by the logistics and costs of the culture techniques together with the timeframe 
of 2-3 weeks required to manufacture them. More recently, direct selection techniques 
such as IFN-γ capture (Feuchtinger et al, 2010; Peggs et al, 2011) and HLA-peptide 
tetramers/streptamers (Cobbold et al, 2005; Schmitt et al, 2011) have demonstrated that 
CMV-T manufacture can be simple, fast and relatively inexpensive, with the generation 
of clinically relevant cell numbers for adoptive transfer. Both approaches are amenable 
to GMP standards, which makes these strategies attractive and more accessible to the 
wider cellular therapy community. However, the availability of GMP-grade 
tetramers/streptamers is limited to a small number of HLA Class I specificities and 
therefore prevents a sizeable number of HSCT patients from receiving this treatment 
option and restricts the cellular therapy product to a CD8 phenotype.  
 
The principle aim of the work described in this thesis was the detection, isolation and 
expansion of CMV-T from G-CSF-mobilised PBMCs, and the subsequent design and 
implementation of a large-scale protocol to allow this methodology to be translated into 
routine clinical practice. 
 
7.1 Optimisation of CD154+ CMV-T manufacture from G-CSF-mobilised 
 donors 
 
To date, the methods for generating CMV-T have focussed primarily on using PBMCs 
collected by leukapheresis from the original HSCT donor. In the case of related donors, 
procuring a second apheresate for CMV-T generation is inconvenient to the donor and 
is associated with some level of pain and discomfort. Obtaining a second apheresate 
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from unrelated donors has proven more difficult, either due to donor refusal, registry 
refusal or simply scheduling difficulties. Using an aliquot of the original apheresis 
collection avoids duplication of donor assessment, infectious disease marker screening, 
and product collection and shipping, all of which are often impractical in unrelated 
donors. Therefore, the prospect of manufacturing antigen-specific T cells from an 
aliquot of the original HSCT sample, following G-CSF mobilisation, is attractive but 
has yet to be fully investigated.  
 
The identification and isolation of CMV-T from G-CSF-mobilised PBMCs described in 
this thesis initially used the IFN-γ catch method due to the commercially available 
reagents and relative simplicity of enrichment using the CliniMACS device. However, 
upon identification of CMV-T determined by IFN-γ secretion, a reduction was observed 
in G-CSF-mobilised compared with non-mobilised PBMCs. Furthermore, following 
enrichment of CMV-T, a decrease in both purity and yield of IFN-γ secreting CD3+ T 
cells was observed compared with non-mobilised PBMCs. Although there was no 
significant difference in the intensity of IFN-γ staining after CMVpp65 stimulation, the 
reduction in purity and yield after IFN-γ enrichment is most likely a consequence of a 
reduction in the frequency of IFN-γ secreting cells. It remains unclear whether the use 
of individual CMVpp65 peptides based upon donor HLA type or the use of CMV IE-1 
peptides would result in a more efficient system for the identification and isolation of 
CMV-T (Gratama et al, 2008; Zandvliet et al, 2010; Slezak et al, 2007) as the kinetics 
for IFN-γ secretion in G-CSF-mobilised PBMCs may differ between epitopes at 
different peptide concentrations. But nonetheless, such a tailored donor-specific process 
would not lend itself to widespread adoption. 
 
The data presented Chapters 3 and 4 of this thesis reported on the investigation of 
activation markers as a potential route for the isolation of CMV-T following CMVpp65 
peptide stimulation; and subsequently focussed on CD25 and CD154 expression as two 
optimal targets. The successful expansion of CMV-T from G-CSF-mobilised PBMCs 
was demonstrated, and upon re-challenge expanded cells showed a high level of 
specificity for CMVpp65 and secreted inflammatory cytokines demonstrating 
functionality. Furthermore, CMV-T cell lines were capable of lysing CMVpp65 PHA 
target cells in a Calcein-AM cytotoxicity assay (Neri et al, 2001). These results, 
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presented in Chapter 5, have been published (Samuel et al, 2013). Following the novel 
finding described here of the feasibility of identifying, isolating and expanding 
functional CMV-T from G-CSF-mobilised donors, the first phase I/II clinical trial using 
CMV-T expanded from G-CSF-mobilised PBMCs has also been reported (Clancy et al, 
2013). The study of Clancy and colleagues supports the data presented in this thesis and 
demonstrates the proof-of-principle of using only a small aliquot of the original HSC 
apheresis (1.5–4ml) without any detrimental impact on the quality of the graft itself. 
However, the Clancy study raises two important questions that potentially compromise 
the widespread application of this manufacturing process. First CMV-T were expanded 
in culture over 21 days in order to generate sufficient numbers for adoptive transfer. 
This required the generation of monocyte-derived DCs transfected with an adenovirus 
vector (Ad5f35pp65) encoding the entire CMVpp65 protein, which are both time- and 
labour-intensive and difficult to establish under current GMP regulations (Fuji et al, 
2011). In comparison, the advantages of direct selection, including that of CD154+ 
CMV-T generation, are the reduced level of manufacturing required and the potential 
for a much more rapid production, which allows for a more cost-effective ad-hoc 
production. Second, there are considerable regulatory compliance issues with using a 
transfected cell line in the manufacture process, with regards to gene therapy vs. 
somatic cell therapy licenses. Effective demonstration of containment of transfected 
cells, to prevent cross contamination through viral integration, would inevitably need to 
be provided to national regulatory bodies for this system to become globally applicable. 
These complicated regulatory issues might impede the effective translation of this 
strategy into widespread clinical use.  
 
7.2 Alternative strategies for anti-viral T cell culture and expansion 
 
New technology is emerging to overcome many of the limitations associated with scale-
up when using conventional cultureware. A number of bioreactors, for example the 
WAVE bioreactor (GE Healthcare Life Sciences) have been explored for the expansion 
of T cells in suspension, (Tran et al, 2007) that could be easily transferred for the 
manufacture of CMV-T. However, this culture system cannot be accommodated in a 
conventional incubator and requires accessory devices for heating, rocking and medium 
change which makes the process more complex logistically and also expensive. The 
 Chapter 7 
 
220 
 
optimisation of cell culture has led to new cultureware on the market, such as gas-
permeable bioreactors (G-Rex, Wilson Wolf Manufacturing Corporation). In this 
system O2 and CO2 are exchanged across a silicone membrane at the base of the flask, 
resulting in reduced medium change and increased final cell numbers (Lapteva & Vera, 
2011). A recent study has demonstrated that the expansion of EBV-CTLs using this 
system results in a decreased frequency of culture manipulation, increased cell output 
(3-20-fold) and a shortening of culture time (Vera et al, 2010).  
 
In circumstances where an aliquot of G-CSF-mobilised PBMCs is not sufficient for the 
manufacture of a clinically relevant CMV-T dose after direct CD154 selection, the  
G-Rex culture system offers a GMP-ready solution that could enable CD154+ CMV-T 
translation into clinical production with a high level of simplicity. Furthermore, the 
manufacture of multi-virus specific T cells using CD154 selection still requires a short-
term culture period (Khanna et al, 2011), where the G-Rex system would offer an 
alternative to current culture limitations. The new technology now available offers the 
exciting potential to build on the work reported in this thesis, in order to achieve the 
clinical scale bioprocess optimisation of a CD154+ CMV-T isolation strategy from  
G-CSF-mobilised PBMCs. 
 
7.3 CMV-seronegative donors 
 
The direct isolation approach of both CD154 and CD25 activation-induced expression 
reported in this thesis, as well as IFN-γ catch and streptamer/pentamer technology, 
could be seen as having a limited application due to its requirement for CMV-
seropositive donors. CMV-seropositive patients receiving a HSCT from a CMV-
seronegative donor cannot presently benefit from such adoptive cellular therapy 
treatment strategies. Current investigations to overcome this limitation have included 
the use of third-party T cell donors for the manufacture of anti-viral immunotherapies. 
This strategy was first successfully tested using partially HLA-matched EBV-specific T 
cells in a phase II multicentre clinical trial to treat post-transplant lymphoproliferative 
disease (Haque et al, 2007; Haque et al, 2010). Following adoptive transfer, cells were 
highly effective and did not induce any GvHD. Third party CMV-T generated using the 
IFN-γ catch system has also been successfully demonstrated, albeit in only two patients, 
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with in vivo expansion of CMV-T and clearance of CMV infection observed in one 
patient (Feuchtinger et al, 2010;Schottker et al, 2008). The effectiveness of third-party 
donor-derived T cells in treating CMV is now being investigated in a phase II trial 
(NCT01646645) with an estimated study completion date of July 2015 (Eiz-Vesper et 
al, 2012). The strategy of using third party donors to overcome the limitations 
associated with only manufacturing from CMV-seropositive donors represents a 
potential translation of the approach of utilising CD154-selected CMV-T. Whether 
CD154 CMV-T manufactured from G-CSF-mobilised third-party donors or whether it 
would be restricted to non-mobilised donors would have to be assessed in future clinical 
trials.  
 
7.4 Future strategies for anti-viral treatment of CMV Infection 
 
The promise that cell therapies hold for the reconstitution of CMV-T responses after 
allogeneic HSCT as an alternative strategy to anti-viral drugs is more profound when 
dose-related toxicities and the emergence of resistance and late-onset CMV disease 
associated with drugs such as ganciclovir, foscarnet and cidovir (Harter & Michel, 
2012) are considered. Several clinical trials are ongoing for the assessment of 
alternative compounds for future CMV treatment including CMX-001 (Harter & 
Michel, 2012) and letermovir (known as AIC246) which interact with the viral UL56 
subunit (Kaul et al, 2011). The next 5 years is expected to reveal potential new CMV 
management strategies with these new substances. However, even anti-viral drugs that 
have shown great promise in early clinical trials, such as maribavir, a competitive 
inhibitor of the UL97 protein, have shown limitations in recent phase III clinical trials 
(Marty et al, 2011) and the first patient with maribavir-resistance during therapy has 
already been reported (Strasfeld et al, 2010). A common theme that has emerged from 
studies that have reported on the clinical application of CMV-T adoptive transfer has 
been the reconstitution of CMV immunity in the majority of cases (Peggs, 2009). This 
is a critical factor in assessing the long-term success of HSCT and, therefore, represents 
compelling evidence that the adoptive transfer of CMV-T is the optimal approach to the 
treatment of CMV disease.  
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7.5 Translation of a GMP-compliant process for CD154+ CMV-T 
 manufacture from G-CSF-mobilised PBMCs 
 
The final results Chapter of this thesis focussed on performing a large-scale CD154+ 
CMV-T isolation to assess the feasibility of translating the process into clinical practice. 
One of the main issues concerning the potential translation of this process is the 
availability of GMP-grade reagents for CD154 labelling and subsequent isolation. Even 
with the introduction of GMP-grade anti-biotin beads for selection, the process still 
requires non-GMP grade anti-CD154 biotin and anti-CD40 antibodies. Whilst the 
production of both antibodies to GMP-grade remains a viable option through industry 
GMP biopharmaceutical manufacturing, it is likely to be very expensive. Two Phase I 
studies using an anti-CD40 humanised monoclonal antibody, lucatumumab (HCD122, 
Novartis) have recently been reported for clinical use in relapsed CLL (Byrd et al, 
2012) and multiple myeloma (Bensinger et al, 2012), which holds promise for its 
possible use in clinical grade manufacture of CD154+ CMV-T. However, its assessment 
for use in the manufacturing process described in this thesis would need to assessed, and 
it would also need to be determined whether it could be provided at a significantly 
smaller size (~100µg)  for clinical scale-up. A clinical trial investigating the use of an 
anti-CD40L (CD154) antibody (BG9588, Biogen Inc.), in patients with proliferative 
lupus glomerulonephritis (Boumpas et al, 2003) and an ongoing Phase I/II trial for use 
in systemic lupus erythematosus (NCT00001789) have also been published. This is 
suggestive that a commercially available anti-CD154 antibody for clinical use could be 
realised in the immediate future. However, the same questions that arise with an anti-
CD40 antibody apply equally to an anti-CD154 antibody, and the possibility of its use 
in clinical scale manufacture of CD154+ CMV-T would require further extensive 
studies.  
 
Future experiments investigating the isolation of CMV-T from G-CSF-mobilised 
PBMCs could focus on targeting of CD137 activation-induced expression (Watanabe et 
al, 2008; Wehler et al, 2008). Isolation of multi-virus specific CD4+ and CD8+ T cells 
through CD137 expression has been demonstrated for application in anti-viral immune 
reconstitution after allogeneic HSCT (Zandvliet et al, 2011). Initial experiments 
reported in this thesis revealed optimal CD137 expression at 24 hours in support of 
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Wehler and colleagues (Wehler et al, 2008), with a similar level of expression between 
G-CSF-mobilised and non-mobilised PBMCs (0.88% ± 0.45; 0.56% ± 0.16, 
respectively). A 24-hour stimulation might be considered to be sub-optimal in terms of 
the logistical operation of manufacture compared to a 6 hour or 16 hour overnight 
stimulation. However, Watanabe and colleagues (Watanabe et al, 2008) suggest 16 
hours to be the optimal time of expression for CD137. Investigating CD137-based 
isolation has become an attractive option with the introduction of a commercially 
available, fully GMP-compliant CD137/anti-biotin reagent (Miletnyi Biotec) for use 
with the CliniMACS system. Furthermore, the isolation of both CD4+ and CD8+ T cells 
directed against CMV could also be deemed as a more attractive option than CD4+ 
alone using CD154+ isolation; however, it still remains unclear whether co-transfer is 
likely to be more successful than transfer of either population alone. Further 
investigation of CD137-based enrichment from G-CSF-mobilised PBMCs is warranted 
due to its relative ease of GMP-translation with the availability of clinical grade 
reagents and a widely applicable method. 
 
7.6 Alloreactivity of CMV-T isolated from G-CSF-Mobilised PBMCs 
 
The assessment of alloreactivity of CD154+ and CD25+ CMV-T following direct 
selection and after short-term expansion in culture is an area of future work that would 
expand on the results reported in this thesis. Future experiments would look to include 
ethical approval for the collection of recipient blood samples for use in a modified 
mixed lymphocyte reaction (MMLR) to assess alloreactivity (Bishara et al, 1999) of 
donor CD154+ CMV-T. The use of third party allogeneic PBMCs as effectors in a MLR 
is a possible strategy to bypass the need for collecting recipient blood. However, this 
strategy would mean conducting experiments in a HLA-mismatched setting, where a 
degree of alloreactivity of CMV-T would be expected. Given that HLA disparity in the 
HSCT field is associated with graft failure, GvHD and non-relapse mortality (Fuchs, 
2012), most immunologists would consider this to be a non-productive experimental 
approach. Other functional assays that would form the basis of future experiements to 
measure alloreactivity include, limiting diltution analysis to monitor the frequency of 
donor anti-recipient cytotoxic and helper T lymphocyte precursors (CTL-p and HTL-p), 
which have been shown to predict the occurrence of aGvHD after BMT (Kaminski et al, 
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1989; Schwarer et al, 1993). Perhaps more difficult to achieve logisitically would be the 
use of a skin expalant model for prediciting GvHD (Vogelsang et al, 1985). Although 
the skin expant model has been shown to be a clear predictor of GvHD and a more 
accurate indicator of aGvHD than CTL-p and HTL-p frequency analysis (Dickinson et 
al, 1994; Dickinson et al, 1998), it would require patient consent for the procurement of 
punch biopsies of skin, which could be difficult to achieve from an ethics perspective.  
 
The mean purity of CD154+ and CD25+ cells amongst the CD3+ T cell population was 
48.9% (9.6–78.7) and 89.9% (85.1–96.5) respectively, whilst CD154+ purity after 
selection was 48.9% (9.6-78.7) and 54.6% after clinical scale enrichment. The variable 
purity in CD154-selection from donor to donor could have a potentially detrimental 
effect on both the safety and efficacy of CD154+ CMV-T, in the context of those cells 
that are not CMV-specific and may be alloreactive and capable of inducing GvHD. It 
has been reported, however, that no correlation was observed between GvHD and IFN-γ 
purity of cellular therapy products infused in the Phase I/II clinical trial conducted by 
Peggs and colleagues (Peggs et al, 2011).  
 
Khanna and colleagues (Khanna et al, 2011) demonstrated that alloreactivity of ex-vivo 
generated CD154+ T cell lines to third party DCs is nearly abrogated. Autologous 
PBMCs exposed to third party DCs showed a strong proliferative response, whereas 
proliferation of antigen-specific T cell lines was nearly abrogated. However, CMV-T 
lines were not analysed in isolation, but were included in a multi-virus-specific T cell 
line; nor were they analysed immediately after direct selection when purity was only 8–
15%. The assessment of alloreactivity of CD25+ CMV-T was confounded by the high 
frequency of Tregs present following CD25 enrichment in G-CSF-mobilised PBMCs, as 
reported in Chapter 4. CD25+ CMV-T were shown to be capable of suppressing 
proliferation of autologous PBMCs after polyclonal T cell activation. In agreement with 
this finding, CD25-enriched CTL have been reported to show a marked reduction in 
proliferation in response to culture with allogeneic stimulators, compared to 
unmanipulated PBMCs, and to be capable of suppressing alloreactive proliferative 
responses in a dose-dependent manner (Lugthart et al, 2012).  
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The functional population of Tregs present after CD25-selection makes the true 
alloreactivity of CD25+ CMV-T difficult to evaluate. As with the studies of Khanna, 
Lugthart’s studies isolated multi-virus-specific T cells, which do not allow for the 
assessment of CMV-T alone, and therefore make it difficult to a make a meaningful 
comparison with the CD154+ and CD25+ CMV-T data described in this thesis. The 
statistically significant higher background expression of CD25 (mean, 4.55 ± 0.59%) on 
G-CSF-mobilised PBMCs compared to CD154+ (mean, 1.14 ± 0.27%; p=0.0008) 
expression would also suggest that CD25-selected CMV-T may contain a significant 
proportion of non-CMV-T and non-Tregs potentially capable of inducing alloreactivity. 
Indeed, the role of CD25 in driving alloreactivity has been assessed in three clinical 
trials using CD25 expression as a tool for allodepletion of donor T cells (Solomon et al, 
2005; Amrolia et al, 2006; Andre-Schmutz et al, 2002). Allodepletion in these studies 
was performed using a CD25-immunotoxin in order to reduce GvHD after adoptive 
transfer, and demonstrated feasibility and safety, whilst retaining a population of 
functional CMV-T.  
 
In both CD25+ and CD154+ isolated CMV-T, the predominant T cell subset was CD4 
(>90%). From an alloreactivity stand point, the lack of a significant proportion of CD8+ 
T cells could be viewed as beneficial in terms of reducing the possible incidence of 
GvHD, since CD8+ T cells are the major effectors of GvHD in experimental models of 
BMT, whereas CD4+ T cells have a more variable role (Korngold et al, 2005). A study 
of the adoptive transfer of CD8-depleted DLI as a treatment strategy for relapse and 
mixed chimerism reported that no acute infusional toxicity occurred and enhanced 
frequencies of circulating CD4+ and CD8+ CMV-T were observed after transfer (Meyer 
et al, 2007). However, a similar trial transferring CD8-depleted DLI reported GvHD as 
the major toxicity, with two patients dying as a result of complication relating to GvHD 
(Orti et al, 2009). In this trial, however, CD8-depleted DLI were administered in a high-
risk group of patients. Additional studies are clearly needed to further assess the safety 
and efficacy profile of these cells with regard to GvHD.  
 
In this thesis, the memory phenotype of CMV-T generated from G-CSF-mobilised 
PBMCs consisted predominantly of effector memory and central memory. Several 
groups have independently reported that effector memory cells are unable to induce 
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GvHD in different animal models (Anderson et al, 2003;Chen et al, 2004;Xystrakis et 
al, 2004). This finding was extended in a mouse model to include central memory cells 
and demonstrate that the GvHD-inducing potential was exclusively contained in the 
naïve phenotype T cells (Chen et al, 2007). This would suggest that both CD25+ and 
CD154+ CMV-T contain a minimal population of cells capable of inducing GvHD. 
Contradictory to results from G-CSF-mobilised CMV-T expansions, the memory 
phenotyping of CD154+ CMV-T following clinical scale manufacture revealed a 
significant population of naïve T cells (45.5%). However, this result was only observed 
in 1 donor and the population of naïve cells did not survive in culture after 6 days, 
which questions their survival in vivo.  
 
The alloreactivity of both CD154+ and CD25+ CMV-T and the memory T cell 
responses in GvHD are important future research questions to address that will facilitate 
the clinical translation of CMV-T for adoptive transfer. The phase I/II trials published to 
date evaluating the transfer of IFN-γ selected CMV-T have reported no apparent 
increase in incidence or severity of acute or of chronic GvHD above that seen in 
comparable untreated patients (Feuchtinger et al, 2010; Peggs et al, 2011).  
 
7.7 CMV-specific Tregs and G-CSF-mobilised PBMCs – future development 
 
Isolation of CD25+ CMV-T from G-CSF-mobilised PBMCs revealed a high frequency 
of FoxP3+ Tregs (mean, 64.24% ± 4.88) that were capable of suppressing polyclonal T 
cell activation in a CFSE proliferation assay. This observation contrasted with the 
significantly reduced frequency of FoxP3+ Tregs in non-mobilised PBMCs (mean, 
33.84% ± 7.17; p=0.008). The high frequency of FoxP3+ Tregs in CD25+ enriched 
CMV-T from G-CSF-mobilised PBMCs was shown to fall markedly during expansion 
in short-term culture (mean, 4.28%; p=0.0001). However, in the same CFSE 
proliferation assay, CD25+ expanded CMV-T were still capable of exerting 
suppression. Together, these results supported the selection of CD154 as an optimal 
activation-induced expression marker for isolating CMV-T at a clinical scale, as 
opposed to CD25. However, the observation of such a significant population of Tregs in 
G-CSF-mobilised PBMCs following CMVpp65 stimulation opens up another research 
avenue for future consideration. In much the same way that CMV-T manufactured from 
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G-CSF-mobilised PBMCs was thought not to be advantageous due to the alteration of 
cytokine networks and polarisation of T cell function induced by G-CSF (Arpinati et al, 
2000;Pan et al, 1999;Tayebi et al, 2001), major concerns also surround the clinical use 
of Tregs manufactured from the same starting material. The results reported in this 
thesis support the work of Ukena and colleagues (Ukena et al, 2012), which suggests 
that concerns surrounding the functionality of G-CSF-mobilised Tregs, in terms of 
suppressive capacity, are perhaps not warranted. The isolation of donor Tregs from the 
original HSC graft is an attractive option, as it removes the need for a second steady-
state leukapheresis, thereby simplifying the current clinical application and allowing an 
extension of this therapeutic strategy into the unrelated donor setting.  
 
Brincks and colleagues (Brincks et al, 2013) proposed that during secondary influenza 
virus infection, Treg activation is specific to the pathogen and results in regulation of 
pathogen-specific responses. As already discussed in Chapter 4, very little data exist 
regarding the emergence and generation of Tregs during CMVpp65 stimulation and 
certainly none with regard to G-CSF-mobilisation. Future experiments to build on the 
initial results reported in this thesis would look to test the hypotheses that adaptive 
Tregs arise as a consequence of CMVpp65 stimulation, and that these cells are capable 
of suppressing the proliferation of expanded CMV-T in response to CMVpp65 re-
challenge. Furthermore, the capacity of CD25+ Tregs isolated from G-CSF-mobilised 
PBMCs, following CMVpp65 stimulation, to suppress alloreactivity in an MLR would 
provide data on their value as a potential treatment strategy for GvHD in HSCT. Fully 
GMP-compliant clinical scale manufacture of CD25+ multi-virus specific T cells has 
been successfully demonstrated (Lugthart et al, 2012) in non-mobilised PBMCs. 
CD25+ enriched cells contained FoxP3+ CD127– Tregs at a median frequency of 21% 
and were capable of suppressing alloreactivity. The hypothesis of Lughart and 
colleagues, that a cellular therapy T cell product containing a mixture of Tregs and anti-
viral T cells could prevent GvHD whilst maintaining anti-viral immunity after adoptive 
transfer could be extended to studies in G-CSF-mobilised PBMCs. 
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7.8 Final concluding remarks 
 
The strategy of identifying, isolating and expanding CMV-T from G-CSF-mobilised 
PBMCs has been examined, resulting in the development of a clinical scale system to 
demonstrate the feasibility of this approach as a therapeutic option for the treatment of 
CMV disease following allogeneic HSCT. Prior to the start of the research reported in 
this thesis, no published study had shown the feasibility of this approach. The E-
publication in October 2012 of the data presented here was the first report of the novel 
finding that functional CMV-T can be isolated from G-CSF-mobilised PBMCs (Samuel 
et al, 2013). This work was supported by the subsequent publication demonstrating the 
effectiveness of utilising G-CSF-mobilised PBMCs for CMV-T manufacture and their 
safety following adoptive transfer in 7 patients (Clancy et al, 2013). The clinical 
application of G-CSF-mobilised PBMCs for cellular therapy has also developed to 
include the feasibility of Treg manufacture as a strategy for treating GvHD (Ukena et al, 
2012). The efficacy of G-CSF-mobilised PBMCs for CMV-T manufacture will be 
determined with the likely publication of several clinical studies over the next 5 years, 
which could pave the way for this strategy to be adopted as a routine therapy with 
widespread application. The question remains as to whether CD154+ CMV-T are 
capable of conferring protection against CMV infection in vivo in recipients of HSCT, 
but this can only be addressed with future clinical trials. 
 
A limitation of this study was the failure to procure paired donor samples to allow a 
comparison of the CMV response in G-CSF-mobilised and non-mobilised PBMCs to be 
made in the same donor. The use of paired samples could have allowed for greater 
statistical power when analysing the effect of G-CSF mobilisation, given the high inter-
donor variability of the CMV immune response.  
 
As a final conclusion, the work presented in this thesis represents a general approach to 
manufacturing anti-viral immunotherapies that does not require successive donations, 
thereby alleviating the many practical problems incurred with procuring cells from 
unrelated donors. 
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 Samuel E, Newton K, Mackinnon S and Lowdell MW. (2012) Successful isolation and 
expansion of CMV-reactive T cells from G-CSF mobilized donors that retain a strong 
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Appendix 3: Abstracts 
 
 T regulatory cells enriched from G-CSF mobilised apheresates do not survive short 
term culture – Impact on adoptive immunotherapy 
International Society of Cellular Therapy, Seattle, 2012 
 
 CMV-reactive T cells can be isolated from G-CSF mobilised peripheral blood 
apheresates 
American Society of Haematology, Orlando, 2010 
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